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NANOCHANNELED DEVICE AND RELATED 
METHODS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a national phase application under 35 
U.S.C. § 371 of International Application No. PCT/US2010/ 
030937 filed Apr. 13, 2010, which claims priority to U.S. 
Provisional Patent Application Ser. No. 61/114,687, filed 
Nov. 14, 2008, U.S. Provisional Patent Application Ser. No. 
61/168,844, filed Apr. 13, 2009, and U.S. patent application 
Ser. No. 12/618,233, filed Nov.13, 2009, entitled "Nanochan-
neled Device and Method of Use", the entire disclosures of 
which are specifically incorporated herein by reference with-
out disclaimer. 
This invention was made with government support under 
contract NNJ06HE06A awarded by NASA. The government 
has certain rights in this invention. 
BACKGROUND INFORMATION 
Considerable advances have been made in the field of 
therapeutic agent (e.g. drug) delivery technology over the last 
three decades, resulting in many breakthroughs in clinical 
medicine. The creation of therapeutic agent delivery devices 
that are capable of delivering therapeutic agents in controlled 
ways is still a challenge. One of the maj or requirements for an 
implantable drug delivery device is controlled release of 
therapeutic agents, ranging from small drug molecules to 
larger biological molecules. It is particularly desirable to 
achieve a continuous passive drug release profile consistent 
with zero order kinetics whereby the concentration of drug in 
the bloodstream remains constant throughout an extended 
delivery period. 
These devices have the potential to improve therapeutic 
efficacy, diminish potentially life-threatening side effects, 
improve patient compliance, minimize the intervention of 
healthcare personnel, reduce the duration of hospital stays, 
and decrease the diversion of regulated drugs to abusive uses. 
Nanochannel delivery devices may be used in drug deliv-
ery products for the effective administration of drugs. In 
addition, nanochannel delivery devices can be used in other 
applications where controlled release of a substance over time 
is needed. 
SUMMARY 
Embodiments of this invention comprise a nanochannel 
delivery device having nanochannels within a structure con-
figured to yield high mechanical strength and high flow rates. 
Various fabrication protocols may be used to form the 
nanochannel delivery device. Embodiments of the fabricated 
devices feature horizontal nanochannel lay-out (e.g., the 
nanochannel is parallel to the primary plane of the device), 
high molecule transport rate, high mechanical strength, 
optional multilayered lay-out, amenability to select channel 
lining materials, and possible transparent top cover. Based on 
silicon microfabrication technology, the dimensions of the 
nanochannel area as well as concomitant microchannel areas 
can be precisely controlled, thus providing a predictable, 
reliable, constant release rate of drug (or other) molecules 
over an extended time period. In certain embodiments, the 
nanochannel delivery device can be used to build a multilay-
ered nanochannel structure. Multilayered nanochannel struc-
tures can extend the limit of release rate range of a single layer 
nanochannel delivery device or system, and allow a wide 
range of pre-defined porosity to achieve an arbitrary release 
rate using any preferred nanochannel size. 
In certain embodiments, the nanochannel delivery device 
is made of a "sandwich" of materials, composed of a thin top 
5 layer, the horizontal nanochannels, and a thicker bottom 
wafer. The thin top layer can house an array of microchannels 
that offer an inlet or outlet for diffusing molecules. It can also 
serve as the lid or ceiling for the nanochannels by providing 
the channels' top surface. The thickerbottom wafer can house 
io an array of microchannels that offer a collateral outlet or inlet. 
Note that in the following, inlets are indicated in the bottom 
wafer and outlets are indicated in the top layer, but this is not 
a limit of the invention. In certain embodiments, the 
nanochannels are fabricated by a sacrificial layer technique 
15 that provides smooth surfaces and precisely controlled 
dimensions. The nanochannels can be formed in between the 
two layers and connect the outlet microchannels with the 
array of inlet microchannels formed in the bottom wafer, 
additionally allowing thin surface layers to be applied to both 
20 the top and the bottom surfaces independently, in order to 
optimize channel properties such as surface charge, hydro-
phobicity, wetting and conductivity. Each inlet and outlet 
microchannel can be connected to one, two, or more 
nanochannels. The height, width, and length of the nanochan- 
25 nel can be used to maintain a constant (zero-order) delivery. 
By the help of nanofabrication, a nanochannel length of 10 
mu or less is feasible. 
In certain embodiments, the nanochannel delivery device 
is designed to yield high strength. This can be achieved by a 
30 supporting structure obtained in the bottom side of the thick 
wafer. The structure can be composed by a regular mesh of 
micrometric walls which create the side surfaces of larger 
inlet macrochannels. Moreover, the top portion of the bottom 
wafer (in or on which nanochannels may be fabricated) can be 
35 engineered to provide good mechanical stability. 
The thickness of the supporting layer underneath the 
nanochannels can be optimized, and can be realized by con-
trolling the depth of the inlet microchannels and outlet mac-
rochannels or by selecting an SOI wafer with appropriate 
4o depth of buried oxide layer. The materials and thickness of top 
layers is also optimized for the attributes noted above. 
Certain embodiments include a nanochannel delivery 
device comprising: an inlet microchannel; a nanochannel; 
and an outlet microchannel, wherein the inlet microchannel 
45 and the outlet microchannel are in direct fluid communication 
with the nanochannel. In specific embodiments, the 
nanochannel is oriented parallel to the primary plane of the 
nanochannel delivery device. In particular embodiments, a 
flow path from the inlet microchannel to the nanochannel to 
50 the outlet microchannel requires a maximum of two changes 
in direction. 
In specific embodiments, the inlet microchannel has a 
length, a width, and a depth; the outlet microchannel has a 
length, a width, and a depth; and the nanochannel has a 
55 length, a width, and a depth. In certain embodiments, the ratio 
of the nanochannel length to the inlet microchannel length is 
between 0.01 and 10.0, and the ratio of the nanochannel 
length to the outlet microchannel length is between 0.01 and 
10.0. In particular embodiments, the nanochannel length is 
60 greater than the inlet microchannel length and the nanochan- 
nel length is greater than the outlet microchannel length. In 
specific embodiments, the ratio of the nanochannel length to 
either the inlet microchannel length or the outlet microchan- 
nel length is between 0.2 and 5.0, between 0.3 and 3.0, 
65 between 0.4 and 2.0, or between 0.5 and 1.0. In certain 
embodiments, the nanochannel length is greater than the 
length, width, and depth of the outlet microchannel. In par- 
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tcular embodiments, the inlet microchannel is in direct fluid 
communication with the outlet microchannel via a single 
nanochannel. 
Certain embodiments include a nanochannel delivery 
device comprising: an inlet microchannel; a nanochannel; an 5 
outlet microchannel; and a fluid flow path from the inlet 
microchannel to the outlet microchannel, where the fluid flow 
path requires a maximum of two changes in direction. In 
specific embodiments, the nanochannel is oriented parallel to 
the primary plane of the nanochannel delivery device. In io 
particular embodiments, the inlet microchannel and the outlet 
microchannel are in direct fluid communication with the 
nanochannel. 
Certain embodiments include a nanochannel delivery com-
prising: a substantially planar body comprising a first surface 15 
and a second surface opposing the first surface; a nanochannel 
disposed within the substantially planar body; an inlet micro-
channel in fluid communication with the nanochannel; and an 
outlet microchannel in fluid communication with the 
nanochannel. In particular embodiments, the inlet micro- 20 
channel extends from the nanochannel to the first surface and 
wherein the outlet microchannel extends from the nanochan-
nel to second surface. 
Certain embodiments include a nanochannel delivery 
device comprising: a plurality of inlet microchannels; a plu- 25 
rality of nanochannels; and a plurality of outlet microchan-
nels, where each inlet microchannel is in direct fluid commu-
nication with an outlet microchannel via a single 
nanochannel. In particular embodiments, the nanochannel is 
oriented parallel to the primary plane of the nanochannel 30 
delivery device, and/or an inlet microchannel and an outlet 
microchannel are in direct fluid communication with a com-
mon nanochannel. In particular embodiments, individual 
inlet and outlet microchannels are arranged perpendicular to 
a primary plane of the nanochannel delivery device; the plu- 35 
rality of inlet microchannels form a first array; the plurality of 
outlet microchannels form a second array; and the first array 
and the second array are overlapping so that individual inlet 
microchannels are distributed between individual outlet 
microchannels when viewed along a section taken perpen- 40 
dicular to the primary plane. 
Certain embodiments include a nanochannel delivery 
device comprising: a substantially planar body including: a 
length, a width, and a thickness, wherein the length and the 
width are each greater than the thickness; an inlet surface on 45 
a first side of the substantially planar body, wherein the inlet 
surface is bounded by the length and the width of the substan-
tially planar body; and an outlet surface on a second side of 
the substantially planar body. In particular embodiments, the 
outlet surface is bounded by the length and the width of the 50 
substantially planarbody, andthe inlet surface is substantially 
parallel with the outlet surface. Specific embodiments com-
prise a nanochannel disposed within the substantially planar 
body, where the nanochannel comprises an inlet end and an 
outlet end; an inlet microchannel in fluid communication with 55 
the nanochannel; and an outlet microchannel in fluid commu-
nication with the nanochannel, where the inlet microchannel 
and nanochannel are configured such that a first linear axis 
can extend between the inlet surface and the inlet end of the 
nanochannel. In particular embodiments, the outlet micro- 60 
channel and nanochannel are configured such that a second 
linear axis can extend between the outlet surface and the 
outlet end of the nanochannel. In certain embodiments, a 
primary axis of the inlet microchannel is perpendicular to a 
plane that is parallel to the substantially planar body. Particu- 65 
lar embodiments comprise an inlet macrochannel between 
the inlet surface and the inlet microchannel, where the inlet 
macrochannel comprises boundary walls that are generally 
perpendicular to the inlet surface. In specific embodiments, 
the inlet macrochannel is formed by deep reactive-ion etch-
ing. In particular embodiments, a primary axis of the outlet 
microchannel is perpendicular to a plane that is parallel to the 
substantially planar body. 
Certain embodiments comprise an apparatus comprising a 
first nanochannel delivery device inserted into a capsule. In 
particular embodiments, the first nanochannel delivery 
device is installed perpendicular to the primary axis of the 
capsule. In particular embodiments, the capsule comprises a 
septum. In certain embodiments, the septum comprises a 
self-sealing material. In specific embodiments, the septum 
comprises silicone rubber. In certain embodiments, the sep-
tum is configured to receive an injection of a therapeutic 
agent. 
Particular embodiments comprise a cap covering the sep-
tum. In certain embodiments, the cap comprises an orifice 
configured to guide a needle towards the septum. In specific 
embodiments, the capsule comprises a cover extending over 
the first nanochannel delivery device. In particular embodi-
ments, the cover comprises one or more orifices. In certain 
embodiments, the one or more orifices are sized so that they 
do not limit diffusion of a therapeutic agent from the capsule 
during use. In certain embodiments, the cover is configured to 
protect the first nanochannel delivery device from mechanical 
damage. In particular embodiments, the cover is configured to 
protect the first nanochannel delivery device from incursion 
by biological tissue structures after the capsule has been 
implanted in a living body. In certain embodiments, the cap-
sule comprises a first inner reservoir. In specific embodi-
ments, the first nanochannel delivery device is in fluid com-
munication with the first inner reservoir. 
In specific embodiments, the capsule comprises a second 
inner reservoir in fluid communication with a second 
nanochannel delivery device. In certain embodiments, the 
first and second inner reservoir are not in fluid communica-
tion with each other. In particular embodiments, the first and 
second inner reservoir are separated by a wall. In specific 
embodiments, the first inner reservoir contains a first thera-
peutic agent and the second inner reservoir comprises a sec-
ond therapeutic agent. In particular embodiments, the first 
nanochannel delivery is configured to diffuse a first therapeu-
tic agent at a first diffusion rate and the second nanochannel 
delivery device is configured to diffuse the second therapeutic 
agent a second diffusion rate. 
In certain embodiments the volume of the first inner reser-
voir can be modified by replacing a first removable compo-
nent of the capsule with a larger removable component. In 
particular embodiments, the first inner reservoir comprises a 
coating compatible with a therapeutic substance. In specific 
embodiments, the capsule comprises an outer coating config-
ured to prevent deleterious tissue encapsulation. In particular 
embodiments, the capsule comprises a cylindrical shape. In 
certain embodiments, the capsule comprises a disc shape. In 
certain embodiments, the capsule comprises a rectangular 
surface and an arched surface. In specific embodiments, the 
capsule comprises a uniform cross-section. 
In certain embodiments, the capsule comprises one or more 
of the following materials: stainless steel, titanium, poly-
etheretherkeytone, polysulfone, epoxy, silicone rubber, poly-
etherketoneketone, and thermoplastic polyurethane. In par-
ticular embodiments, the capsule comprises an anchor 
member. In certain embodiments, the anchor member is con-
figured to receive a suture. In specific embodiments, the cap-
sule comprises a color coding to indicate a characteristic of 
the capsule or the nanochannel delivery device. In particular 
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embodiments, the color coding indicates a characteristic of a 	 microchannels and inlet macrochannels. In particular 
therapeutic agent contained within the capsule. In specific 	 embodiments of the method, each nanochannel is between 
embodiments the capsule comprises a translucent ortranspar- 	 approximately one and ten nanometers deep, between 
ent cover extending over the first nanochannel delivery 	 approximately ten and twenty nanometers deep, between 
device. 	 5 approximately twenty and thirty nanometers deep, between 
Certain embodiments include a method of fabricating a 	 approximately thirty and forty nanometers deep, or between 
nanochannel delivery device. In particular embodiments, the 	 approximately forty and two hundred nanometers deep. 
method comprises: providing a first substrate; forming a plu- 	 In certain embodiments of the method, the first sacrificial 
rality of nanochannels in the first substrate; forming a plural- 	 material can be subsequently removed by selective etching. In 
ity of inlet microchannels in the nanochannels of the first io particular embodiments, the first sacrificial material is tung- 
substrate; providing a second substrate; forming a plurality of 	 sten. In specific embodiments, the second sacrificial material 
outlet microchannels in the second substrate; and coupling 	 can be subsequently removed by selective etching. In certain 
the second substrate to the first substrate, wherein each inlet 	 embodiments of the method, the second sacrificial material is 
microchannel is in direct fluid communication with a 	 selected from the group consisting of: tungsten, copper, 
nanochannel. 	 15 doped glass, and undoped glass. In particular embodiments, 
In particular embodiments of the method, the first substrate 	 the second sacrificial material is filled into the plurality of 
comprises a silicon-on-insulator wafer. In certain embodi- 	 inlet microchannels so that the second sacrificial material 
ments, the height of each nanochannel is between approxi- 	 extends above the top of the inlet microchannels and is pla- 
mately one and ten nanometers. In specific embodiments, the 	 narized by chemical-mechanical planarization (CMP). 
height of each nanochannel is between approximately ten and 20 In particular embodiments of the method, the capping layer 
twenty nanometers, between approximately twenty and thirty 	 is selected from silicon nitride, silicon oxide, silicon carbo- 
nanometers, between approximately thirty and fifty nanom- 	 nitride, silicon carbide, and silicon. In certain embodiments, 
eters, between approximately fifty and one hundred nanom- 	 the capping layer comprises multiple depositions of materials 
eters, or between approximately one hundred and two hun- 	 comprising tensile and compressive stresses such that the net 
dred nanometers. In certain embodiments the second 25 capping layer stress is tensile. In certain embodiments of the 
substrate comprises a sacrificial release layer of indium tin 	 method, the capping layer is between approximately 0.5 and 
oxide film on silicon. Particular embodiments further com- 	 1.0 microns thick, between approximately 1.0 and 2.0 
prise depositing a glass film on the second substrate prior to 	 microns thick, between approximately 2.0 and 4.0 microns 
forming the plurality of inlet microchannels in the second 	 thick, or between approximately 4.0 and 10.0 microns thick. 
substrate. In specific embodiments, the second substrate com-  30 In specific embodiments, the capping layer is greater than 
prises a glass wafer and the glass wafer is bonded to the first 	 10.0 microns thick. 
substrate and the glass wafer is ground to reduce the thickness 	 Particular embodiments comprise a method of fabricating 
prior to forming the plurality of outlet microchannels. 	 a nanochannel delivery device, where the method comprises: 
Certain embodiments include a method of fabricating a 	 providing a first substrate; forming a plurality of nanochan- 
nanochannel delivery device where the method comprises: 35 nels on a first side of the first substrate; filling in the plurality 
providing first substrate; forming a plurality of nanochannels 	 of nanochannels with  sacrificial material; coupling an initial 
on the first substrate; filling in the plurality of nanochannels 	 capping layer to the first side of the first substrate; forming a 
with a first sacrificial material; forming a plurality of inlet 	 plurality of inlet microchannels in the capping layer; prepar- 
microchannels in the first substrate; filling in the plurality of 
	
ing a second substrate with a bonding layer; coupling the 
inlet microchannels with a second sacrificial material; form-  40 second substrate to a second side of the first substrate; remov- 
ing a capping layer that covers the plurality of nanochannels; 	 ing a first portion of the second substrate; providing an addi- 
forming a plurality of outlet microchannels in the capping 	 tional capping layer to the second substrate; forming a plu- 
layer; removing the first sacrificial material from the plurality 	 rality of outlet microchannels in the second substrate; and 
of nanochannels; and removing the second sacrificial mate- 	 removing the sacrificial material to open the plurality of 
rial from the plurality of inlet microchannels. 	 45 nanochannels. 
In particular embodiments of the method, an inlet micro- 	 In certain embodiments of the method, the second substrate 
channel is arranged perpendicular to a primary plane of the 	 comprises a release layer, and the release layer can be selec- 
first substrate. In specific embodiments, an outlet microchan- 	 tively removed to cause separation of the second substrate 
nel is arranged perpendicular to a primary plane of the first 	 from the first substrate. In particular embodiments of the 
substrate. In certain embodiments of the method, an inlet 50 method, an outlet microchannel is in direct fluid communi- 
microchannel is in direct fluid communication with a 	 cation with the a nanochannel. In certain embodiments, the 
nanochannel. In particular embodiments, an outlet micro- 	 first substrate comprises a silicon-on-insulator wafer com- 
channel is in direct fluid communication with a nanochannel. 	 prising an internal oxide layer. In specific embodiments, 
In certain embodiments of the method, the first substrate 	 forming the plurality of inlet microchannels comprises etch- 
comprises a silicon-on-insulator wafer comprising an internal 55 ing material from the capping layer, and the etching is tenni-
oxide layer. In particular embodiments, the inlet and outlet 	 nated at the internal oxide layer. 
microchannels are patterned using a photolithography pro- 	 In certain embodiments, forming a plurality of inlet mac- 
cess. In certain embodiments, forming the plurality of inlet 	 rochannels comprises etching material from aback side of the 
microchannels comprises etching material from the first sub- 	 first substrate, and the etching is terminated at the internal 
strate, and the etching is terminated at the internal oxide layer. 60 oxide layer. In particular embodiments, the removal of the 
In particular embodiments of the method, forming a plurality 	 internal oxide layer after etching material to form the inlet 
of inlet macrochannels comprises etching material from a 	 microchannel and inlet macrochannels opens a pathway 
back side of the first substrate, and the etching is terminated at 	 between the inlet microchannels and inlet macrochannels. 
the internal oxide layer. 	 In certain embodiments, each nanochannel is formed 
In certain embodiments the removal of the internal oxide 65 between approximately one and ten nanometers deep, 
layer after etching material to form the inlet microchannel 
	
between approximately ten and twenty nanometers deep, 
and inlet macrochannels opens a pathway between the inlet 	 between approximately twenty and thirty nanometers deep, 
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between approximately thirty and forty nanometers deep, or 
between approximately forty and two hundred nanometers 
deep. 
In particular embodiments, the sacrificial material can be 
subsequently removed by selective etching. In specific 
embodiments, the sacrificial material is tungsten. In certain 
embodiments, the initial capping layer is silicon nitride 
deposited by plasma enhanced chemical vapor deposition. In 
certain embodiments of the method, the initial capping layer 
is between approximately 0.01 and 0.5 microns thick, 
between approximately 0.5 and 1.0 microns thick, between 
approximately 1.0 and 2.0 microns thick, between approxi-
mately 2.0 and 4.0 microns thick, or between approximately 
4.0 and 10.0 microns thick. In specific embodiments of the 
method, the initial capping layer is greater than 10.0 microns 
thick. In certain embodiments of the method, the initial cap-
ping layer is selected from silicon nitride, silicon oxide, sili-
con carbonitride, silicon carbide, and silicon. In particular 
embodiments, the initial capping layer comprises multiple 
depositions of materials comprising tensile and compressive 
stresses such that the net capping layer stress is tensile. In 
certain embodiments of the method, the bonding layer is 
selected from the group consisting of benzocyclobutene, sili-
con oxide, copper, doped glass, gold and gold alloys. 
In certain embodiments, the method of coupling the second 
substrate to the first substrate is selected from the group 
consisting of anodic bonding, fusion bonding, and thenno-
compression bonding. 
Particular embodiments include a nanochannel delivery 
device comprising: a plurality of inlet microchannels, where 
each of the inlet microchannels has a length, a width, and a 
depth, and where the inlet microchannel length is greater than 
the inlet microchannel width and depth; a plurality of outlet 
microchannels, where each of the outlet microchannels has a 
length, a width, and a depth; and a plurality of nanochannels 
in fluid communication with the plurality of inlet microchan-
nels and outlet microchannels. In certain embodiments, the 
plurality of inlet micro channels are arranged so that the inlet 
micro channel width and depth define a first plane that is 
parallel to the primary plane of the nanochannel delivery 
device; and the plurality of outlet microchannels are arranged 
so that the outlet microchannel width and depth define a 
second plane that is parallel to the primary plane of the 
nanochannel delivery device. 
Particular embodiments include a method of treating a 
condition of a person, the method comprising: providing a 
nanochannel delivery device as described herein; providing a 
reservoir in fluid communication with the nanochannel deliv-
ery device; providing a substance in the reservoir, where the 
substance is configured to treat the condition; and adminis-
tering the substance to the person via the nanochannel deliv-
ery device. In particular embodiments of the method, the 
substance is selected from the group consisting of: leuprolide, 
letrozole, laptinib, buprenorphine, interferon, and zidovu-
dine. In certain embodiments, the condition is selected from 
the group consisting of: prostate cancer, breast cancer, opiate 
dependencey, giant cell angioblastoma and HIV. In particular 
embodiments of the method, administering the substance to 
the person via the nanochannel delivery device comprises 
subcutaneously inserting the nanochannel delivery device 
into the person. 
Certain embodiments compris an apparatus comprising: a 
capsule; a bladder located within the capsule; a first port 
where the first port extends through the capsule and bladder; 
and a second port where the second port extends through the 
capsule but does not extend through the bladder. In specific 
embodiments, the capsule comprises a nanochannel delivery 
8 
device. In particular embodiments, the nanochannel delivery 
device is in fluid communication with the bladder. 
In certain embodiments, the first port and the second port 
are configured so that the first port and the second port can be 
5 accessed externally when the capsule is implanted in vivo. In 
particular embodiments, the capsule is generally disc-shaped 
and comprises a first side and a second side, and the first port 
and the second port are both located on either the first side or 
the second side. In certain embodiments, the capsule com-
prises a first end and a second end, and the first port and the 
second port are aligned when the capsule is viewed from the 
first end or the second end. 
In particular embodiments, the capsule comprises a pri- 
es mary axis extending from the first end to the second end, and 
a reference line connecting the first port and the second port is 
generally parallel to the primary axis. In certain embodi-
ments, the first port comprises a first septum and the second 
port comprises a second septum. In particular embodiments, 
20 the first septum and the second septum are self-sealing after 
being punctured by a needle. 
Certain embodiments comprise a method of in vivo refill-
ing of a therapeutic agent contained in an capsule, the method 
comprising: implanting in vivo a capsule comprising a first 
25 port, a second port, and an internal bladder, wherein the first 
port extends through the capsule and the internal bladder and 
the second port extends through capsule but does not extend 
through the bladder; inserting a first needle into the first port; 
inserting a second needle into the second port; injecting thera- 
so peutic agent into the first port; and withdrawing fluid from the 
second port. 
Particular embodiments comprise a method of in vivo 
refilling of a therapeutic agent contained in a capsule, the 
method comprising: implanting in vivo a capsule comprising 
35 a first port that extends through the capsule; inserting a needle 
into the first port, wherein: the needle comprises a first lumen 
that extends into the capsule a first distance; the needle com-
prises a second lumen that extends into the capsule a second 
distance, wherein the first distance is greater than the second 
4o distance; extracting fluid from the capsule with the first 
needle or second needle; and injecting the therapeutic agent 
into the capsule with the first needle or the second needle, 
wherein the needle used to inject the thereapeutic agent is not 
the same needle that is used to extract the fluid from the 
45 capsule. In particular embodiments, extracting the fluid from 
the capsule and injecting the therapeutic agent into the cap-
sule are performed at the same time. 
Certain embodiments comprise a method of treating a con-
dition of a person, the method comprising: providing a 
5o nanochannel delivery device; providing a reservoir in fluid 
communication with the nanochannel delivery device; pro-
viding methotrexate in the reservoir; and administering the 
methotrexate to the person via the nanochannel delivery 
device. In particular embodiments, the methotrexate is 
55 administered to treat adult rheumatoid arthritis. In certain 
embodiments, the methotrexate is administered to treat pso-
riasis. 
In the following, the term "coupled" is defined as con-
nected, although not necessarily directly, and not necessarily 
60 mechanically. 
The use of the word "a" or "an" when used in conjunction 
with the term "comprising" in the claims and/or the specifi-
cation may mean "one," but it is also consistent with the 
meaning of "one or more" or "at least one." The term "about' 
65 means, in general, the stated value plus or minus 5%. The use 
of the term "or" in the claims is used to mean "and/or" unless 
explicitly indicated to refer to alternatives only or the alter- 
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native are mutually exclusive, although the disclosure sup- 
ports a definition that refers to only alternatives and "and/or." 
The terms "comprise" (and any form of comprise, such as 
"comprises" and "comprising"), "have" (and any form of 
have, such as "has" and "having"), "include" (and any form of 
include, such as "includes" and "including") and "contain" 
(and any form of contain, such as "contains" and "contain-
ing") are open-ended linking verbs. As a result, a method or 
device that "comprises," "has," "includes" or "contains" one 
or more steps or elements, possesses those one or more steps 
or elements, but is not limited to possessing only those one or 
more elements. Likewise, a step of a method or an element of 
a device that "comprises," "has," "includes" or "contains" one 
or more features, possesses those one or more features, but is 
not limited to possessing only those one or more features. 
Furthermore, a device or structure that is configured in a 
certain way is configured in at least that way, but may also be 
configured in ways that are not listed. 
The term "inlet microchannel" is defined as a microchan-
nel through which a molecule travels prior to entering a 
nanochannel in a nanochanneled delivery device. 
The term "outlet microchannel" is defined as a microchan-
nel through which a molecule travels immediately prior to 
exiting a nanochanneled delivery device. 
The term "nanochannel" is defined as a channel with a 
cross-section having at least one dimension (e.g. height, 
width, diameter, etc.) that is less than 200 mu. 
The term "macrochannel" is defined as a channel with a 
cross-section having a maximum dimension (e.g. height, 
width, diameter, etc.) that is greater than about 10 µm. 
Other objects, features and advantages of the present 
invention will become apparent from the following detailed 
description. It should be understood, however, that the 
detailed description and the specific examples, while indicat-
ing specific embodiments of the invention, are given by way 
of illustration only, since various changes and modifications 
within the spirit and scope of the invention will be apparent to 
those skilled in the art from this detailed description. 
BRIEF DESCRIPTION OF THE FIGURES 
FIGS. 1A-1J are schematic views of a manufacturing pro-
cess according to an exemplary embodiment. 
FIGS. 2A-2E are perspective views of a first portion of a 
nanochannel delivery device during the manufacturing pro-
cess. 
FIGS. 3A-3F are perspective views of a second portion of 
a nanochannel delivery device during the manufacturing pro-
cess. 
FIG. 3G is a partial perspective view of a nanochannel 
delivery device with representative dimensions labeled. 
FIG. 4A-4L are schematic views of a manufacturing pro-
cess according to an exemplary embodiment. 
FIGS. 5A-5H are schematic cross-section views of a 
nanochannel delivery device during the manufacturing pro-
cess according to an exemplary embodiment. 
FIGS. 6A-6J are schematic views of a manufacturing pro-
cess according to an exemplary embodiment. 
FIG. 7 is a cross-sectional side view of a schematic of an 
exemplary embodiment of a nanochannel delivery device. 
FIGS. 8A-8I are schematic views of a manufacturing pro-
cess according to an exemplary embodiment. 
FIGS. 8J-8P are orthogonal and perspective views of 
exemplary embodiments during various stages of the manu-
facturing process. 
FIG. 9 is a perspective view of a nanochannel delivery 
device according to an exemplary embodiment. 
10 
FIG. 10 is a cross-sectional side view of a schematic of an 
exemplary embodiment of a nanochannel delivery device. 
FIG. 11 is a scanning electron microscope image of a 
portion of a nanochannel delivery device according to an 
5 exemplary embodiment. 
FIG. 12 is an optical image of a bonded wafer of a 
nanochannel delivery device according to an exemplary 
embodiment. 
10 	 FIG. 13 is an optical image of a front surface of a nanochan- 
nel delivery device according to an exemplary embodiment 
after polishing. 
FIG. 14 is a scanning electron microscope image of a 
portion of a nanochannel delivery device according to an 
15 exemplary embodiment. 
FIG. 15 is an optical image of a portion of a nanochannel 
delivery device according to an exemplary embodiment after 
polishing. 
FIG. 16 is scanning electron microscope image of a portion 
20 of a nanochannel delivery device according to an exemplary 
embodiment. 
FIG. 17 is scanning electron microscope image of a portion 
of a nanochannel delivery device according to an exemplary 
embodiment. 
25 
FIG. 18 is a table of materials that may be used in exem-
plary embodiments of manufacturing processes. 
FIG. 19 is an exploded perspective view of a capsule and a 
nanochannel delivery device according to an exemplary 
30 embodiment. 
FIG. 20 is an assembled perspective view of the embodi-
ment of FIG. 19. 
FIG. 21 is an assembled perspective view of a capsule 
according to an exemplary embodiment. 
35 	 FIG. 22 is an exploded perspective view ofthe embodiment 
of FIG. 21. 
FIG. 23 is an exploded perspective view of a capsule and a 
nanochannel delivery device according to an exemplary 
40 embodiment. 
FIG. 24 is an exploded perspective view of a capsule and a 
nanochannel delivery device according to an exemplary 
embodiment. 
FIG. 25 is an assembled perspective view of a capsule 
45 according to an exemplary embodiment. 
FIG. 26 is an exploded perspective view of the embodiment 
of FIG. 25. 
FIG. 27 is an assembled perspective view of a capsule 
50 
according to an exemplary embodiment. 
FIG. 28 is an exploded perspective view of the embodiment 
of FIG. 27. 
FIG. 29 is a perspective view of a capsule according to an 
exemplary embodiment. 
55 	 FIG. 30 is a perspective view of a capsule according to an 
exemplary embodiment in an installed location. 
FIG. 31 is a perspective view and a section view of a 
capsule according to an exemplary embodiment. 
FIG. 32A is a section view of a capsule according to an 
60 exemplary embodiment. 
FIGS. 3213-32C are perspective views of the embodiment 
of FIG. 32A. 
FIG. 33 is a section view of a capsule according to an 
65 exemplary embodiment. 
FIG. 34 is a section view of a capsule according to an 
exemplary embodiment. 
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DETAILED DESCRIPTION OF ILLUSTRATIVE 
	
is selected so that it can be removed in a solution that is safe 
EMBODIMENTS 
	
for silicon and top cover materials. 
The top cover of the nanochannel delivery devices is 
Protocol 1: Bonded Capping Layer 	 deposited on the sacrificial layer (see FIGS. 1(g) and 313), and 
FIGS. la-1j, 2A-2E, and 3A-3G provide illustrations of 5 the outlets are patterned on the structure, as shown in FIGS. 
steps performed in an exemplary first method of manufactur- 	 1(h) and 3C). As an alternative, a lift-off technique may be 
ing a nanochannel delivery device. Specific dimensions are 	 applied for the cases of sputtered glass or e-beam evaporated 
provided for purposes of illustration only, and it is understood 	 glass. The materials may be any suitable material, e.g. spin- 
that other exemplary embodiments may comprise different 	 on-glass, sputtered glass, e-beam evaporated glass, ITO-glass 
dimensions. 	 io sandwich, silicon, polymer, etc. The materials may include 
In one exemplary embodiment manufactured according to 	 glass and glass materials known to those skilled in the art to 
this protocol, the top layer is a cover of a 5 µm thick evapo- 	 bond to silicon by specific means, e.g., anodic bonding or 
rated glass layer and the bottom wafer is a 4 inch SOI wafer 	 fusion bonding. The materials should be able to bond to 
with a 30 µm device layer, and a 500 µm bulk layer, so that the 	 silicon by certain means. For instance of glass, anodic bond- 
supporting layer under the nanochannels has 30 µm thickness. 15 ing can be applied. A spin-on-glass layer may also applicable. 
In this exemplary structure, the inlet and outlet microchannels 	 Depending on the surface quality, a planarization process 
are 5 µm by 5 µm, and the in-plane dimension of each 	 may be needed. 
nanochannel is 5 µm by 5 µm. The space between adjacent 	 The structure wafer and the top cover are bonded together 
openings (e.g., the distance between adjacent nanochannels) 	 by a technique such as anodic bonding or Si Si direct bond- 
is 2 µm. The inlet macrochannel under the support network is 20 ing or intermediate layer aided bonding, as shown in FIGS. 
approximately 200 µm by 200 µm up through the 500 µm 	 1(c), 3D, and 3E, and the support wafer of top cover is 
thick bulk layer. 	 removed (as shown in FIGS. 1(j) and 3F). Finally, the indi- 
A general overview of this method of manufacturing will 	 vidual nanochannel delivery devices are obtained by dicing 
first be presented, followed by a more detailed discussion of 	 the wafer, and cleaning 
the features comprised in the nanochannel delivery device. In 25 	 In another exemplary embodiment manufactured accord- 
this embodiment, fabrication of the nanochannel delivery 	 ing to this protocol, while keeping the bottom silicon sub- 
device does not utilize chemical mechanical polishing 	 strate is the same 4 inch SOI wafer with a 30 µm device layer 
(CMP), and the microfabrication protocol comprises the fol- 	 and a 500 µm bulk layer as that mentioned in above embodi- 
lowing steps. Starting with a SOI (silicon on insulator) wafer 	 ment, the top layer is a 10 µm thick glass film. The 10 um thick 
(see FIG. 2A), a hard mask layer such as silicon nitride film or 30 glass film is manufactured by thinning a thicker glass layer. 
LTO (low temperature oxidation) film that will protect under- 	 To make this thin film, a 100 um to 500 um thick glass wafer 
neath silicon during thermal oxidation process is deposited. If 
	
is bonded to the structural silicon substrate. A planarization 
silicon nitride is used, a silicon dioxide pad layer may be 	 technique such as backgrinding, or lapping, or CMP, or 
deposited before nitride deposition. As an alternative, the 	 chemical etching, or dry etching is then applied to thin the 
bottom substrate can also be a silicon wafer instead of SOI if 35 glass layer until the designed thickness such 10 um is reached. 
the etching process rates are well characterized. In this case, 	 The outlets are then patterned on the thinned glass film, and 
the etching depth is controlled by timing. 	 etched down to the underneath silicon surface to open the 
The nanochannel areas can then be patterned on the mask 	 outlets. In this exemplary structure, the inlet and outlet micro- 
layer using photolithography process. (see FIGS. 1(a) and 	 channels are 5 µm by 5 µm, and the in-plane dimension of 
213), and the mask materials on nanochannel areas are selec-  40 each nanochannel is 5 µm by 5 µm. The space between adja- 
tively removed but do not affect underneath silicon. A com- 	 cent openings (e.g., the distance between adjacent nanochan- 
bination of dry etching, and short time wet etching may be 	 nels) is 2 µm. The inlet macrochannel under the support 
applied for this purpose. Then a silicon dioxide film (with a 	 network is 200 µm by 200 µm up through the 500 µm thick 
thickness that is well-controlled) can be deposited on bare 	 bulk layer. 
silicon area by thermal oxidation. In this embodiment, the 45 	 Referring specifically now to FIGS. 2A-2E and 3A-3F, a 
thickness of the oxidation layer is used to define the height of 	 more detailed view of the features of nanochannel delivery 
nanochannels, and the mask layer is stripped. 	 device 100 is provided. Referring initially to FIG. 2A, an SOI 
A mask layer suitable for deep silicon etching can then be 	 wafer 10 comprises a top layer 15 over a substrate 20 and 
deposited. The mask layer should be able to be patterned, and 	 separated by an oxide layer 35. As shown in FIG. 213, a series 
have a high selectivity to silicon during deep silicon etching 50 of nanochannels 25 are formed using a pattern mask in top 
process. Depending on the technique for deep silicon etching, 	 layer 15. One or more inlet microchannels 30 is formed using 
a layer of silicon oxide, photoresist, or metal film may be 	 a pattern mask in each nanochannel 25, as shown in FIG. 2C, 
used. 	 exposing an oxide layer 35 between the substrate 20 and the 
In this embodiment, the inlet microchannels are patterned 	 top layer 15. For purposes of clarity not all features, for 
on the mask layer, and the inlet microchannels are etched 55 example inlet microchannels 30, are labeled in the figures. 
down to the oxide layer of the SOI wafer by deep RIE (Reac- 	 As shown in FIG. 2D, a portion of substrate 20 is removed 
tive Ion Etch) or ICP (Inductive Coupled Plasma) technique, 	 using a pattern mask from below the oxide layer 35. Oxide 
as shown FIGS. 1(b) and 2C. If a silicon wafer is used, the 	 layer 35 is then removed (as shown in FIG. 2E), and inlet 
etching depth is determined by etching rate and time. 	 microchannels 30 are formed to allow passage of material 
The inlet macrochannels (the large openings from the 60 through the substrate 20 and top layer 15. At this stage, the 
back) are laid out and etched to the oxide layer of SOI wafer, 	 lower portion 40 of nanochannel delivery device 100 is com- 
as shown in FIGS. 1(c) and 2D, and the exposed oxide areas 	 plete. 
are cleaned by HE solution. (see FIGS. 1(i) and 2E). To 	 Referring now to FIGS. 3A-3F, the fabrication of the upper 
fabricate the top cover of the nanochannel delivery devices in 	 portion 45 of nanochannel delivery device 100 begins with a 
this embodiment, starting with a support wafer (e.g., a silicon 65 sacrificial layer 50 deposited on a support substrate 55. In 
wafer), a sacrificial layer is deposited. (see FIGS. 1(e), 10 	 addition, an additional layer 60 (e.g., spin-on-glass, sputtered 
and 3A). This sacrificial layer (e.g., indium tin oxide (ITO)), 	 glass, e-beam evaporated glass, ITO-glass sandwich, silicon, 
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polymer, etc.) may be used in processes utilizing a lift-off 
technique, as shown in FIG. 3B. Exit microchannels 70 are 
formed in sacrificial layer (and additional layer 60, if utilized) 
as shown in FIG. 3C. 
At this stage, upper portion 45 is ready to be bonded to 
lower portion 40 of nanochannel delivery device 100. It is 
understood, the designations "upper" and "lower" are used 
only for purposes of clarification in the description of the 
figures, and do not dictate the relationship of components 
during use of the device. As shown in FIGS. 3D and 3E, upper 
portion 45 and lower portion 40 are bonded together (through, 
e.g., anodic bonding or Si Si direct bonding or intermediate 
layer aided bonding). Support substrate 55 is removed from 
upper portion 45, and nanochannel delivery device 100 is 
completed, as shown in FIGS. 3F and 3G. The embodiment 
shown in FIG. 3G comprises optional tapered surfaces in the 
transitions between outlet microchannels 70 and nanochan-
nels 25, as well as between nanochannels 25 and inlet micro-
channels 30. 
As shown in FIG. 3G, nanochannels 25 lie in a plane 
parallel to the primary plane of nanochannel delivery device 
100 (e.g., the plane defined by the larger dimensions [in this 
example, L and W] of nanochannel delivery device 100). 
Such a configuration allows for the length of nanochannel 25 
(e.g., approximately the distance between adjacent outlet 70 
and inlet 30) and the height and width of the nanochannel to 
be varied without varying the length L, width W, and thick-
ness T of nanochannel delivery device 100. The thickness T of 
nanochannel delivery device 100 can therefore be based on 
other criteria (such as mechanical integrity) rather than the 
need to control the flow of a substance being delivered via 
nanochannel delivery device 100. 
The embodiments shown in FIGS. 3A-3G also provide for 
each outlet 70 to be in fluid communication with any inlet 30 
via a single nanochannel 25. Such a configuration can provide 
for greater control over the diffusion of a substance being 
delivered via nanochannel delivery device 100. For example, 
the diffusion rate through nanochannel delivery device 100 is 
more closely related to the dimensions of nanochannel 25, as 
compared to configurations that have numerous nanochan-
nels in fluid communication with a single extended inlet. In 
such configurations, the inlet (rather than the nanochannel) 
may become a restriction on flow and limit the ability to 
control the flow by varying the dimensions of the nanochan-
nel. 
As shown in the detailed view of FIG. 3G (not to scale), 
nanochannel 25 comprises a length nL, a width nW and a 
height nH. Outlet microchannel 70 comprises a length oL, a 
width oW, and a height oH. In addition, inlet microchannel 30 
comprises a length iL, a width iW and a height iH. As shown 
in FIG. 3G, the "length" of each channel is measured along 
the path that a molecule would travel as it moves from inlet 
microchannel 30, through nanochannel 25, and out through 
outlet microchannel 70. In certain embodiments oL°4 um, 
oW-5 um, off-5 um while nH=50 mu, nW=4 um, and nL -5 
um and oL=30 um, oW-5 um, off-5 um. 
In certain embodiments, the ratio of oL/nL or iL/nL can be 
0. 1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.1, 1.2, 1.3, 1.4, 1.5, 
1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 
3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 
4.4, 4.5, 4.6, 4.7, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 
5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 
7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 
8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 
20, 30, 40 50, 60, 70, 80, 90, or 100. 
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Protocol 2: Multilayered Structure With Bonded Capping 
Layer 
In a second embodiment, a multilayered nanochannel 
structure can be fabricated by modifying the above-described 
5 protocol 1. This embodiment comprises the following steps. 
Starting with a SOI (silicon on insulator) silicon wafer, a 
silicon dioxide layer (with a thickness that is well-controlled) 
is deposited by thermal oxidation. The thickness of the oxi-
dation layer can be used to define the height of nanochannels. 
io As an alternative, the bottom substrate can also be silicon 
wafer instead of SOI if the etching process rates are well 
characterized. The nanochannel areas can be patterned on the 
oxide layer using photolithography process. 
The silicon oxide on non-nanochannel areas can be selec- 
15 tively removed but not affect the oxide on nanochannel area. 
(See FIG. 4(a)). A polysilicon structure layer can be depos-
ited on the top of oxide nanochannel spacing layer. (see FIG. 
4(b)). A second defined thickness oxide layer can be depos-
ited again, and the nanochannel areas can be patterned on the 
20 oxide layer using photolithography process. The silicon oxide 
on non-nanochannel areas can be selectively removed but do 
not affect the oxide on nanochannel area. (See FIG. 4(c)). 
This process finishes the second layer of nanochannels. The 
previous two steps can be repeated to achieve desired number 
25 of layers. 
As an alternative to the previous steps, the silicon oxide 
nanochannel spacing layer and multilayer structure layer may 
also use other materials. For example, an aluminum film as 
nanochannel spacing layer, and evaporated glass film as mul- 
30 tilayer structure layers. 
A first mask layer suitable for deep silicon etching can be 
deposited. The mask layer should be able to be patterned, and 
have high selectivity to silicon during deep silicon etching 
process. Depending on the technique for deep silicon etching, 
35 a layer of silicon oxide, photoresist, or metal film may be 
used. 
The inlet microchannels are patterned on the first mask 
layer, and a second mask layer is deposited on the top of first 
mask layer. The inlet microchannels are patterned on the both 
40 first and second mask layers. The outlet microchannels are 
etched down to a certain depth close to oxide layer of the SOI 
wafer, and the secondmask layer is stripped to expose the first 
mask layer. The outlet microchannel is etched through mul-
tiple layers of the nanochannel spacing layer and structure 
45 layer. A combination of wet etching and DRIE may be 
applied. 
This will also etch the inlet down to the insulator layer of 
SOI wafer. (See FIG. 4(d)). If a silicon wafer is used, the 
etching depth is determined by etching rate and time. Then the 
50 inlet macrochannels on the back are laid out and etched to the 
oxide layer of SOI wafer (see FIG. 4(e)), and the oxide on the 
exposed areas is cleaned. (See FIG. 40). 
To fabricate the top cover of the nanochannel delivery 
devices, starting with a support wafer (e.g., a silicon wafer), a 
55 sacrificial layer is deposited. (See FIG. 4(h)). This sacrificial 
layer is selected so that it can be removed in a solution that is 
safe for silicon and top cover materials. The top cover of the 
nanochannel delivery device is deposited on the supporting 
wafer and the inlet microchannels are etched. A lift off tech- 
6o nique may be applied for certain cases. (See FIG. 4(ij)). The 
materials may include, for example, spin-on-glass, sputtered 
glass, e-beam evaporated glass, ITO-glass sandwich, silicon, 
etc. The materials should be able to bond to silicon by some 
means. For instance, a transparent glass layer can be depos- 
65 ited by e-beam evaporation. A spin-on-glass layer may also 
usable. Depending on the surface quality, a planarization may 
be needed. The structure wafer from the previous step and the 
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top cover can be bonded together by a technique such as 
anodic bonding or Si Si direct bonding or intermediate 
layer aid bonding. (See FIG. 4(k)). The support wafer of top 
cover can be removed (See FIG. 4(o), and the devices 
obtained by dicing the wafer and cleaning 5 
Protocol 3: Monolithically Fabricated Capping Layer 
As a third embodiment, a nanochannel structure can be 
fabricated monolithically (e.g., without bonding) and option-
ally utilizing CMP in the process. This exemplary microfab-
rication protocol comprises the following steps as shown in io 
FIGS. 5A-511 
Specific dimensions are provided for purposes of illustra-
tion only, and it is understood that other exemplary embodi-
ments may comprise different dimensions. In this embodi-
ment, the top layer is approximately 2 µm of deposited silicon 15 
nitride. This embodiment also comprises a bottom wafer that 
is a 8 inch SOI wafer with a 30 µm device layer, and a 725 µm 
bulk layer, so that the supporting layer under the nanochan-
nels has 30 µm thickness. In this exemplary structure, the 
openings for the inlet and outlet microchannels are 3µm by 5 20 
µm, and the in-plane dimension of each nanochannel is 3 µm 
by 5 µm. The space between adjacent microchannel openings 
is 2 µm. As in previously-described embodiments, the inlet 
macrochannel under the support network is approximately 
200 µm by 200 µm up through the 725 µm thick bulk layer. 25 
Starting with an SOI (silicon on insulator) wafer 210, a 
nanochannel spacing layer 220 (with a thickness that is well 
controlled, for example, ±5% over the relevant portion of SOI 
wafer 210) is deposited. The thickness of spacing layer 220 
can be used to define the height of the nanochannels. This 30 
spacing layer 220 is a sacrificial layer, and the material will be 
removed in a subsequent step, so the silicon surface immedi-
ately under it is the "floor" of the eventually formed 
nanochannels. The spacing material should have a high wet 
etch selectivity to other materials in the nanochannel delivery 35 
device (nDD). As an example, a thin film of tungsten, genna-
nium, or silicon oxide can be used for the nanochannel spac-
ing layer 220. 
As shown in FIG. 5A, a capping layer 230 is deposited over 
the nanochannel spacing layer 220. Capping layer 230 will 40 
ultimately be the "ceiling" of the nanochannels. Silicon 
nitride, silicon oxide, silicon carbide, or other material which 
has a high etch selectivity to the material for spacing layer 220 
may be used for capping layer 230. 
A mask layer (not shown) suitable for deep reactive-ion 45 
etching (DRIE) is deposited, and the inlet microchannels 240 
are patterned on the mask layer using photolithography. As 
shown in FIG. 513, the DRIE process(es) etch microchannels 
240 through the capping layer 230 and spacing layer 220 and 
silicon down to the buried oxide layer 250 of SOI wafer 210. 50 
The mask layer can then be removed. 
As shown in FIG. 5C, inlet microchannels 240 are filled 
with a fill material 260 that canbe polishedby CMP or etched. 
Non-limiting examples of fill material 260 include copper, 
tungsten, polysilicon, or phosphosilicate glass, each depos- 55 
ited by techniques known in the art. Fill material 260 should 
have a wet etch with high selectivity to silicon and the mate-
rial of capping layer 230. In this exemplary embodiment, fill 
material 260 only needs to fill in the top of inlet microchan-
nels 240. A CMP or etch back process can be used to remove 60 
the excess fill material 260 that extends above or outside of 
inlet microchannels 240. The surface of the remaining fill 
material 260 should be above the level of spacing layer 220. 
Referring now to FIG. 5D, additional material may be 
deposited onto capping layer 230. The areas of capping layer 65 
230 and spacing layer 220 above and between the inlet micro-
channels 240 can be patterned using a photolithography pro- 
cess. The spacing layer 220 and capping layer 230 outside of 
the inlet nanochannels 240 (e.g., regions 221 and 231) can be 
etched to or slightly below the silicon surface. 
Referring now to FIG. 5E, a final capping layer 270 is 
deposited over the entire surface of wafer 210 to provide 
structural rigidity and seal the sidewalls of the nanochannel 
areas. Using a photolithography process, outlet microchan-
nels 280 can be patterned and etched through capping layers 
230, 270 and optionally through spacing layer 220 into silicon 
210 for additional process latitude. As shown in FIG. 5F, a 
protective layer 275 is deposited over capping layer 270 and 
outlet microchannels 280. 
Referring now to FIG. 5G, wafer 210 can then be inverted 
and large openings for inlet macrochannels 245 on the back of 
wafer 210 can be formed by DRIE down to the buried oxide 
layer 250 of wafer 210. As shown in FIG. 5H, sacrificial and 
protective layers used during processing (e.g. spacing layer 
220, fill material 260, capping layer 270, and portions of 
oxide layer 250) are removed by appropriate processes 
known in the art. As shown in FIG. 5H, when spacing layer 
220 is removed, nanochannels 205 are formed. The wafers 
can then be diced to get individual nanochannel delivery 
devices. 
As illustrated in this embodiment, nanochannels 205 are in 
direct fluid communication with inlet microchannels 240 and 
outlet microchannels 280. Specifically, inlet microchannels 
240 and nanochannels 205 are directly connected so that a 
fluid exiting an inlet microchannel will immediately enter the 
nanochannel without flowing through an intermediate body. 
As a variant of this protocol, and in analogy to protocol 2 
above, a multilayered structure can be built by repeated appli-
cation of the monolithic top layer process. A plurality of 
capping layer 230 and spacing layer 220 pairs can be depos-
ited. The inlet microchannels can be etched through all layers 
down to the buried oxide and filled with fill material 260 and 
polished as above. The final capping layer 270 can be applied 
and outlet microchannels 280 etched as above. 
Protocol 4: Varying the Length of Nanochannels 
In certain embodiments, Protocol I can be modified to 
make a nanochannel delivery device with different a 
nanochannel length while keep other features unchanged. An 
exemplary microfabrication protocol comprises the follow-
ing steps. 
Starting with a SOI (silicon on insulator) wafer, a hard 
mask layer such as silicon nitride film or LTO (low tempera-
ture oxidation) film that will protect the underneath silicon 
during thermal oxidation process is deposited. If silicon 
nitride is used, a silicon dioxide pad layer may be deposited 
before nitride deposition. As an alternative, the bottom sub-
strate can also be silicon wafer instead of SOI if the etching 
process rates are well characterized. 
The nanochannel areas can be patterned on the mask layer 
using photolithography process. (See FIG. 6(a)), and the 
mask materials on nanochannel areas are selectively removed 
but do not affect underneath silicon. A combination of dry 
etching, and short time wet etching may be applied for this 
purpose. A silicon dioxide film (with a well-controlled thick-
ness) is deposited on the bare silicon area by thermal oxida-
tion. The thickness of the oxidation layer defines the height of 
nanochannels, and the mask layer and oxide is stripped. 
A mask layer suitable for potassium hydroxide (KOH) wet 
etching is deposited, such as silicon nitride. A new mask is 
designed to lay-out both inlet micro channels and outlet 
microchannels on the same layer, and the nanochannel length 
is defined by the spacing between adjacent inlet and outlet 
microchannels. The mask layer is patterned using the new 
mask by standard photolithography process. The mask mate- 
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rials on open areas are selectively removed. Then a KOH wet 
etching is applied to form openings with the slope wall, and 
the mask layer is stripped. (See FIG. 6(b)). 
A mask layer suitable for deep silicon etching can be 
deposited. The mask layer should be able to be patterned, and 
have a high selectivity to silicon during deep silicon etching 
process. Depending on the technique for deep silicon etching, 
a layer of silicon oxide, photoresist, metal film, or other 
suitable material may be used. 
The outlet microchannels are patterned on the mask layer 
and the outlet micro channels are etched down to the oxide 
layer of the SOI wafer by a suitable technique, for example a 
deep RIE or ICP technique. (See FIG. 6(c)). If a silicon wafer 
is used, the etching depth can be determined by etching rate 
and time. 
The inlet macrochannels from the back are laid out and 
etched to the oxide layer of the SOI wafer, and the exposed 
oxide areas are cleaned by HE solution. (See FIG. 6(d)). To 
fabricate the top cover of the nanochannel delivery devices, 
starting with a support wafer (e.g., silicon wafer), a sacrificial 
layer is deposited. (See FIG. 6(e, f)). This sacrificial layer 
(e.g. ITO), is selected so that it can be removed in a solution 
that is safe for silicon and top cover materials. 
The top cover of the nanochannel delivery devices is 
deposited on the sacrificial layer. (See FIG. 6(g)), and the 
outlets are patterned on the structure. (See FIG. 6(h)). As an 
alternative, a lift-off technique may be applied for the cases of 
sputtered glass or e-beam evaporated glass. In certain 
embodiments, the materials may be spin-on-glass, sputtered 
glass, e-beam evaporated glass, ITO-glass sandwich, silicon, 
polymer, etc. The materials should be able to bond to silicon 
by certain means. For instance of glass, anodic bonding can 
be applied. A spin-on-glass layer may also applicable. 
Depending on the surface quality, a planarization process 
may be needed. 
The structure wafer from step (6) and the top cover can be 
bonded together by a technique such as anodic bonding or 
Si Si direct bonding or intermediate layer aided bonding. 
(See FIG. 6(i)). The support wafer of top cover is removed 
(See FIG. 6(j)), and the devices are obtained by dicing the 
wafer, and cleaning 
If the preferred length of nanochannel is less than 500 mu, 
a nanofabrication technique such as e-beam or nanoimprint 
may be applied. Isotropic silicon etching technique may also 
be applied. A schematic structure view of a short nanochannel 
delivery device is shown in FIG. 7. As shown in FIG. 7, inlet 
microchannel 340 has a portion 341 that is flared or tapered 
proximal to nanochannel 305. Similarly, outlet microchannel 
380 has a portion 381 that is flared or tapered proximal to 
nanochannel 305. Nanochannel 305 is therefore shortened as 
a result of portions 341 and 381. 
Protocol 5: Hybrid Monolithic-Bonded Capping Layer 
As a fifth embodiment, a nanochannel structure can be 
fabricated without the use of a CMP process, while utilizing 
bonding as a non-critical step in the capping layer fabrication. 
This exemplary microfabrication protocol comprises the fol-
lowing steps as seen in FIGS. 8A-8P. 
Referring initially to FIG. 8A, starting with an SOI (silicon 
on insulator) substrate wafer 410, a nanochannel spacing 
layer 420 (with a thickness that is well-controlled, for 
example, ±5% over the relevant portion of SOI substrate 
wafer 410) is deposited. The thickness of spacing layer 420 
can be used to define the height of the nanochannels. This 
spacing layer 420 is a sacrificial layer, and the material will be 
removed in a subsequent step, so the silicon surface immedi-
ately under it is the "floor" of the eventually formed 
nanochannels. The spacing material should have a high wet 
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etch selectivity to all other materials in the nanochannel deliv-
ery device. As an example, a thin film of tungsten, germa-
nium, or silicon oxide can be used for nanochannel spacing 
layer 420. 
5 	 A capping layer430 is deposited overnanochannel spacing 
layer 420. Capping layer 430 will ultimately be the "ceiling" 
of the nanochannels. Silicon nitride, silicon oxide, silicon 
carbide, or other material which has a high wet etch selectiv-
ity to the material for spacing layer 420 may be used for 
to capping layer 430. The nanochannel areas can be patterned on 
spacing layer 420 and capping layer 430 using a photolithog-
raphy process. As shown in FIG. 813, spacing layer 420 and 
capping layer 430 on non-nanochannel areas 432 and 433 are 
15 etched to or slightly below the silicon surface of silicon wafer 
410. 
Referring now to FIG. 8C, additional capping material 431 
is deposited, and optionally planarized by CMP to provide a 
flat surface. Inlet microchannels 440 are patterned on the 
20 mask layer (not shown) using photolithography. The DRIE 
process(es) etch inlet microchannels 440 through the capping 
layer 430 and spacing layer 420 and silicon down to a buried 
oxide layer 450 of SOI substrate wafer 410. The mask layer is 
removed and additional appropriate surface layers useful for 
25 bonding can be deposited on this surface, as needed. 
Referring now to FIG. 8D, on another silicon substrate (e.g. 
a capping wafer 411), a layer 421 (comprising, for example, 
silicon nitride or silicon oxide) can be deposited. On top of 
layer 421, a bonding layer 441 is deposited. The material for 
so bonding layer 441 can be chosen so as to adhere well to the 
material on the surface of wafer 410 (e.g. capping material 
431). The material for bonding layer 441 can also be designed 
so that any surface particles can be absorbed into bonding 
layer 441 to prevent any delamination between capping wafer 
35 410 and substrate wafer 411 after bonding. Alternatively, a 
highly clean process before and during bonding can be used 
without this requirement. Exemplary materials for bonding 
layer 441 include polymeric materials, silicon oxide, and 
copper. Before the application of bonding layer 441, option- 
4o ally, a material with a very high etch rate, "the release layer" 
421, can also be applied with an additional silicon nitride or 
silicon oxide layer (not shown) on top of this release layer. 
Layer 421 can comprise a material with a high selectivity to 
other materials in the nanochannel delivery device. 
45 Referring now to FIG. 8E, capping wafer 411 and substrate 
wafer 410 are then bonded onto each other. In certain embodi-
ments, the bonding can be polymer-silicon nitride bond, such 
as Benzocyclobutene (BCB)-silicon nitride, copper-copper 
then nocompres sion bond or oxide-to-oxide fusion bond, 
50 each with appropriate pre- and post-bond treatments known 
to those skilled in the art. 
Referring now to FIG. 8F, the silicon portion of capping 
wafer 411 is then removed through a suitable process, e.g. 
mechanical thinning, a chemical etch, or a combination of 
55 both. In the case of the optionally added "release layer" 421, 
the release layer can be selectively removed to cause separa-
tion of the silicon capping wafer 411 from substrate wafer 
410. 
Referring now to FIG. 8G, using a photolithography pro- 
60 cess, outlet microchannels 480 can be patterned and etched 
through optional release layer 421, bonding layer 441, cap-
ping material 431, capping layer 430, and optionally through 
spacing layer 420 into the silicon for additional process lati-
tude. 
65 	 Referring now to FIG. 8H, a protective capping layer 470 is 
deposited over the surface of substrate wafer 410. Wafer 410 
(with layer 421 and bonding layer 441 from wafer 411) is then 
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inverted and inlet macrochannels 445 on the back of wafer 
410 can be formed by DRIE down to the buried oxide layer 
450 of wafer 410. 
Referring now to FIG. 81, sacrificial layers (e.g. spacing 
layer 420, capping layer 470, andportions of oxide layer 450) 5 
are removed by appropriate processes known in the art. As 
shown in FIG. 81, when spacing layer 420 is removed, 
nanochannels 405 are formed. As illustrated in this embodi-
ment, nanochannels 405 are in direct fluid communication 
with inlet microchannels 440 and outlet microchannels 480. 10 
Referring now to FIG. 87, atop view of the entire wafer 410 
is illustrated. As shown in this view, wafer 410 (prior to 
dicing) comprises several nanochannel delivery devices 400 
(only one of which is identified in the figure). Wafer 410 can 15 
be diced to separate the individual nanochannel delivery 
devices 400 from each other. A detailed view of an individual 
nanochannel delivery device 400 with exemplary dimensions 
is illustrated in FIG. 8K. In this view, a plurality of inlet 
macrochannels 445 are visible on one side of nanochannel 20 
delivery device 400. This exemplary embodiment of 
nanochannel delivery device 400 is approximately 6.0 mm 
square, and the inlet macrochannels form a generally circular 
shape approximately 3.6 mm in diameter. It is understood that 
while wafer 410 of Protocol 5 is illustrated in FIG. 87, other 25 
protocols will also yield wafers that comprise multiple 
nanochannel delivery devices, and can be diced or separated 
into the individual devices. It is also understood that other 
exemplary embodiments may comprise different dimensions 
than those shown in FIG. 8K. In some embodiments, the 30 
wafer 410 may remain whole, effectively forming a 
nanochannel delivery device with dimensions similar to that 
of a silicon wafer, for example, approximately 500 to 750 
micrometers in thickness and 100, 150, 200, 300, 450, or 675 
mm in diameter. 35 
For example, referring to FIGS. 8L and 8M a nanochannel 
delivery device 500 is shown comprising a body 501 that is 
substantially planar and has a rectangular shape with a thick-
ness "T", a length "L" that is 4 mm and a width "W" that is 3 
mm. The thickness "T" may be varied, but in certain embodi- 40 
ments is approximately 550-700 µm, and is less than either 
length L or width W. Length L and width W define the primary 
plane of nanochannel delivery device 500. As shown in the 
figures, body 501 has an inlet surface 502 on one side and an 
outlet surface 503 on the opposite side. Inlet surface 502 and 45 
outlet surface 503 are generally parallel to each other and 
parallel to the primary plane of nanochannel delivery device 
500. Visible in FIG. 8M are a plurality of inlet macrochannels 
545 (only one of which is identified in the figure). FIG. 8N 
provides a perspective view of a partial cross-section of 50 
nanochannel delivery device 500 taken along line 8N-8N in 
FIG. 8M. The portion illustrated in FIG. 8N comprises a 
single inlet macrochannel 545 and multiple inlet microchan-
nels 540 and outlet microchannels 580. As shown in FIGS. 
8L-8N, inlet microchannels 540 and outlet microchannels 55 
580 are formed so that individual inlet and outlet microchan-
nels are perpendicular to the primary plane of nanochannel 
delivery device 500 (e.g., the length of the microchannels is 
measured along a line that is perpendicular to the primary 
plane of the device). In addition, the plurality of inlet micro- 60 
channels 540 and outlet microchannels 580 form overlapping 
arrays so that individual inlet microchannels 580 are distrib-
uted between individual outlet microchannels 580, and vice 
versa. Referring now to FIG. 8 As shown in the detailed view 
of FIG. 80, each nanochannel 505 is in direct fluid commu- 65 
nication with an inlet microchannel 540 and an outlet micro-
channel 580.  
20 
Referring now to FIG. 8P, a detailed section view of a 
section of nanochannel delivery device 500 is illustrated. In 
this view, three inlet nanochannels 540 are visible, along with 
a pair of outlet microchannels 580 and a pair of nanochannels 
505. As shown, nanochannel 505 comprises an inlet end 506 
and an outlet end 507. In this embodiment, a first linear axis 
508 extends between inlet end 506 and inlet surface 502. Also 
visible in FIG. 8P, a second linear axis 509 extends between 
outlet end 507 and outlet surface 503. 
Also shown in FIG. 8P, inlet microchannel 540 comprises 
a primary axis 512 and outlet microchannel 580 comprises a 
primary axis 511. As shown in this embodiment, primary axis 
511 andprimary axis 512 are perpendicular to aplane513 that 
is parallel to a substantially planar body 550 of nanochannel 
delivery device 500. In FIG. 8P, only aportion of substantially 
planar body 550 is shown. A complete view of substantially 
planar body 550 is visible in FIGS. 8L and 8M. 
Referring now to FIG. 9, specific dimensions for an exem-
plary embodiment of a nanochannel delivery device manu-
factured according to the above protocol are provided. It is 
understood that these dimensions are illustrative of the spe-
cific embodiment shown, and that other embodiments may 
incorporate different dimensions. 
Referring now to FIG. 10, a partial cross-section of 
nanochannel delivery device 500 illustrates the diffusionpath 
575 for a molecule passing through nanochannel delivery 
device 500. It is understood that nanochannel delivery device 
500 may be oriented in any direction during use. As shown in 
FIG. 10, flow path 105 requires a maximum of two changes in 
direction between the point where the molecule enters 
nanochannel delivery device 500 and the point at which the 
molecule exits nanochannel delivery device 500. For 
example, the molecule enters nanochannel delivery device 
500 and is initially located within inlet macrochannel 545. 
The molecule then enters inlet microchannel 540. In the 
embodiment shown, flow path 575 turns at a 90 degree angle 
to the right as the molecule enters the nanochannel 505 that is 
in direct fluid communication with inlet microchannel 540. 
After the molecule exits the nanochannel 505, the flow path 
turns again (this time, a 90 degree turn to the left) as it enters 
the outlet microchannel 580, which is also in direct fluid 
communication with the nanochannel 505. Therefore, flow 
path 575 requires a maximum of two changes in direction as 
the molecule diffuses through nanochannel delivery device 
500. While a molecule may undergo more than two changes 
in direction as it passes through nanochannel delivery device 
500, it is only required to make two changes in direction. 
EXAMPLE 
Protocol 1: Bonded Capping Layer 
The following example is provided as an illustration of one 
non-limiting embodiment of a method of manufacturing a 
nanochannel delivery device according to Protocol 1 (de-
scribed above). This example is provided for illustration pur-
poses only and is not intended to limit the scope of the inven-
tion described herein. 
Processing begins with a double polished 4" SOI wafer 
(available from Silicon Quest). The wafer comprises a device 
layer that is 30 um thick, <100> orientation P-type, Boron 
doped, and a 1-10 Ohm-cm surface resistivity, a buried oxide 
layer that is 0.4 um thick and a handle layer that is 500 um 
thick, P-type, Boron doped, and 1-10 Ohm-cm surface resis-
tivity. The wafer was cleaned in a fresh Piranha solution (3:1 
98% sulfuric acid: 30% hydrogen peroxide, over 100 C) for 
10 min, and spun dried. A 50 nm pad oxide layer was then 
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thermally grown on the surface. Then a 100 mn low-stress 
nitride was deposited on the pad oxide layer by low-pressure 
chemical vapor deposition (LPCVD). The 5 um wide 
nanochannel patterns were transferred from the photo mask 
onto the silicon nitride layer by standard photolithography 
using an EVG 620 aligner. The exposed nitride area was 
removed by CF4 RIE. 
After the photoresist was stripped, the pad oxide was 
cleaned by dipping in 1:10 HE water solution. Then the wafer 
was placed in a thermal oxide furnace to grow sacrificial 
oxide. The thickness of this sacrificial oxide determined the 
height of nanochannels, i.e. height of 
nanochannel-0.46 *Thickness of Oxide. In this example, a 39 
mn oxide was grown for 18 mn nanochannels. Then the 
nitride and oxide were removed in dilute HE solution. A 3 um 
thick low temperature oxide (LTO) layer was then deposited 
on the surface by LPCVD. Then the backside of wafer was 
protected by 3 um spun-on Futurrex negative photoresist. The 
LTO on front side was removed in a buffered oxide etch 
(BOE) solution, and the wafer was cleaned in piranha solu-
tion. 
A 500 nm LTO film was deposited on the wafer using 
LPCVD. The 5 umx5 um inlet microchannel patterns were 
transferred to the LTO film on the device side of wafer using 
standard lithography on an EVG 620 aligner, and LTO were 
etched using CF4 RIE. Then the 200 umx200 um inlet mac-
rochannel patterns were transferred onto the backside of the 
wafer, and RIE was done. 
After cleaning out the photoresist, deep silicon etching of 
inlet microchannels was done using an Oerlikon DSE etcher. 
The etching was stopped on the buried oxide layer. The wafer 
was flipped over, and attached onto a handle wafer using 
thermal grease (Al Technology). The 190 umx190 um inlet 
macrochannels were then etched on the Oerlikon DSE etcher, 
and stopped on the oxide layer. FIG. 11 shows a SEM image 
of deep etched 190 um openings. The wafer was detached 
from the handle wafer, and cleaned. The wafer was dipped in 
BOE for 5 min to open the buried oxide layer, and spun dried. 
Then mask LTO films on both sides of wafer were removed in 
HE water solution. 
A 500 um thick double side polished Pyrex 7740 glass 
wafer was bonded onto the silicon substrate as a nanochannel 
cap by anodic bonding using an EVG 520 bonder. The anodic 
binding was performed at 800 volts, and 325° C. for 10 min. 
FIG. 12 shows an optical image of the bonded wafer. The 
bonded wafer pair was adhered on a wafer holder using wax, 
and backlapping was applied to thin the glass down to 30 um, 
and then CMP polished to a final thickness of 5-10 um (by 
Valley Design Corp). 
FIG. 13 shows an optical image of the front surface after 
polishing. The contrast indicates that nanochannels are open. 
The 5 umx5 um outlet microchannels were formed by CF4/ 
Ar RIE using Ni film as mask layer. To do so, a copper seed 
layer was firstly deposited on the glass surface. The 5 umx5 
um outlet microchannel patterns were transferred to the cop-
per film using standard lithography on an EVG 620 aligner, 
and were wet etched. Then Ni was electroplated onto the 
patterned copper film. The CF4/Ar RIE was used to etch the 
inlet microchannels into the glass film to reach the silicon 
surface. After stripping the mask layer, the wafer was cleaned, 
and diced using DAD321 Dicing Saw (Disco). The fabricated 
devices are 6 mmx6 mm overall dimension. There are 161 in 
total 190 umx190 um openings arranged in a 3.6 mm diam-
eter circle. Each such opening is connected to 501 in total 5 
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umx5 um inlet channels, and the inlet channels are connected 
to nanochannel and outlet channels. 
EXAMPLE 
Protocol 3: Monolithically Fabricated Capping Layer 
The following example is provided as an illustration of one 
non-limiting embodiment of a method of manufacturing a 
io nanochannel delivery device according to Protocol 3 (de-
scribed above). This example is provided for illustration pur-
poses only and is not intended to limit the scope of the inven-
tion described herein. 
Processing begins with a double-side polished Silicon On 
15 Insulator (SOI) wafer using a 690 um thick base wafer with a 
top silicon layer thickness of 30 um and a buried oxide thick-
ness of 2 um. This wafer is cleaned with a piranha solution 
(3:198% Sulfuric acid: 30% Hydrogen peroxide, over 100 C) 
to remove any organic and metal contamination. A smooth 
20 (typically<5 A nns), uniform (typically<2%non-uniformity,) 
tungsten metal layer is sputtered on this wafer, using a physi-
cal vapor deposition (PVD) process at a temperature of 100 C. 
The thickness of this tungsten layer is selected to be the height 
of the nanochannel layer, for example 5 nm. 
25 	 The nanochannel space layer is then covered by a plasma 
enhanced chemical vapor deposition (PECVD) silicon nitride 
(" SiNI ") with low stress (380 C, appropriate stoichiometry), 
with a target thickness of 500 nm and a non-uniformity of less 
than 2%. Positive resist is then spun on, with a thickness of 2 
30 um. The inlet microchannels are exposed in this resist, with 
the sizes varying from 1 um to over 5 um, as needed. Using 
this resist, the applied silicon nitride is etched through, along 
with tungsten, using a conventional C4F8 etch chemistry with 
appropriate plasma powers, and other reactive and inert 
35 gases. 
The etch in this process is timed to be deep enough that it 
goes through the tungsten layer also, which takes a few min-
utes. Another etch is performed, still using the resist as the 
mask, to etch a deep via in the silicon that is deep enough to 
40 go into the buried oxide. A 5 dep/5 etch per cycle Bosch etch 
is used in this step since the etch automatically terminates at, 
and is highly selective to, the buried oxide. A small overetch 
of 10-20% of the most critical structure is provided to com-
pensate for the non-uniformity of the process. The remaining 
45 resist is then removed using an oxygen plasma and the wafers 
are additionally cleaned of all polymer residues using an 
appropriate wet chemistry FIG. 14 presents an example of a 
device at this stage of process. 
The next module consists of filling or capping these inlet 
50 microchannels. This can be accomplished by plugging the 
inlets with copper. A TiN barrier layer is deposited by sputter, 
with a thickness of 300 A. A copper seed layer, with a nominal 
thickness of about 4000A is deposited through a PVD sputter 
process. A low current (2 A, 10-15 minutes) electroplating 
55 process is used to fill or plug the inlet microchannels. The 
excess copper overburden is then polished away using a pad/ 
slurry combination, under moderate pressure/speed (2-4 psi, 
30-90 rpm) process. In this same process, the TiN in the 
non-microchannel area (field) is also completely removed. 
6o Finally, the inlet microchannel process is hardened with a 
short bake anneal at 150-250 C, for about 30 minutes, and the 
surface is cleaned. FIG. 15 presents a top view of the device 
after filling with copper. 
A thin silicon nitride ("SiN2") layer of about 50 nm is 
65 deposited by PECVD to cap the copper. The nanochannel 
lines are then exposed in resist (1.3 um) using photolithogra- 
phy and the silicon nitride (SiNI as well as SiN2) layers are 
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etched, along with the tungsten nanochannel material, with 	 clean container and cleaned with acetone with a final rinse of 
the etch proceeding a few tens of nanometers into the silicon. 	 IPA to promote channel drying. A die is attached by epoxy or 
A thicker, tensile silicon nitride ("SiN3") is then deposited, 	 other fixing method to a capsule mating surface. 
of a thickness of about 1-1.5 um. The tensile stress of this 	 Capsule Configurations 
layer is chosen so as to make the overall dielectric stack 5 	 Referring now to FIGS. 19 and 20, nanochannel delivery 
slightly tensile by about 20 MPa. The outlet microchannels 	 device 500 may form part of a larger assembly, e.g., a capsule 
are then exposed on a resist layer (of nominal thickness 2 um) 	 600 that may be used to administer drugs or other therapeutic 
and a further etch of all silicon nitride layers (SiNI, SiN2, 	 agents to a patient. FIG. 19 shows a detailed view of one end 
SiN3) along with the W nanochannel layer are etched so that 	 of capsule 600 in an exploded view, while FIG. 20 illustrates 
the bottom of the outlet microchannels end in the device io an assembled view of capsule 600. It is understood that in 
silicon. The resist is stripped after this stage. FIG. 16 presents 	 other embodiments, nanochannel delivery device 500 may be 
a cross-section of a device at this stage of processing. 	 used in other applications where it is desired to precisely 
An appropriate protection layer is applied to the surface 	 control the diffusion or passage of small amounts of any 
Ti/TiN (250/300A), Tungsten (5000 A) followed by Phospho 	 substance. 
silicate Glass (PSG) of thickness of 1 um, which can be used 15 	 In the embodiment shown in FIGS. 19 and 20, capsule 600 
as both an HE protectant as well as a surface protectant. The 	 comprises a generally cylindrical body 620 having an end 
wafer is then turned upside down and a thick resist (10 um) is 	 portion 630 configured to receive a first cap 610 and a second 
spun on. Using the front side alignment marks, macrochan- 	 cap 625. In this embodiment, nanochannel delivery device 
nels are exposed on the backside. The macrochannels are 	 500 is installed in a plane that is perpendicular to the primary 
etched all the way through the wafer (about 700 um) using a 20 axis of capsule 600 (e.g., an axis that is parallel to the length 
Bosch DRIE process. This process lands on the buried oxide, 	 of cylindrical body 620 and concentric with cylindrical body 
which forms an effective etch stop. FIG. 17 presents a cross- 	 620). End portion 630 also comprises a recessed portion 640 
section of a test device at this stage of processing. This buried 	 configured to receive nanochannel delivery device 500. In 
oxide is then removed by a plasma etch. 	 certain embodiments, a glue or other boding agent may be 
A series of wet etches are done to remove all the sacrificial 25 used to secure nanochannel delivery device 500 in recessed 
materials. A short buffered HE etch, for about 5 minutes, is 	 portion 640. When assembled, nanochannel delivery device 
done to remove any residual oxide (of the buried oxide), as 	 500 can be inserted into recessed portion 640, and first cap 
well as to remove the PSG layer. The wafers are then wet- 	 610 may be fitted onto end portion 630. 
etched in an SC-1 solution (hot Ammonium hydroxide-hy- 	 During use, drugs (or any other substance administered via 
drogen peroxide mixture) for about 10 minutes to remove the 30 capsule 600) can pass from cylindrical body 620 to nanochan- 
TiN barrier at the top surface as well as at the bottom of the 	 nel delivery device via an inner volume 650 contained within 
inlet microchannels. The wafers are subjected to a piranha 	 cylindrical body 620. After diffusing through nanochannel 
etch for about 20 minutes to remove the copper in the inlet 	 delivery device 500 and into first cap 610, the administered 
microchannels. This is followed by another SC-1 etch to 	 substances can exit cap 610 via exit ports 615. In exemplary 
remove all the TiN from the sidewalls of the inlet microchan-  35 embodiments, the dimensions of exit ports 615 (and other 
nels. Finally, the Tungsten is removed from the nanochannels 	 aspects of capsule 610, such as inner volume 650 and cap 610) 
by placing the wafers in wafer hydrogen peroxide for 2 hours, 	 are large enough so that these features do not restrict the 
followed by a rinse with DI water. The wafers are then cleaned 
	
diffusion of the administered substance from capsule 600. As 
with Iso-Propyl Alcohol (IPA) to displace the water with IPA, 	 a result, the diffusion of the administered substance can be 
and the wafers are allowed to dry. 	 40 more precisely controlled by selecting the dimensions of 
Material Selection 	 nanochannel delivery device 500, particularly the dimensions 
Regardless of the protocol used to manufacture the 	 of nanochannels 505. Cap 610 may also provide dimensional 
nanochannel delivery device, the materials used during the 	 rigidity and protect nanochannel delivery device 500 from 
manufacturing process should be selected to successfully 	 mechanical damage and the incursion of biological tissue 
remove sacrificial materials while leaving the non-sacrificial 45 structures after implantation. 
materials. As shown in FIG. 18, the selection of a nanochan- 	 In certain embodiments, inner volume 650 is configured to 
nel "placeholder" (e.g., the sacrificial material used to fill the 	 minimize capture points for air bubbles. For example, inner 
space of the nanochannel) and nanochannel "ceiling" and 	 volume 650 may comprise radiused corners and surfaces that 
"floor" materials (e.g., the substrate and capping layers) 	 are not angled in a manner (when capsule 600 is installed) 
should be coordinated with the selection of a solvent or 50 which could trap air bubbles. 
etchant. Examples of suitable solvents and etchants that can 	 Referring now to FIGS. 21 and 22, capsule 700 is similar to 
be used to remove sacrificial materials while leaving the 	 the previously-described capsule 600. However, in this 
substrate and capping layers are shown in FIG. 18. It is 	 embodiment capsule 700 is fitted with a septum 760 on the 
understood that other combinations of materials may be uti- 	 end of cylindrical body 720 that is distal from end portion 
lized as well. 	 55 630. Septum 760 comprises a self-sealing material (e.g., sili- 
Post Wafer Processing 	 cone rubber) that permits injection of a therapeutic agent into 
During post wafer processing, each wafer is attached to a 	 inner volume 750 of cylindrical body 720. In certain embodi- 
tape-ring with an adhesive tape. A UV release tape is pre- 	 ments, a therapeutic agent can be injected with a hypodermic 
ferred since it has better adhesion. Since both surfaces of the 	 needle just prior to implantation of capsule 700. 
wafer have critical device structures, UV tape is attached to 60 	 Referring now to FIG. 23, a capsule 800 comprises com- 
both top and bottom surfaces. The wafers are then diced into 	 ponents equivalent to previously-described embodiments. 
individual die and cleaned. The tapeframe is then exposed to 	 However, this embodiment comprises a cap 825 that covers 
a UV light source to decrease the adhesion of the tape to the 	 septum 860. Cap 825 may comprise an orifice (not visible in 
surface. The dice are individually picked and placed into a 	 the perspective view of FIG. 21) configured to guide a needle 
bare-die holder using an automated pick and place sorter tool. 65 or other device used to penetrate septum 860 and inject a 
The tape on the top surface of the die is subsequently peeled 	 therapeutic agent into inner volume 850 of cylindrical body 
off manually. The dice are then individually placed in a final 
	
820. 
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Referring now to FIG. 24, a capsule 900 comprises a cylin- 	 volume of capsule 1300 (similar to the embodiments 
	
drical body 922 coupled to a separate end component 935 and 
	
described in FIGS. 27 -29). The inner volume of capsule 1300 
	
a cap 925. In this embodiment, cylindrical body 922 can be 	 may be divided into separate compartments so that each 
	
replaced with another cylindrical body having a different 	 nanochannel delivery device can be used to administer a 
length in order to vary the internal volume of capsule 900 (and 5 specific and distinct therapeutic agent. Capsule 1300 also 
	
the amount of therapeutic agent that capsule 900 can contain). 	 comprises an anchor member 1305 configured to serve as a 
	
Similar to previous embodiments, end component 935 com- 	 point at which a suture (not shown) can be attached to capsule 
	
prises an end portion 930 configured to receive cap 910. End 
	
1300 when it is installed. Anchor member 1305 may also be 
	
component 935 also comprises a recessed portion 940 con- 	 coupled to a string or other device (not shown) used to remove 
figured to receive nanochannel delivery device 500. 	 io or retrieve capsule 1300. 
	
Referring now to FIGS. 25 and 26, a capsule 1000 com- 	 Referring now to FIG. 31, another embodiment of a cap- 
	
prises a disc-shaped body 1020 with a cap 1010 comprising a 	 sule 1400 is shown. This capsule is a minimal covering of the 
	
series of exit ports 1015. In this embodiment, disc-shaped 
	
back and sides of the nanochannel device, such that the "res- 
	
body 1020 comprises a septum 1060 through which a thera- 	 ervoir" for a contained drug is limited to the volume of the 
peutic agent may be injected. As shown in the exploded view 15 macrochannels on the back of the chip (e.g., the nanochannel 
	
of FIG. 26, supports 1050 can be used to hold nanochannel 
	
delivery device), which is about 4.5 mm 3 for the embodiment 
	
delivery device 500 proximal to exit ports 1015. In this man- 	 shown in FIG. 8K. This embodiment canbe made particularly 
	
ner, a therapeutic agent contained within capsule 1000 is 	 small, for example 2 mmx2 mmx0.5 mm, and is, therefore, 
	
forced to pass through nanochannel delivery device 500 	 especially suited for implantation with very high potency 
proximal before exiting capsule 1000. 	 20 drugs into sensitive locations, e.g., glaucoma medication into 
	
In the embodiment shown in FIGS. 27 and 28, a capsule 	 the inner portion of the eye. 
	
1100 comprises a rectangular planar surface 1121 and an 	 Exemplary embodiments of the previously-described cap- 
	
arched surface 1120. Capsule 1100 also comprises a closed 	 sules can be sized so that the capsule may be implanted 
	
end 1125 and a septum 1160 that can be inserted into an open 	 subcutaneously. In specific embodiments, the capsule may 
end 1161. In the embodiment shown, septum 1160 covers the 25 have a diameter of 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 
	
entire open end 1161. In other embodiments, a septum may 	 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 
	
cover part of an open end, and a cap may cover the remaining 	 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 
	
portions. Similar to previously-described embodiments, sep- 	 4.3,4.4,4.5,4.6,4.7,4.8,4.9,5.0,6.0,7.0,8.0,9.0, 10.0, 11.0, 
	
tum 1160 is self-sealing and can be punctured with a needle to 	 12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0 or 20.0 mm. In 
insert a therapeutic agent. Capsule 1100 also comprises a first 30 other embodiments, the capsule may be greater than 20.0 mm 
	
recessed portion 1140 configured to receive nanochannel 
	
in diameter. 
	
delivery device 500, and a second recessed portion 1130 
	
In certain embodiments, the capsule may have a thickness 
	
configured to receive a cap 1110 comprising exit ports 1115. 	 of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9,1.0,1.1,1.2,1.3,1.4, 
	
An aperture 1135 extends through recessed portion 1140 into 	 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 
an inner volume 1150 bounded by rectangular planar surface 35 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 
	
1121, arched surface 1120, closed end 1125 and septum 1160. 	 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 
	
In this embodiment, a therapeutic agent can be contained 
	
5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 
	
within inner volume 1150 and dispensed through aperture 	 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7., 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 
	
1135, nanochannel delivery device 500, and exit ports 1115. 	 8. 5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9. 8, 
Referring now to FIG. 29, another embodiment of a cap-  40 9.9 or 10.0 mm. In other embodiments, the capsule may have 
	
sule 1200 is generally equivalent to capsule 1100, but com- 	 a thickness greater than 10.0 mm. 
	
prises features that accommodate two nanochannel delivery 	 In specific embodiments, a capsule may have a width of 1, 
	
devices (not shown). In this embodiment, capsule 1200 com- 	 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 
	
prises a rectangular planar surface 1221, arched surface 1220, 	 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 
closed end 1225 and septum 1260. Capsule 1200 also com-  45 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 
	
prises a pair of first recessed portion 1240 each configured to 	 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 
	
receive nanochannel delivery device (not shown), and a sec- 	 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 
	
ond pair of recessed portions 1230 each configured to receive 	 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 mm. In other 
	
a cap with exit ports (not shown). Each recessed portion 1240 	 embodiments, the capsule may have a width greater than 100 
comprises an aperture 1235 that provides fluid communica-  50 mm. 
	
tion between inner volume 1250 and the environment sur- 	 In specific embodiments, a capsule may have a length of 1, 
rounding capsule 1200. 	 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 
	
In certain embodiments, inner volume 1250 comprises 	 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 
	
separate, internal reservoirs in which each reservoir is in fluid 
	
38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 
communication with a single aperture 1235. The internal 55 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 
	
reservoirs may be separated by inner walls within aperture 	 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 
	
1235. In such embodiments, each reservoir may be filled with 
	
89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 
	
a separate therapeutic agent. Each nanochannel device can be 	 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 
	
configured to provide the preferred dosage of each individual 
	
116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 
therapeutic agent. 	 60 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 
	
Referring now to FIG. 30, another embodiment of a cap- 	 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 
	
sule 1300 is shown in an installed position so that it partially 	 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 
	
extends beneath an epidermal surface 1301 of a patient into 	 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 
	
which capsule 1300 has been inserted. Capsule 1300 com- 	 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 
prises multiple covers 1310 with exit ports 1315. Beneath 65 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199 or 
	
each cover 1310, a nanochannel delivery device is inserted 
	
200 mm. In other embodiments, the capsule may have a 
	
over an aperture that is in fluid communication with an inner 	 length greater than 200 mm. 
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It is noted that the various embodiments of capsules 
described in this disclosure comprise a cross-section that is 
nominally constant along the length of the capsule. Such an 
optional configuration can facilitate sliding removal from a 
surgical site within the body without damage to surrounding 
tissue. 
In exemplary embodiments a capsule may comprise suit-
able materials such as stainless steel, titanium, polyethere-
therkeytone, polysulfone, and other plastics and metals. In 
certain embodiments, a capsule may comprise coating(s) on 
the interior to provide an optimal environment for a therapeu-
tic substance and/or coating(s) on the exterior to prevent 
deleterious tissue encapsulation. In specific embodiments, 
the capsule may comprise color coding to indicate the model 
of the capsule or a particular characteristic (e.g., the thera-
peutic agent, rate of administering the agent, the capacity of 
the capsule, etc.). In certain embodiments, a capsule may 
comprise a translucent or transparent portion or component 
(e.g. a cap) to facilitate observation of the quantity of thera-
peutic agent contained within the capsule. For example, a 
translucent or transparent cap covering the nanochannel 
delivery device can allow a person to confirm the capsule is 
full by orienting the capsule so that the nanochannel delivery 
device is positioned towards the top of the capsule. A needle 
(or other loading device) can then penetrate the septum and 
the therapeutic agent can be injected into the capsule. When 
liquid appears on the top of the nanochannel delivery device 
(as viewed throughthe cap), the person filling the capsule will 
have an indication that the capsule is full. 
In-Vivo Refill Capability 
In certain applications of the nanochannel delivery device 
in a capsule, the duration of implant may be advantageously 
extendedby refilling the capsule while it remains in vivo. This 
facilitates the use of a shorter lifetime therapeutic agent which 
needs to be regularly replaced or a lower concentration thera-
peutic agent which needs to be regularly replenished. In some 
treatments, the minor surgical procedure of explanting and 
re-implanting a capsule can be replaced by a simpler refilling 
operation. Refill capability for the nanochannel device in a 
capsule should account for the operational characteristics of 
the system, including features and methods to support the 
refill procedure. 
In exemplary embodiments, a capsule using a nanochannel 
device releases molecules from within the capsule through 
the nanochannel device into the body; the contained fluid is 
generally not moved in or out of the capsule. The primary 
diffusion from the capsule is that of the molecules of the 
therapeutic agent. The vessel walls of a capsule using a 
nanochannel device should be stiff enough to prevent a vol-
ume change that would inadvertently "pump" fluid in or out. 
When a significant fraction of the therapeutic agent has dif-
fused out of the capsule, the capsule is still filled with the 
carrier fluid. Replacing this expended fluid with new fluid 
containing more therapeutic agent should occur with the vol-
ume of the capsule remaining nominally constant. Otherwise, 
either an internal low pressure can be created that can draw 
body fluids into the capsule or an internal high pressure can be 
created that can expel the carrier fluid into the body. 
Referring now to FIGS. 32A-32C, one embodiment with in 
vivo refill capability comprises a collapsible bladder 1510 
located within a capsule 1500 having a first end 1501, a 
second end 1502 and a primary axis 1503. FIG. 32A provides 
a cross-section view of capsule 1500, while FIGS. 32B and 
32C provide perspective views of cylindrical and disc-shaped 
embodiments, respectively. It is understood that disc-shaped 
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embodiments are not limited to the circular shape shown in 
FIG. 32C, but also includes other shapes, e.g., circular or 
rectangular. 
In exemplary embodiments, collapsible bladder 1510 can 
5 be constructed of a biocompatible elastic material, e.g. sili-
cone, and line the interior surface of capsule 1500. Bladder 
1510 can be filled with a therapeutic agent and then capsule 
1500 implanted in vivo into a patient (e.g. subcutaneously). 
During use, therapeutic agent molecules may exit the interior 
10 
of bladder 1510 through a nanochannel delivery device 1550, 
which is in fluid communication with bladder 1510. 
Nanochannel delivery device 1550 can control the diffusion 
rate of the therapeutic molecules as described in the embodi- 
15 ments above. 
Refill access to an inner bladder volume 1512 of bladder 
1510 can be provided through a port 1514 which extends 
through both capsule 1500 and bladder 1510. In exemplary 
embodiments, port 1514 may comprise a septum 1524 that 
20 can be penetrated by a needle 1534. In specific embodiments, 
septum 1524 is self-sealing when punctured by a needle. 
In certain embodiments, capsule 1500 comprises a second 
port 1516 placed on the same side of capsule 1500 as port 
1514. As used herein the "side" of capsule 1500 may include, 
25 but is not limited to, generally flat surfaces shown in FIG. 
32C. For example, if capsule 1500 is generally cylindrical as 
shown in FIG. 32B (e.g., circular in shape when viewed from 
ends 1501 or 1502), ports 1514 and 1516 are on the same side 
of capsule 1500 if they are generally aligned when viewed 
30 from end 1501 or 1502. Stated another way, a reference line 
1504 connecting ports 1514 and 1516 is generally parallel to 
primary axis 1503. If capsule 1500 is generally disc-shaped 
(e.g. surfaces 1508 or 1509 are generally flat) as shown in 
FIG. 32C, then ports 1514 and 1516 are on the same side if 
35 they are both located on either surface 1508 or 1509. In other 
embodiments comprising a disc-shaped capsule similar to 
that shown in FIG. 32C, the ports may be on the surfaces 
indicated by reference numbers 1501 and 1502 (i.e. the ends 
or "edges" of the disc-shape), rather than surfaces 1508 or 
40 1509. 
Placing ports 1514 and 1516 on the same side of capsule 
1500 allows accessibility to both ports externally from the 
outside of the patient's body. This configuration also provides 
access via port 1516 to a capsule volume 1513 that is exterior 
45 of bladder 1510, but within capsule 1500, to provide backfill 
air, fluid, etc., so that bladder 1510 may collapse as the 
expended carrier fluid is withdrawn from bladder 1510. In the 
embodiment shown, port 1516 extends through capsule 1500 
but does not extend through bladder 1510. Port 1516 there- 
50 fore provides access to capsule volume 1513 but does not 
provide access to inner bladder volume 1512. 
An example refill procedure includes: (1) palpating and 
orienting capsule 1500 so that ports 1514 and 1516 are easily 
accessed (e.g. directed towards the closest external skin sur- 
55 face of the patient); (2) inserting a backfill needle into the 
backfill port; (3) inserting an evacuation needle 1534 through 
port 1514 and septum 1524 into inner bladder volume 1512 of 
bladder 1510; (4) withdrawing the fluid contained within 
inner bladder volume 1512 of bladder 1510 via needle 1534; 
60 (5) withdrawing needle 1534 from port 1514 and septum 
1524; (6) inserting needle 1536 throughport 1516 and septum 
1526; and (7) inserting a refill needle 1544 (which is coupled 
to a reservoir—e.g., a syringe with new a therapeutic agent) 
through port 1514 and septum 1516; (8) injecting the new 
65 therapeutic agent fluid into the inner bladder volume 1512 of 
bladder 1510; (9) removing the needles 1544 and 1536. This 
embodiment may also contain internal protection features to 
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prevent the backfill, evacuation, or refill needles from touch- 	 from capsule 1700 and second lumen 1736 can be used to 
ing, puncturing, or otherwise damaging the bladder. 	 inject new therapeutic agent into capsule 1700 (or vice versa). 
Referring now to FIG. 33, another embodiment with in 	 With end portions 1744 and 1746 sufficiently separated 
vivo refill capability comprises a capsule 1600 with a 	 within capsule 1700, the injection and extraction of material 
nanochannel delivery device 1650, a first end 1601, a second 5 can be performed at the same time so that the new material 
end 1602 and two separated ports 1614 and 1616. As in the 	 displaces the expended material in an effort to maintain a 
previous embodiments, nanochannel delivery device 1650 	 constant volume and pressure within capsule 1700. 
can control the diffusion of molecules of a therapeutic agent 	 In exemplary embodiments, a capsule may be used to 
from capsule 1650. 	 administer one or more of the following substances: adrener- 
In this embodiment, capsule 1600 does not comprise an io gic agent; adrenocortical steroid; adrenocortical suppressant; 
internal bladder as described in the previous embodiment, but 	 aldosterone; alkylating agent; antagonist; amino acid; ana- 
is generally equivalent in other aspects. Capsule 1600 com- 	 bolic; analeptic; analgesic; anesthetic; anorexogenic; anti- 
prises a first port 1614 with a septum 1624 and a second port 	 acne agent; anti-adrenergic; anti-allergic; anti-alopecia 
1616 with a septum 1626 that are placed on the same side of 	 agent; anti-amebic; anti-anemic; anti-anginal; antiangio- 
capsule 1600 (in a manner similar to that described in the 15 genic, anti-anxiety; anti-arthritic; anti-asthmatic; anti-athero- 
embodiment shown in FIGS. 32A-32C). Capsule 1600 canbe 	 sclerotic; antibacterial; antibiotic; anticancer; anticholin- 
implanted in a patient and refilled with a therapeutic agent in 	 ergic; anticoagulant anticonvulsane antidepressant; 
the manner described below. 	 antidiabetic; antidiarrheal; antidiuretic; anti-dyskinetic; anti- 
With capsule 1600 implanted in a patient and ports 1614 	 emetic; anti-epileptic; antifibrinolytic; antifungal; anti-hem- 
and 1624 aligned to allow external access, a first needle 1634 20 orrhagic; antihistamine; anti-hypercalcemic, anti-hypercho- 
can be used to inject new therapeutic fluid while a second 	 lesterolaemic; anti-hyperlipidaemic; anti-hypertensive; anti- 
needle 1636 can be used to withdraw the expended fluid. First 	 hypertriglyceridemic; anti-hypotensive; anti-infective; anti- 
needle 1634 can be inserted through the patient's skin and 
	
inflammatory; anti-ischemic; antimicrobial; antimigraine; 
port 1614 so that it is in fluid communication with an inner 	 antimitotic; antimycotic; anti-nauseant; anti-neoplastic; anti- 
volume 1613 of capsule 1600. In addition, second needle 25 neutropenic; anti-obesity agent; anti -o steoporotic, antipara- 
1636 can be inserted through the patient's skin and port 1616 	 sitic; antiproliferative; antipsychotic; antiretroviral; anti-re- 
so that it is in fluid communication with inner volume 1613. 	 sorptives; anti-rheumatic; anti-seborrheic; antisecretory; 
In one exemplary embodiment, first needle 1634 is coupled 	 antispasmodic; antisclerotic; antithrombotic; antitumor; anti- 
to a syringe containing new (i.e., fresh, unused) therapeutic 	 ulcerative; antiviral; appetite suppressant bisphosphonate; 
agent, while second needle 1636 is coupled to an empty 3o blood glucose regulator; bronchodilator; cardiovascular 
syringe that can be used to withdraw fluid from inner volume 	 agent; central nervous system agent; contraceptive; cholin- 
1613. The plunger of the empty syringe can be pulled back 	 ergic; concentration aid; depressant; diagnostic aid; diuretic; 
slightly to create a small vacuum and then the plunger of the 	 DNA-containing agent, dopaminergic agent; estrogen recep- 
syringe with the new therapeutic agent is depressed to force 	 tor agonise fertility agent; fibrinolytic; fluorescent agent; free 
the new therapeutic agent fluid through needle 1634 and into 35 oxygen radical scavenger; gastric acid supressant; gas- 
capsule 1600. The expended fluid inside capsule 1600 will be 	 trointestinal motility effector; glucocorticoid; glutamatergic 
expelled through needle 1636 and into the empty syringe. In 	 agent; hair growth stimulant; hemostatic; histamine H2 
this manner, inner volume 1613 of capsule 1600 can be filled 	 receptor antagonist; hormone; hypocholesterolemic; 
with the new therapeutic agent. Since any residual expended 
	
hypoglycemic; hypolipidemic; hypotensive; imaging agent; 
fluid may dilute the new therapeutic agent, the new therapeu-  40 immunizing agent; immunomodulator; immunostimulant; 
tic agent syringe coupled to needle 1634 could contain a 	 immunosuppressant; interleukin, keratolytic; LHRH agonise 
larger volume than inner volume 1613 of capsule 1600. This 	 mood regulator; mucolytic; mydriatic; nasal decongestant; 
can insure a suitably high fraction of the final contents in 	 neuromuscular blocking agent; neuroprotective; NMDA 
capsule 1600 comprises the new therapeutic agent. 	 antagonist; non- hormonal sterol derivative; nootropic agent; 
In certain embodiments, an optional washout fluid may be 45 parasympathomimetic agent; plasminogen activator; platelet 
injected through port 1614 and withdrawn through port 1616 	 activating factor antagonist; platelet aggregation inhibitor; 
prior to the introduction of the new therapeutic agent fluid to 	 platinum-containing agent, psychotropic; radioactive agent; 
further eliminate residual expended fluid. In specific embodi- 	 raf antagonist, RNA-containing agent, scabicide; sclerosing 
ments, ports 1614 and 1616 should be maximally separated 	 agent; sedative; sedative-hypnotic; selective adenosine Al 
(e.g., first port 1614 is proximal to first end 1601 and second 5o antagonist; selective estrogen receptor modulator, serotonin 
port 1616 is proximal to second end 1602) for efficient expul- 	 antagonist; serotonininhibitor; serotonin receptor antagonist; 
sion of the expended fluid. 	 steroid; stimulant; thrombic agent; thyroid hormone; thyroid 
Referring now to FIG. 34, an exemplary embodiment com- 	 inhibitor; thyromimetic; tranquilizer; vasoconstrictor; 
prises a capsule 1700 comprising a nanochannel delivery 	 vasodilator; wound healing agent; xanthine oxidase inhibitor; 
device 1750, a single port 1716 and septum 1726 that pro-  55 and the like; Abacavir, Abacavir sulfate, abatacept Acarbose, 
vides access for both extracting expended fluid from capsule 	 Acetaminophen, Aciclovir, Adalimumab, Adapalene, Alen- 
1700 and injecting new therapeutic agent into capsule 1700. 	 dronate, Alendronate sodium, Alfuzosin, aliskiren, allopu- 
In this embodiment, a double or dual lumen needle 1735 	 rinol, alvimopan, ambrisentan, Aminocaproic acid, Amitrip- 
(comprising first lumen 1734 and second lumen 1736) may be 	 tyline hydrochloride, amlodipine, amlodipine besylate, 
used to inject and extract material. 	 6o amoxicillin, amoxicilline, Amphetamine, Anastrozole, Arip- 
In certain embodiments, first lumen 1734 comprises an end 
	
iprazole, annodafinil, Atazanavir, atenolol, Atomoxetine, 
portion 1744 that extends farther into capsule 1700 than does 	 atorvastatin calcium, atorvastatin, Atropine sulfate, Azelas- 
end portion 1746 of second lumen 1736. As shown in FIG. 34, 	 tine, azithromycin, Balsalazide, Benazepril, bendamustine 
first lumen 1734 extends into capsule 1750 a distance of D2, 	 hydrochloride, Benzepril hydrochloride, bevacizumab, 
which is greater than distance D1 that second lumen 1744 65 Bicalutamide, Bimatoprose Bisoprolol, Bisoprolol fumarate, 
extends into capsule 1700. With this configuration, first 	 Bosentan, Botulin toxin, Budesonide, Buformin, Buprenor- 
lumen 1734 can be used to extract or withdraw expended fluid 	 phine, Bupropion, bupropion hydrobromide, Bupropion 
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Hydrochloride, Cabergoline, Calcipotriol, calcitriol, cande- 	 sodium, Pioglitazone, Piperacillin, Potassium chloride, 
sartan cilexetil, Capecitabine, Captopril, carbidopa, cariso- 	 Pramipexole, Pravastatin, Pravastatin sodium, prednisolone 
prodol, Carvedilol, Caspofungin, Cefdinir, Cefoperazone, 	 quetiapine fumerate, Pregabalin, Primaquine phosphate, 
Cefotiam, cefprozil, Cefuroxime, Celecoxib, cephalaxin, 	 Progesterone, Promethazine, Promethazine hydrochloride, 
Certolizumab Pegol, Cetirizine, Cetrizine hydrochloride, 5 Proponolol hydrochloride, Propoxyphene hydrochloride, 
Cetuximab, Chlorpromazine hydrochloride, Chlorphe- 	 pseudoephedrine, Pseudophedrine hydrochloride, Pyri- 
niramine maleate, ciclesonide, Cilastatin, cimetidine, Cina- 	 dostigmine bromide, Pyridoxine hydrochloride, Quetiapine, 
calcet, Ciprofloxacin, citalopram hydrobromide, Clarithro- 	 quetiapine fumarate, Quinapril hydrochloride, Rabeprazole, 
mycin, 	 Clindamycin, 	 Clindamycin, 	 clindamycin 	 raloxifene, raltegravir, Ramipril, Ranitidine, Ranitidine 
hydrochloride, Clomipramine hydrochloride, Clonidine io hydrochloride, Recombinant factor VIII, retapamulin, 
hydrochloride, clopidogrel, Clopidogrel bisulfate, Cloxacil- 	 Rimonabant, Risedronate, Risedronate sodium, risperidone, 
lin Sodium, Co-Amoxiclav, Codeine phosphate, Colchicines, 	 Ritonavir, rituximab, Rivastigmine, rivastigmine tartrate, 
Colesevelam, cyclobenzaprine hydrochloride, Cyclophos- 	 Rizatriptan, Ropinirole, rosiglitazone, Rosiglitazone male- 
phamide, Cyclosporine, darbepoetin alfa, Darifenacin, 	 ate, Rosuvastatin, Rotavirus vaccine, rotigotine, Salbutamol, 
DCRM 197 protein, Desloratadine, desloratidine, Desmo-  15 Salbutamol sulfate, salmeterol, sapropterin dihydrochloride, 
pressin 	 sulfate, 	 Desoximetasone, 	 dexamethasone, 	 Sertraline, sertraline hydrochloride, Sevelamer, Sevoflurane, 
Diclofenac, Diethylcarbamazine citrate, difluprednate, 	 Sildenafil, sildenafil citrate, simvastatin, Simvastatin, Sita- 
diphenhydramine, Dipyridamole, DL-methionine, Doc- 	 gliptin, Sodium valproate, Solifenacin, Somatostatin, Soma- 
etaxel, Donepezil, doripenem, Dorzolamide, Doxazosin, 	 tropin, 	 Stavudine, 	 Sulfomethoxazole, 	 Sumatriptan, 
doxazosin mesylate, doxycydine, Drospirenone, Duloxetine, 20 Sumatriptan succinate, Tacrolimus, Tadalafil, tamoxifen cit- 
Dutasteride, eculizumab, Efavirenz, Emtricitabine, Enala- 	 rate, Tamsulosin, tamsulosin hydrochloride, Tegaserod, 
pril, enalapril maleate, Enoxaparin Sodium, Eprosartan, Erlo- 	 Telmisartan, temazepam, Temozolomide, temsirolimus, 
tinib, Erythromycin, Erythropoetin, Escitalopram, esomepra- 	 Tenofovir, Terazosin Hydrochloride, Terbinafine, Teri- 
zole, estradiol, Estrogen, Eszopiclone, etanercept, 	 paratide, testosterone, Tetracycline hydrochloride, Thalido- 
Ethembutol hydrochloride, Ethosuximide, ethynl estradiol, 25 wide, thymopentin, Timolol meleate, Tiotropium, tipranavir, 
etonogestrel, etoricoxib, etravirine, Exenatide, Ezetimibe, 	 Tolterodine, tolterodine tartrate, topiramate, topotecan, Tra- 
Ezetimibe, Factor VII, famotidine, Famotidine, Fenofibrate, 	 madol, Tramodol hydrochloride, trastuzumab, trazodone 
Fenofibrate, Fentanyl, Fentanyl citrate, Ferrous sulfate, Fex- 	 hydrochloride, trimethoprim, Valaciclovir, Valacyclovir 
ofenadine, fexofenadine hydrochloride, Filgrastim, Finas- 	 hydrochloride, Valproate semisodium, valsartan, Vancomy- 
teride, fluconazole, Fluoxetine hydrochloride, Fluticasone, 30 cin, Vardenafil, Varenicline, venlafaxine, Venlafaxine hydro- 
Fluvastatin, folic acid, Follitropin alfa, Follitropin beta, For- 	 chloride, Verapamil Hydrochloride, vildagliptin, Voglibose, 
moterol, Fosinopril sodium, Gabapentin, Gabapentin, Gem- 	 Voriconazole, Wafarin sodium acetylsalicylic acid, Zaleplon, 
citabine, glargine insulin, Glatiramer, glimepride, Goserelin, 	 Zidovudine, Ziprasidone, Zoledronate, Zolpidem, or phar- 
histrelin acetate, Human growth hormone, Hydralazine 	 maceutically acceptable salts thereof; 16-alpha fluoroestra- 
hydrochloride, Hydrocodone bitartrate, Hydroxyurea, 35 diol, 17-alpha dihydroequilenin, 17-alpha estradiol, 17-beta 
Hydroxyzine hydrochloride, Ibandronate, Imatinib, Imigluc- 	 estradiol, 17-hydroxyprogesterone, 1-dodecpyrrolidinone, 
erase, Imipenem, imiquimod, Indinavir sulfate, infliximab, 	 22-oxacalcitriol, 3-isobutyl-gammabutyric acid, 6-fluorour- 
Interferon beta-la, Ipratropium, Irbesartan, Irinotecan, Iso- 	 sodeoxycholic acid, 7-methoxytacrine, Abacavir, Abacavir 
niazid, Isosorbide moninitrate, ixabepilone, ketamine, keto- 	 sulfate, Abamectin, abanoquil, abatacept, abecarnil, abirater- 
conazole, Ketorolac, Lactobionate, Lamivudine, Lamivu-  40 one, Ablukast, Ablukast Sodium, Acadesine, acamprosate, 
dine, Lamotrigine, lameotide acetate, Lansoprazole, 	 Acarbose, Acebutolol, Acecainide Hydrochloride, Aceclid- 
lapatinib, laropiprant, Latanoprost, Letrozole, Leuprolide, 	 ine, aceclofenae, Acedapsone, Acedapsone, Aceglutamide 
Levalbuterol, Levamisole hydrochloride, Levetiracetam, 	 Aluminum, Acemannan, Acetaminophen, Acetazolamide, 
levocetirizine dihydrochloride, levodopa, Levofloxacin, 	 Acetohexamide, Acetohydroxamic Acid, acetomepregenol, 
levonorgestrel, Levothyroxine, levothyroxine sodium, 45 Acetophenazine Maleate, Acetosulfone Sodium, Acetylcho- 
Lidocaine, Linezolid, Lisdexamfetamine Dimesylate, Lisi- 	 line Chloride, Acetylcysteine, acetyl-L-carnitine, acetyl- 
nopril, Lispro insulin, Lopinavir, Loratadine, lorazepam, 	 methadol, Aciclovir, Acifran, acipimox, acitemate, Acitretin, 
Losartan potassium, maraviroc, Marinol, meclizine hydro- 	 Acivicin, Aclarubicin, aclatonium, Acodazole Hydrochlo- 
chloride, Meloxicam, Memantine, Meropenem, metaxalone, 	 ride, aconiazide, Acrisorcin, Acrivastine, Acronine, Actiso- 
metformin, Metformin Hydrochloride, methadone, methoxy 50 wide, Actodigin, Acyclovir, acylfulvene, Adatanserin Hydro- 
polyethylene glycol-epoetin beta, Methylphenidate, Meth- 	 chloride, adafenoxate, Adalimumab, Adapalene, adatanserin, 
ylphenidate hydrochloride, Metoprolol, Metoprolol tartrate, 	 adecypenol, adecypenol, Adefovir, adelmidrol, ademetion- 
metronidazole, Metronidazole, miglitol, Minocycline, 	 ine, Adenosine, Adinazolam, Adipheinine Hydrochloride, 
Minocycline hydrochloride, mirtazepine, Modafinil, 	 adiposin, Adozelesin, adrafinil, Adrenalone, Aiclometasone 
Mometasone, montelukast, Montelukast sodium, Morphine, 55 Dipropionate, airbutamine, alacepril, Alamecin, Alanine, 
Moxifloxacin, Mycophenolate mofetil, Naloxone, Naproxen 	 Alaproclate, alaptide, Albendazole, albolabrin, Albuterol, 
sodium, natalizumab, Neostigmine bromide, Niacin, Nicoti- 	 Alclofenae, Alcloxa, aldecalmycin, Aldesleukin, Aldioxa, 
namide, Nifedipine, Nifurtimox, nilotinib hydrochloride 	 Aletamine Hydrochloride, Alendronate, Alendronate 
monohydrate, nitrofurantoin, Nortriptyline hydrochloride, 	 Sodium, alendronic acid, alentemol, Alentemol Hydrobro- 
nystatin, olanzapine, Olanzepine, Olmesartan, olmesartan 60 wide, Aleuronium Chloride, Alexidine, alfacalcidol, Alfenta- 
medoxomil, olopatadine hydrochloride, Omalizumab, 	 nil Hydrochloride, alfuzosin, Algestone Acetonide, algluc- 
Omega-3 acid ethyl esters, Omeprazole, Ondansetron, Orl- 	 erase, Aliflurane, alinastine, Alipamide, aliskiren, Allantoin, 
istat, Oseltamivir, Oxaliplatin, Oxcarbazepine, Oxybytynin 	 Allobarbital, Allopurinol, Alonimid, alosetron, Alosetron 
chloride, oxycodone hydrochloride, Paclitaxel, Palivizumab, 	 Hydrochloride, Alovudine, Alpertine, alpha-idosone, Alpi- 
Pantoprazole, paracetamol, Paroxetine, paroxetine hydro-  65 dem, Alprazolam, Alprenolol Hydrochloride, Alprenoxime 
chloride, Pegylated interferon alfa-2a, Pemetrexed, Penicil- 	 Hydrochloride, Alprostadil, Alrestatin Sodium, Altanserin 
lamine, Penicillin V potassium, Phenformin, Phenytoin 	 Tartrate, Alteplase, Althiazide, Altretamine, altromycin B, 
US 8,632,510 B2 
33 34 
Alverinc Citrate, alvimopan, Alvircept Sudotox, Amadinone 
Acetate, Amantadine Hydrochloride, ambamustine, Ambo-
mycin, ambrisentan, Ambruticin, Ambuphylline, Ambuside, 
Amcinafal, Amcinonide, Amdinocillin, Amdinocillin Piv-
oxil, Amedalin Hydrochloride, amelometasone, Ameltolide, 5 
Amesergide, Ametantrone Acetate, amezinium metilsulfate, 
amfebutamone, Amfenac Sodium, Amfiutizole, Amicycline, 
Amidephrine Mesylate, amidox, Amifloxacin, amifostine, 
Amilcacin, Amiloride Hydrochloride, Aminacrine Hydro-
chloride, Aminobenzoate Potassium, Aminobenzoate io 
Sodium, Aminocaproic Acid, Aminoglutethimide, Amino-
hippurate Sodium, aminolevulinic acid, Aminophylline, 
Aminorex, Aminosalicylate sodium, Aminosalicylic acid, 
Amiodarone, Amiprilose Hydrochloride, Amiquinsin Hydro-
chloride, amisulpride, Amitraz, Amitriptyline Hydrochlo- 15 
ride, Amlexanox, amlodipine, amlodipine besylate, Amobar-
bital Sodium, Amodiaquine, Amodiaquine Hydrochloride, 
Amorolfine, Amoxapine, Amoxicillin, Amphecloral, 
Amphetamine, Amphetamine Sulfate, Amphomycin, 
Amphoterin B, Ampicillin, ampiroxieam, Ampyzine Sulfate, 20 
Amquinate, Amrinone, amrubicin, Amsacrine, Amylase, 
amylin, amythiamicin, Anagestone Acetate, anagrelide, 
Anakinra, ananain, anaritide, Anaritide Acetate, Anastrozole, 
Anazolene Sodium, Ancrod, andrographolide, Androstenedi-
one, Angiotensin Amide, Anidoxime, Anileridine, Anilopam 25 
Hydrochloride, Aniracetam, Anirolac, Anisotropine Methyl-
bromide, Anistreplase, Anitrazafen, anordrin, antagonist D, 
antagonist G, antarelix, Antazoline Phosphate, Anthelmycin, 
Anthralin, Anthramy ci antiandrogen, antiestrogen, antine-
oplaston, Antipyrine, antisense oligonucleotides, apadoline, 30 
apafant, Apalcillin Sodium, apaxifylline, Apazone, aphidi-
colin glycinate, Apixifylline, Apomorphine Hydrochloride, 
apraclonidine, Apraclonidine Hydrochloride, Apramycin, 
Aprindine, Aprindine Hydrochloride, aprosulate sodium, 
Aprotinin, Aptazapine Maleate, aptiganel, apurinic acid, apu- 35 
rinic acid, aranidipine, Aranotin, Arbaprostil, arbekicin, arbi-
dol, Arbutamine Hydrochloride, Arclofenin, Ardeparin 
Sodium, argatroban, Arginine, Argipressin Tannate, Aril-
done, Aripiprazole, armodafinil, arotinolol, Arpinocid, Arte-
flene, Artilide Fumarate, asimadoline, aspalatone, Asparagi- 40 
nase, Aspartic Acid, Aspartocin, asperfuran, Aspirin, 
aspoxicillin, Asprelin, Astemizole, Astromicin Sulfate, asu-
lacrine, atamestane, Atazanavir, Atenolol, atevirdine, Ati-
pamezole, Atiprosin Maleate, Atolide, Atomoxetine, atorvas-
tatin, Atorvastatin Calcium, Atosiban, Atovaquone, atpenin 45 
B, Atracurium Besylate, atrimustine, atrinositol, Atropine, 
Atropine sulfate, Auranofin, aureobasidin A, Aurothioglu-
cose, Avilamycin, Avoparcin, Avridine, Axid, axinastatin 1, 
axinastatin 2, axinastatin 3, Azabon, Azacitidinie, Azaclo-
rzine Hydrochloride, Azaconazole, azadirachtine, Azalanstat 50 
Dihydrochloride, Azaloxan Fumarate, Azanator Maleate, 
Azanidazole, Azaperone, Azaribine, Azaserine, azasetron, 
Azatadine Maleate, Azathioprine, Azathioprine Sodium, aza-
toxin, azatyrosine, azelaic acid, Azelastine, azelnidipine, 
Azepindole, Azetepa, azimilide, Azithromycin, Azlocillin, 55 
Azolimine, Azosemide, Azotomycin, Aztreonam, 
Azumolene Sodium, Bacampicillin Hydrochloride, baccatin 
III, Bacitracin, Baclofen, bacosideA, bacoside B, bactobola-
mine, balanol, balazipone, balhimycin, balofloxacin, bal-
salazide, Bambermycins, bambuterol, Bamethan Sulfate, 60 
Bamifylline Hydrochloride, Bamnidazole, baohuoside 1, 
Barmastine, bamidipine, Basic, Basifungin, Batanopride 
Hydrochloride, batebulast, Batelapine Maleate, Batimastat, 
beau vericin, Becanthone Hydrochloride, becaplermin, becli-
conazole, Beclomethasone Dipropionate, befloxatone, Bein- 65 
serazide, Belfosdil, Belladonna, Beloxamide, Bemesetron, 
Bemitradine, Bemoradan, Benapryzine Hydrochloride, 
Benazepril, Benazepril Hydrochloride, Benazeprilat, Benda 
calol Mesylate, bendamustine hydrochloride, Bendazac, 
Bendroflumethiazide, benflumetol, benidipine, Benorterone, 
Benoxaprofen, Benoxaprofen, Benoxinate Hydrochloride, 
Benperidol, Bentazepam, Bentiromide, Benurestat, Benzbro-
marone, Benzepril hydrochloride, Benzethonium Chloride, 
Benzetimide Hydrochloride, Benzilonium Bromide, Benzin-
dopyrine Hydrochloride, benzisoxazole, Benzocaine, ben-
zochlorins, Benzoctamine Hydrochloride, Benzodepa, ben-
zoidazoxan, Benzonatate, Benzoyl Peroxide, 
benzoylstaurosporine, Benzquinamide, Benzthiazide, benz-
tropine, Benztropine Mesylate, Benzydamine Hydrochlo-
ride, Benzylpenicilloyl Polylysine, bepridil, Bepridil Hydro-
chloride, Beractant, Beraprost, Berefrine, berlafenone, 
bertosamil, Berythromycin, besipirdine, betaalethine, 
betaclamycin B, Betamethasone, betamipron, betaxolol, 
Betaxolol Hydrochloride, Bethanechol Chloride, Bethani-
dine Sulfate, betulinic acid, bevacizumab, bevantolol, Bevan-
tolol Hydrochloride, Bezafibrate, Bialamicol Hydrochloride, 
Biapenem, Bicalutamide, Bicifadine Hydrochloride, Biclodil 
Hydrochloride, Bidisomide, bifemelane, Bifonazole, 
bimakalim, Bimatoprost, bimithil, Bindarit, Biniramycin, 
binospirone, bioxalomycin, Bipenamol Hydrochloride, 
Biperiden, Biphenamine Hydrochloride, biriperone, bisant-
rene, bisaramil, bi saziri dinylspen nine, bis-benzimid zole A, 
bis-benzimidazole B, bisnafide, Bisobrin Lactate, Bisoprolol, 
Bisoprolol fumarate, Bispyrithione Magsulfex, bistramide D, 
bistramide K, bistratene A, Bithionolate Sodium, Bitolterol 
Mesylate, Bivalirudin, Bizelesin, Bleomycin Sulfate, bol-
dine, Bolandiol Dipropionate, Bolasterone, Boldenone 
Undecylenate, Bolenol, Bolmantalate, bopindolol, Bosentan, 
Botulin toxin, Boxidine, brefeldin, breflate, Brequinar 
Sodium, Bretazenil, Bretylium Tosylate, Brifentanil Hydro-
chloride, brimonidine, Brinolase, Brocresine, Brocrinat, Bro-
foxine, Bromadoline Maleate, Bromazepam, Bromchlo-
renone, Bromelain, bromfenac, Brominidione, 
Bromocriptine, Bromodiphenhydramine Hydrochloride, 
Bromoxanide, Bromperidol, Bromperidol Decanoate, Bro-
mpheniramine Maleate, Broperamole, Bropirimine, Broti-
zolam, Bucainide Maleate, bucindolol, Buclizine Hydrochlo-
ride, Bucromar one, Budesonide, budipine, budotitane, 
Buformin, Bumetanide, Bunaprolast, bunazosin, Bunolol 
Hydrochloride, Bupicomide, Bupivacaine Hydrochloride, 
Buprenorphine, Buprenorphine Hydrochloride, Bupropion, 
bupropion hydrobromide, Bupropion Hydrochloride, Bura-
mate, Buserelin Acetate, Buspirone Hydrochloride, Busul-
fan, Butabarbital, Butacetin, Butaclamol Hydrochloride, 
Butalbital, Butamben, Butamirate Citrate, Butaperazine, 
Butaprost, Butedronate Tetrasodium, butenafine, Buterizine, 
buthioninc sulfoximine, Butikacin, Butilfenin, Butirosin Sul-
fate, Butixirate, butixocortpropionate, Butoconazole Nitrate, 
Butonate, Butopamine, Butoprozine Hydrochloride, Butor-
phanol, Butoxamine Hydrochloride, Butriptyline Hydrochlo-
ride, Cabergoline, Cactinomycin, Cadexomer Iodine, Caf-
feine, calanolide A, Calcifediol, Calcipotriene, calcipotriol, 
Calcitonin, Calcitriol, Calcium Undecylenate, calphostin C, 
Calusterone, Cambendazole, Cammonam Sodium, camon-
agrel, canary pox IL-2, candesartan, candesartan cilexetil, 
Candicidin, candoxatril, candoxatrilat, Canighbose, Can-
renoate Potassium, Canrenone, capecitabine, Capobenate 
Sodium, Capobenic Acid, Capreomycin Sulfate, capromab, 
capsaicin, Captopril, Capuride, Car bocysteine, Caracemide, 
Carbachol, Carbadox, Carbamazepine, Carbamide Peroxide, 
Carbantel Lauryl Sulfate, Carbaspirin Calcium, Carbazeran, 
carbazomycin C, Carbenicillin Potassium, Carbenoxolone 
Sodium, Carbetimer, carbetocin, Carbidopa, Carbidopa-
Levodopa, Carbinoxamine Maleate, Carbiphene Hydrochlo- 
US 8,632,510 B2 
35 
	
36 
ride, Carbocloral, Carbol-Fuchsin, Carboplatin, Carboprost, 	 hydrochloride, Clofibrate, Clonixeril, Clonixin, Clopamide, 
carbovir, carboxamide-amino-triazo-le, carboxyamidotriaz- 	 Clopenthixol, Cloperidone Hydrochloride, clopidogrel, Clo- 
ole, carboxymethylated beta-1,3-glucan, Carbuterol Hydro- 	 pidogrel bisulfate, Clopimozide, Clopipazan Mesylate, Clo- 
chloride, CaRest M3, Carfentanil Citrate, Carisoprodol, Car- 	 pirac, Cloprednol, Cloprostenol Sodium, Clorazepate Dipo- 
mantadine, Carmustine, CARN 700, Carnidazole, 5 tassium, 	 Clorethate, 	 Clorexolone, 	 Cloroperone 
Caroxazone, carperitide, Carphenazine Maleate, Carprofen, 	 Hydrochloride, Clorprenaline Hydrochloride, Clorsulon, 
Carsatrin Succinate, Cartazolate, carteolol, Carteolol Hydro- 	 Clortemine Hydrochloride, Closantel, Closiramine Acetu- 
chloride, Carubicin Hydrochloride, carvedilol, carvotroline, 	 rate, Clothiapine, Clothixamide Maleate Cloticasone Propi- 
Carvotroline Hydrochloride, carzelesin, Caspofungin, 	 onate, Clotrimazole, Cloxacillin Benzathine, Cloxacillin 
castanospermine, caurumonam, cebaracetam, cecropin B, io Sodium, Cloxyquin, Clozapine, Co-Amoxiclav, Cocaine, 
Cedefingol, Cefaclor, Cefadroxil, Cefamandole, Cefaparole, 	 Coccidioidin, Codeine, Codeine phosphate, Codoxime, 
Cefatrizine, Cefazaflur Sodium, Cefazolin, cefcapene piv- 	 Colchicine, Colesevelam, colestimide, Colestipol Hydro- 
oxil, cefdaloxime pentexil tosilate, Cefdinir, cefditoren piv- 	 chloride, Colestolone, Colforsin, Colfosceril Palmitate, 
oxil, Cefepime, cefetamet, Cefetecol, cefixime, cefluprenam, 	 Colistimethate Sodium, Colistin Sulfate, collismycin A, col- 
Cefinenoxime Hydrochloride, Cefinetazole, cefminlox, 15 lismycin B, Colterol Mesylate, combretastatin A4, com- 
cefodizime, Cefonicid Sodium, Cefoperazone, Cefoperazone 	 plestatin, conagenin, Conorphone Hydrochloride, contignas- 
Sodium, Ceforanide, cefoselis, Cefotaxime Sodium, 	 terol, contortrostatin, Cormethasone Acetate, Corticorelin 
Cefotetan, cefotiam, Cefoxitin, cefozopran, cefpimizole, 	 Ovine Tnflutate, Corticotropin, Cortisone Acetate, Cortiva- 
Cefpiramide, cefpirome, cefpodoxime proxetil, cefprozil, 	 zol, Cortodoxone, cosalane, costatolide, Cosyntropin, coti- 
Cefroxadine, cefsulodin, Ceftazidime, cefteram, ceftibuten, 2o nine, Coumadin, Coumermycin, crambescidin, Crilvastatin, 
Ceftizoxime Sodium, ceftriaxooe, Cefuroxme, celastrol, 	 crisnatol, Cromitrile Sodium, Cromolyn Sodium, Crotami- 
Celecoxib, celikalim, celiprolol, cepacidiineA, Cephacetrile 	 ton, cryptophycin, cucumariosid, Cuprimyxin, curacin A, 
Sodium, Cephalexin, Cephaloglycin, Cephaloridine, Cepha- 	 curdlan sulfate, curiosin, Cyclacillin, Cyclazocine, cycla- 
lothin Sodium, Cephapirin Sodium, Cephradine, cer- 	 zosin, Cyclindole, Cycliramine Maleate, Cyclizine, 
iclamine, cerivastatin, Cernletide, Ceronapril, Certolizumab 25 Cyclobendazole, cyclobenzaprine, cyclobenzaprine hydro- 
Pegol, certoparin sodium, Cetaben Sodium, Cetalkonium 	 chloride, cyclobut A, cyclobut G, cyclocapron, Cycloguanil 
Chloride, Cetamolol Hydrochloride, Cethuperazone, 	 Pamoate, Cycloheximide, cyclopentanthraquinones, Cyclo- 
cetiedil, cetirizine, Cetophenicol, Cetraxate Hydrochloride, 	 penthiazide, Cyclopentolate Hydrochloride, Cyclophenazine 
Cetrizine hydrochloride, cetrorelix, Cetuximab, Cetylpyri- 	 Hydrochloride, Cyclophosphamide, cycloplatam, Cyclopro- 
dinium Chloride, Chenodiol, Chlophedianol Hydrochloride, 30 pane, Cycloserine, cyclosin, Cyclosporine, cyclothialidine, 
Chloral Betaine, Chlorambucil, Chloramphenicol, Chlordan- 	 Cyclothiazide, cyclothiazomycin, Cyheptamide, cypemycin, 
toin, Chlordiazepoxide, Chlorhexidine Gluconate, chlorins, 	 Cyponamine Hydrochloride, Cyprazepam, Cyproheptadine 
Chlormadinone Acetate, chloroorienticin A, Chloroprocaine 	 Hydrochloride, Cyprolidol Hydrochloride, cyproterone, 
Hydrochloride, Chloropropamide, Chloroquine, chloroqui- 	 Cyproximide, Cysteamine, Cysteine Hydrochloride, Cystine, 
noxaline sulfonamide, Chlorothiazide, Chlorotrianisene, 35 Cytarabine, Cytarabine Hydrochloride, cytarabine ocfosfate, 
Chloroxine, Chloroxylenol, Chlorphe niramine Maleate, 	 cytochalasin B, cytostatin, Dacarbazine, dacliximab, dac- 
Chlorphenesin Carbamate, Chlorpheniramine maleate, Chlo- 	 timicin, Dactinomycin, daidzein, Daledalin Tosylate, dalfo- 
rpromazine, Chlorpromazine hydrochloride, Chlorpropam- 	 pristin, Dalteparin Sodium, Daltroban, Dalvastatin, danap- 
ide, Chlorprothixene, Chlortetracycline Bisulfate, Chlortha- 	 aroid, Danazol, Dantrolene, daphlnodorin A, dapiprazole, 
lidone, Chlorzoxazone, Cholestyramine Resin, Chromonar 4o dapitant, Dapoxetine Hydrochloride, Dapsone, Daptomycin, 
Hydrochloride, cibenzoline, cicaprost, Ciclafrine Hydro- 	 darbepoetin alfa, Darglitazone Sodium, darifenacin, darlucin 
chloride, Ciclazindol, ciclesonide, cicletanine, Ciclopirox, 	 A, Darodipine, darsidomine, Daunorubicin Hydrochloride, 
Cicloprofen, cicloprolol, Cidofovir, Cidoxepin Hydrochlo- 	 Dazadrol Maleate, Dazepinil Hydrochloride, Dazmegrel, 
ride, Cifenline, Ciglitazone, Ciladopa Hydrochloride, 	 Dazopride Fumarate, Dazoxiben Hydrochloride, DCRM 197 
cilansetron, Cilastatin, Cilastatin Sodium, Cilazapril, cilnid-  45 protein, Debrisoquin Sulfate, Decitabine, deferiprone, 
ipine, Cilobamine Mesylate, cilobradine, Cilofungin, cilosta- 	 deflazacort, Dehydrocholic Acid, dehydrodidemnin B, Dehy- 
zol, Cimaterol, Cimetidine, cimetropium bromide, Cinacal- 	 droepiandrosterone, delapril, Delapril Hydrochloride, 
cet, Cinalukast, Cinanserin Hydrochloride, Cinepazet 	 Delavirdine Mesylate, delequamine, delfaprazine, Delmadi- 
Maleate, Cinflumide, Cingestol, cinitapride, Cinnamedrine, 	 none Acetate, delmopinol, delphinidin, Demecarium Bro- 
Cinnarizine, cinolazepam, Cinoxacin, Cinperene, Cinro-  50 mide, Demeclocycline, Demecycline, Demoxepam, Deno- 
mide, Cintazone, Cintriamide, Ciot eronel, Cipamfylline, 	 fungin, deoxypyridinoline, Depakote, deprodone, Deprostil, 
Ciprefadol Succinate, Ciprocinonide, Ciprofibrate, Ciprof- 	 depsidomycin, deramciclane, dermatan sulfate, Desciclovir, 
loxacin, ciprostene, Ciramadol, Cirolemycin, Cis platin, 	 Descinolone Acetonide, Desfiurane, Desipramine Hydro- 
cisapride, cisatracuriumbesilate, Cisconazole, cis-porphyrin, 	 chloride, desirudin, Deslanoside, Desloratadine, deslorelin, 
cistinexine, citalopram, citalopram hydrobromide, Citena-  55 desmopressin, Desmopressin sulfate, desogestrel, Desonide, 
mide, citicoline, citreamicin alpha, cladribine, Clamoxyquin 	 Desoximetasone, desoxoamiodarone, Desoxy-corticoster- 
Hydrochloride, Clarithromycin, clausenamide, Clavulanate 	 one Acetate, detajmium bitartrate, Deterenol Hydrochloride, 
Potassium, Clazolam, Clazolimine, clebopride, Clemastine, 	 DetirelixAcetate, Devazepide, Dexamethasone, Dexamisole, 
Clentiazem Maleate, Clidinium Bromide, clinafloxacin, 	 Dexbrompheniramine Maleate, Dexchlorpheniramine Male- 
Clindamycin, clindamycin hydrochloride, Clioquinol, Cliox-  6o ate, Dexclamol Hydrochloride, Dexetimide, Dexfenflu- 
anide, Cliprofen, clobazam, Clobetasol Propionate, Clobeta- 	 ramine Hydrochloride, dexifosfamide, Deximafen, dexketo- 
sone Butyrate, Clocortolone Acetate, Clodanolene, Clodazon 	 profen, dexloxiglumide, Dexmedetomidine, Dexormaplatin, 
Hydrochloride, clodronic acid, Clofazimine, Clofibrate, Clo- 	 Dexoxadrol Hydrochloride, Dexpanthenol, Dexpemedolac, 
filium Phosphate, Cloge stone Acetate, Clomacran Phos- 	 Dexpropranolol Hydrochloride, Dexrazoxane, dexsotalol, 
phate, Clomegestone Acetate, Clometherone, clomethiazole, 65 dextrin 2-sulphate, Dextroamphetamine, Dextromethorphan, 
clomifene ana logues, Clominorex, Clomiphene, Clomi- 	 Dextrorphan Hydrochloride, Dextrothyroxine Sodium, dex- 
pramine Hydrochloride, Clonazepam, Clonidine, Clonidine 	 verapamil, Dezaguanine, dezinamide, dezocine, Diacetolol 
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Hydrochloride, Diamocaine Cyclamate, Diapamide, Diatri- 	 Sodium, Ethacrynic Acid, Ethambutol Hydrochloride, 
zoate Meglumine, Diatrizoic Acid, Diaveridine, Diazepam, 	 Ethamivan, Ethanolamine Oleate, Ethehlorvynol, Ethembu- 
Diaziquone, Diazoxide, Dibenzepin Hydrochloride, Diben- 	 tol hydrochloride, Ethinyl estradiol, Ethiodized Oil, Ethiona- 
zothiophene, Dibucaine, Dichliorvos, Dichloralphenazone, 	 mide, Ethonam Nitrate, Ethopropazine Hydrochloride, Etho- 
Dichlorphenamide, Dicirenone, Diclofenac, Diclofenac 5 suximide, 	 Ethosuximide, 	 Ethotoin, 	 Ethoxazene 
Sodium, Dicloxacillin, dicranin, Dicumarol, Dicyclomine 	 Hydrochloride, Ethybenztropine, Ethyl Chloride, Ethyl 
Hydrochloride, Didanosine, didemnin B, didox, Dienestrol, 	 Dibunate, Ethylestrenol, Ethyndiol, Ethynerone, ethynl estra- 
dienogest, Diethylcarbamazine Citrate, diethylhomosper- 	 diol, Ethyndiol Diacetate, Etibendazole, Etidocaine, Etidr- 
mine, diethylnorspermine, Diethylpropion Hydrochloride, 	 onate Disodium, Etidronic Acid, Etifenin, Etintidine Hydro- 
Diethylstilbestrol, Difenoximide Hydrochloride, Difenoxin, io chloride, etizolam, Etodolac, Etofenamate, Etoformin 
Diflorasone Diacetate, Difloxacin Hydrochloride, Difluanine 	 Hydrochloride, Etomidate, Etonogestrel, Etoperidone 
Hydrochloride, Diflucortolone, Diflumidone Sodium, 	 Hydrochloride, Etoposide, Etoprine, etoricoxib, Etoxadrol 
Diflunisal, Difluprednate, Diftalone, Digitalis, Digitoxin, 	 Hydrochloride, Etozolin, etrabamine, etravirine, Etretinate, 
Digoxin, Dihexyverine Hydrochloride, dihydrexidine, dihy- 	 Etryptamine Acetate, Eucatropine Hydrochloride, Eugenol, 
dro-5-azacytidine, Dihydrocodeine Bitartrate, Dihydroer-  15 Euprocin Hydrochloride, eveminomicin, Exametazime, 
gotamine Mesylate, Dihydroestosterone, Dihydrostreptomy- 	 examorelin, Exaprolol Hydrochloride, exemestane, 
cin Sulfate, Dihydrotachysterol, Dilantin, Dilevalol 
	
Exenatide, Ezetimibe, Ezetimibe, Factor VII, fadrozole, fae- 
Hydrochloride, Diltiazem Hydrochloride, Dimefadane, 	 riefungin, Famciclovir, Famotidine, Fampridine, fantofarone, 
Dimefline Hydrochloride, Dimenhydrinate, Dimercaprol, 	 Fantridone Hydrochloride, faropenem, fasidotril, fasudil, 
Dimethadione, Dimethindene Maleate, Dimethisterone, 20 fazarabine, fedotozine, Felbamate, felbamate, Felbinac, 
Dimethyl Sulfoxide, dimethylhomospermine, dimethylpros- 	 Felodipine, Felypressin, Fenalamide, Fenamole, Fenbenda- 
taglandin Al, dimiracetam, Dimoxamine Hydrochloride, 	 zole, Fenbufen, Fencibutirol, Fenclofenac, Fenclonine, Fen- 
Dinoprost, Dinoprostone, Dioxadrol Hydrochloride, dioxa- 	 clorac, Fendosal, Fenestrel, Fenethylline Hydrochloride, 
mycin, diphenhydramine, Diphenhydramine Citrate, 	 Fenfluramine Hydrochloride, Fengabine, Fenimide, Fen- 
Diphenidol, Diphenoxylate Hydrochloride, diphenylspiro-  25 isorex, Fenmetozole Hydrochloride, Feumetramide, 
mustine, Dipivefin Hydrochloride, Dipivefrin, diplien- 	 Fenobam, Fenoctimine Sulfate, Fenofibrate, fenoldopam, 
cyprone, diprafenone, dipropylnorspermine, Dipyridamole, 	 Fenoprofen, Fenoterol, Fenpipalone, Fenprinast Hydrochlo- 
Dipyrithione, Dipyrone, dirithromycin, discodermolide, Dis- 	 ride, Fenprostalene, Fenquizone, fenretinide, fenspiride, fen- 
obutamide, Disofenin, Disopyramide, Disoxaril, disulfiram, 	 tanyl, Fentanyl Citrate, Fentiazac, Fenticlor, fenticonazole, 
Ditekiren, Divalproex Sodium, Dizocilpine Maleate, DL-me-  so Fenyripol Hydrochloride, fepradinol, ferpifosate sodium, fer- 
thionine, Dobutamine, docarpamine, Docebenone, Doc- 	 ristene, ferrixan, Ferrous Sulfate, Ferumoxides, ferumoxsil, 
etaxel, Doconazole, docosanol, dofetilide, dolasetron, Done- 	 Fetoxylate Hydrochloride, Fexofenadine, fexofenadine 
pezil, doripenem, Dorzolamide, Doxazosin, doxazosin 	 hydrochloride, Fezolamine Fumarate, Fiacitabine, Fialuri- 
mesylate, doxycydine, Drospirenone, Duloxetine, Dutast- 	 dine, fibmoxef, Fibrinogen, Filgrastim, Filipin, Finasteride, 
eride, Ebastine, ebiratide, ebrotidine, ebselen, ecabapide, 35 fiorfenicol, fiorifenine, fiosatidil, fiumecinol, fiunarizine, 
ecabet, ecadotril, 	 ecdisteron, 	 echicetin, 	 echistatin, 	 fiuparoxan, fiupirtine, fiurithromycin, fiutrimazole, fiuvasta- 
Echothiophate Iodide, Eclanamine Maleate, Eclazolast, eco- 	 tin, fiuvoxamine, Flavodilol Maleate, flavopiridol, Flavoxate 
mustine, Econazole, ecteinascidin 722, eculizumab, edara- 	 Hydrochloride, Flazalone, flecainide, flerobuterol, Fleroxa- 
vone, Edatrexate, edelfosine, Edifolone Acetate, edobaco- 	 cin, flesinoxan, Flestolol Sulfate, Fletazepam, flezelastine, 
mab, Edoxudine, edrecolomab, Edrophonium Chloride, 40 flobufen, Floctafenine, Flordipine, Flosequinan, Floxacillin, 
edroxyprogesteone Acetate, Efavirenz, efegatran, eflorni- 	 Floxuridine, fluasterone, Fluazacort, Flubanilate Hydrochlo- 
thine, efonidipine, egualcen, Elantrine, eleatonin, elemene, 	 ride, Flubendazole, Flucindole, Flucloronide, Fluconazole, 
eletriptan, elgodipine, eliprodil, Elsamitrucin, eltenae, 	 Flucytosine, Fludalanine, Fludarabine Phosphate, Fludazo- 
Elucaine, emailcalim, emedastine, Emetine Hydrochloride, 	 nium Chloride, Fludeoxyglucose, Fludorex, Fludrocortisone 
emiglitate, Emilium Tosylate, emitefur, emoctakin, Emtricit-  45 Acetate, Flufenamic Acid, Flufenisal, Flumazenil, Flume- 
abine, Enadoline Hydrochloride, Enailciren, enalapril, enala- 	 quine, Flumeridone, Flumethasone, Flumetramide, Flumeza- 
pril maleate, enazadrem, Encyprate, Endralazine Mesylate, 	 pine, Fluminorex, Flumizole, Flumoxonide, Flunidazole, 
Endrysone, Enflurane, englitazone, Enilconazole, Eniso- 	 Flunisolide, Flunitrazepam, Flunixin, fluocalcitriol, Fluoci- 
prost, Enlimomab, Enloplatin, Enofelast, Enolicam Sodium, 	 nolone Acetonide, Fluocinonide, Fluocortin Butyl, Fluocor- 
Enoxacin, enoxacin, enoxaparin sodium, Enoxaparin 50 tolone, Fluorescein, fluorodaunorunicin hydrochloride, Fluo- 
Sodium, Enoximone, Enpiroline Phosphate, Enprofylline, 	 rodopa, Fluorometholone, Fluorouracil, Fluotracen 
Enpromate, 	 entacapone, 	 enterostatin, 	 Enviradene, 	 Hydrochloride, Fluoxetine, Fluoxetine hydrochloride, Flu- 
Enviroxime, Ephedrine, Epicillin, Epimestrol, Epinephrine, 	 oxymesterone, Fluperamide, Fluperolone Acetate, Fluphena- 
Epinephryl Borate, Epipropidine, Epirizole, epirubicin, 	 zine Decanoate, Fluprednisolone, Fluproquazone, Flupros- 
Epitetracycline Hydrochloride, Epithiazide, Epoetin Alfa, 55 tenol Sodium, Fluquazone, Fluradoline Hydrochloride, 
Epoetin Beta, Epoprostenol, Epoprostenol Sodium, 	 Flurandrenolide, Flurazepam Hydrochloride, Flurbiprofen, 
epoxymexrenone, epristeride, Eprosartan, eptastigmine, 	 Fluretofen, Flurocitabine, Flurofamide, Flurogestone 
equilenin, Equilin, Erbulozole, erdosteine, Ergoloid Mesy- 	 Acetate, Flurothyl, Fluroxene, Fluspiperone, Fluspirilene, 
lates, Ergonovine Maleate, Ergotamine Tartrate, Erlotinib, 	 Fluticasone, Fluticasone Propionate, Flutroline, Fluvastatin, 
ersentilide, Ersofermin, erythritol, Erythrityl Tetranitrate, 6o Fluvastatin Sodium, Fluzinamide, Folic Acid, Follicle regu- 
Erythromycin, Erythropoetin, Escitalopram, Esmolol Hydro- 	 latory protein, Folliculostatin, Follitropin alfa, Follitropin 
chloride, esomeprazole, Esorubicin Hydrochloride, Espro- 	 beta, Fomepizole, Fonazine Mesylate, forasartan, forfen- 
quin Hydrochloride, Estazolam, Estradiol, Estramustine, 	 imex, forfenirmex, formestane, Formocortal, formoterol, 
Estrazinol Hydrobromide, Estriol, Estrofurate, Estrogen, 	 Fosarilate, Fosazepam, Foscarnet Sodium, fosfomycin, Fos- 
Estrone, Estropipate, esuprone, Eszopiclone, Etafedrine 65 font Sodium, fosinopril, Fosinopril sodium, Fosinoprilat, 
Hydrochloride, etanercept, Etanidazole, etanterol, Etarotene, 	 fosphenytoin, Fosquidone, Fostedil, fostriecin, fotemustine, 
Etazolate Hydrochloride, Eterobarb, ethacizin, Ethacrynate 	 Fuchsin, Fumoxicillin, Fungimycin, Furaprofen, Furazoli- 
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done, Furazolium Chloride, Furegrelate Sodium, Furobufen, 	 tropium, Ipratropium Bromide, ipriflavone, Iprindole, Ipro- 
Furodazole, Furosemide, Fusidate Sodium, Fusidic Acid, 	 fenin, Ipronidazole, Iproplatin, Iproxamine Hydrochloride, 
Gabapentin, Gadobenate Dimeglumine, gadobenic acid, 	 ipsapirone, irbesartan, irinotecan, irloxacin, iroplact, irsogla- 
gadobutrol, Gadodiamide, gadolinium texaphyrin, Gadopen- 	 din, Irtemazole, isalsteine, Isamoxole, isbogrel, Isepamicin, 
tetate Dimegiumine, gadoteric acid, Gadoteridol, Gadover-  5 isobengazole, Isobutamben, Isocarboxazid, Isoconazole, Iso- 
setamide, galantamine, galdansetron, Galdansetron Hydro- 	 etharine, isofloxythepin, Isoflupredone Acetate, Isoflurane, 
chloride, Gallamine Triethiodide, gallium nitrate, gallopamil, 	 Isoflurophate, isohomohalicondrin B, Isoleucine, Isomazole 
galocitabine, Gamfexine, gamolenic acid, Ganciclovir, 	 Hydrochloride, Isomylamine Hydrochloride, Isoniazid, Iso- 
ganirelix, Gemcadiol, Gemcitabine, Gemeprost, Gemfi- 	 propamide Iodide, Isopropyl Alcohol, isopropyl unopros- 
brozil, Gentamicin Sulfate, Gentian Violet, gepirone, Gesta-  10 tone, Isoproterenol Hydrochloride, Isosorbide, Isosorbide 
clone, Gestodene, Gestonorone Caproate, Gestrinone, Gev- 	 Mononitrate, Isotiquimide, Isotretinoin, Isoxepac, Isoxicam, 
otroline Hydrochloride, girisopam, glargine insulin, 	 Isoxsuprine Hydrochloride, isradipine, itameline, itasetron, 
glaspimod, Glatiramer, glaucocalyxinA, Glemanserin, Glia- 	 Itazigrel, itopride, Itraconazole, Ivermectin, ixabepilone, jas- 
milide, Glibomuride, Glicetanile Sodium, Glifiumide, 	 plakinolide, Jemefloxacin, Jesopitron, Josamycin, kahalalide 
Glimepiride, Glipizide, Gloximonam, Glucagon, glutapy-  15 F, Kalafungin, Kanamycin Sulfate, ketamine, Ketanserin, 
rone, Glutethimide, Glyburide, glycopine, glycopril, Glyco- 	 Ketazocine, Ketazolam, Kethoxal, Ketipramine Fumarate, 
pyrrolate, Glyhexamide, Glymidine Sodium, Glyoctamide, 	 Ketoconazole, Ketoprofen, Ketorfanol, ketorolac, Ketotifen 
Glyparamide, Gold Au-198, Gonadoctrinins, Gonadorelin, 	 Fumarate, Kitasamycin, Labetalol Hydrochloride, Lacid- 
Gonadotropins, Goserelin, Gramicidin, Granisetron, grepa- 	 ipine, lacidipine, lactitol, lactivicin, Lactobionate, laennec, 
floxacin, Griseofulvin, Guaiapate, Guaithylline, Guanabenz, 20 lafutidine, 1-alphahydroxyvitamin D2, lamellarin-N triac- 
Guanabenz Acetate, Guanadrel Sulfate, Guancydine, 	 etate, lamifiban, Lamivudine, Lamotrigine, lanoconazole, 
Guanethidine Monosulfate, Guanfacine Hydrochloride, 	 Lanoxin, lanperisone, lanreotide, lanreotide acetate, Lanso- 
Guanisoquin Sulfate, Guanoclor Sulfate, Guanoctine Hydro- 	 prazole,lapatinib,laropiprant,latanoprost,lateritin,lauroca- 
chloride, Guanoxabenz, Guanoxan Sulfate, Guanoxyfen Sul- 	 pram, Lauryl Isoquinolinium Bromide, Lavoltidine Succi- 
fate, Gusperimus Trihydrochloride, Halazepam, Halcinon-  25 pate, lazabemide, Lecimibide, leinamycin, lemildipine, 
ide, halichondrin B, Halobetasol Propionate, halofantrine, 	 leminoprazole, lenercept, Leniquinsin, lenograstim, Lenper- 
Halofantrine Hydrochloride, Halofenate, Halofuginone 	 one, lentinan sulfate, leptin, leptolstatin, lercanidipine, Ler- 
Hydrobromide, halomon, Halopemide, Haloperidol, halopre- 	 gotrile, lerisetron, Letimide Hydrochloride, letrazuril, letro- 
done, Haloprogesterone, Haloprogin, Halothane, Halquinols, 	 zole, Leucine, leucomyzin, leuprolide, Leuprolide Acetate, 
Hamycin, hatomamicin, hatomarubigin A, hatomarubigin B, 30 leuprorelin, Levalbuterol, Levamfetamine Succinate, levami- 
hatomarubigin C, hatomarubigin D, Heparin Sodium, hep- 	 sole, Levdobutamine Lactobionate, Leveromakalim, leveti- 
sulfam, heregulin, Hetacillin, Heterooium Bromide, 	 racetam, Leveycloserine, levobetaxolol, levobunolol, 
Hexachlorophene :Hydrogen Peroxide, Hexafluorenium 	 levobupivacaine, levocabastine, levocarnitine, levocetirizine, 
Bromide, hexamethylenebisacetamide, Hexedine, Hexoben- 	 levocetirizine dihydrochloride, Levodopa, levodropropizine, 
dine, Hexoprenaline Sulfate, Hexylresorcinol, Histamine 35 levofloxacin, Levofuraltadone, Levoleucovorin Calcium, 
Phosphate, Histidine, Histoplasmin, Histrelin, histrelin 	 Levomethadyl Acetate, Levomethadyl Acetate Hydrochlo- 
acetate, Homatropine Hydrobromide, Hoquizil Hydrochlo- 	 ride, levomoprolol, Levonantradol Hydrochloride, Levonor- 
ride, Human chorionic gonadotropin, Human growth hor- 	 defrin, Levonorgestrel, Levopropoxyphene Napsylate, Levo- 
mone, Hycanthone, Hydralazine Hydrochloride, Hydrala- 	 propylcillin Potassium, levormeloxifene, Levorphanol 
zine Polistirex, Hydrochlorothiazide, Hydrocodone 4o Tartrate, levosimendan, levosulpiride, Levothyroxine, 
Bitartrate, Hydrocortisone, Hydroflumethiazide, Hydromor- 	 Levothyroxine Sodium, Levoxadrol Hydrochloride, Lexi- 
phone Hydrochloride, Hydroxyamphetamine Hydrobro- 	 pafant, Lexithromycin, liarozole, Libenzapril, Lidamidine 
mide, Hydroxychloroquine Sulfate, Hydroxyphenamate, 	 Hydrochloride, Lidocaine, Lidofenin, Lidoflazine, Lifarizin, 
Hydroxyprogesterone Caproate, Hydroxyurea, Hydroxyzine 	 Lifibrate, Lifibrol, Linarotene, Lincomycin, Linezolid, 
Hydrochloride, Hymecromone, Hyoscyamine, hypericin, 45 Linogliride, Linopirdine, linotroban, linsidomine, lintitript, 
Ibafloxacin, Ibandronate, ibogaine, Ibopam, ibudilast, 	 lintopride, Liothyronine I-125, liothyronine sodium, Liotrix, 
Ibufenac, Ibuprofen, Ibutilide Fumarate, Icatibant Acetate, 	 lirexapride, Lisdexamfetamine Dimesylate, lisinopril, Lispro 
Ichthammol, Icotidine, idarubicin, idoxifene, Idoxuridine, 	 insulin, lissoclinamide, Lixazinone Sulfate, lobaplatin, 
idramantone, Ifetroban, Ifosfamide, Ilepeimide, illi- 	 Lobenzarit Sodium, Lobucavir, locarmate Meglumine, locar- 
maquinone, ilmofosin, ilomastat, Ilonidap, iloperidone, ilo-  50 mic Acid, locetamic Acid, lodamide, Lodelaben, lodipamide 
prost, Imafen Hydrochloride, Imatinib, Imazodan Hydro- 	 Meglumine, lodixanol, lodoantipyrine I-131, lodocholesterol 
chloride, imidapril, imidazenil, imidazoacridone, Imidecyl 
	
I-131, lodohippurate Sodium I-131, lodopyracet I-125, 
Iodine, Imidocarb Hydrochloride, Imidoline Hydrochloride, 	 lodoquinol, lodoxamate Meglumine, lodoxamide, lodoxamie 
Imidurea, Imiglucerase, Imiloxan Hydrochloride, Imipenem, 	 Acid, Lofemizole Hydrochloride, Lofentanil Oxalate, 
Imipramine Hydrochloride, imiquimod, Impromidine 55 Lofepramine Hydrochloride, lofetamine Hydrochloride 
Hydrochloride, Indacrinone, Indapamide, Indecainide 	 I-123, Lofexidine Hydrochloride, loglicic Acid, loglucol, 
Hydrochloride, Indeloxazine Hydrochloride, Indigotindisul- 	 loglucomide, loglycamic Acid, logulamide, lohexol, lombri- 
fonate Sodium, indinavir, Indinavir sulfate, Indocyanine 	 cine, Lomefloxacin, lomerizine, lomethin I-125, Lometraline 
Green, Indolapril Hydrochloride, Indolidan, indometacin, 	 Hydrochloride, lometrexol, Lomofungin, Lomoxicam, 
Indomethacin Sodium, Indoprofen, indoramin, Indorenate 6o Lomustine, Lonapalene, lonazolac, lonidamine, lopamidol, 
Hydrochloride, Indoxole, Indriline Hydrochloride, inflix- 	 lopanoic Acid, Loperamide Hydrochloride, lophendylate, 
imab, inocoterone, inogatran, inolimomab, Inositol Niaci- 	 Lopinavir, loprocemic Acid, lopronic Acid, lopydol, lopy- 
nate, Insulin, Interferon beta-la, Intrazole, Intriptyline 	 done, loracarbef, Lorajmine Hydrochloride, loratadine, 
Hydrochloride, iobenguane, Iobenzamic Acid, iobitridol, 	 Lorazepam, Lorbamate, Lorcainide Hydrochloride, Lore- 
Iodine, iodoamiloride, iododoxorubicin, iofratol, iomeprol, 65 clezole, Loreinadol, lorglumide, Lormetazepam, Lomoxi- 
iopentol, iopromide, iopyrol, iotriside, ioxilan, ipazilide, 	 cam, lornoxicam, Lortalamine, Lorzafone, losartan, Losartan 
ipenoxazone, ipidacrine, Ipodate Calcium, ipomeanol, Ipra- 	 potassium, losefamic Acid, loseric Acid, losigamone, losox- 
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antrone, losulamide Meglumine, Losulazine Hydrochloride, 	 Minocycline, Minocycline hydrochloride, Minoxidil, 
losumetic Acid, lotasul, loteprednol, lotetric Acid, lothala- 	 Mioflazine Hydrochloride, miokamycin, mipragoside, mir- 
mate Sodium, lothalamic Acid, lotrolan, lotroxic Acid, lov- 	 fentanil, mirimostim, Mirincamycin Hydrochloride, 
astatin, loversol, loviride, loxagiate Sodium, loxaglate 	 Mirisetron Maleate, Mirtazapine, Misonidazole, Misopros- 
Meglumine, loxaglic Acid, Loxapine, Loxoribine, loxotri-  5 tol, Mitindomide, Mitocarcin, Mitocromin, Mitogillin, 
zoic Acid, lubeluzole, Lucanthone Hydrochloride, Lufironil, 	 mitoguazone, mitolactol, Mitomalcin, Mitomycin, mitona- 
Lurosetron Mesylate, lurtotecan, lutetium, Lutrelin Acetate, 	 fide, Mitosper, Mitotane, mitoxantrone, mivacurium chlo- 
luzindole, Lyapolate Sodium, Lycetamine, lydicamycin, 	 ride, mivazerol, mixanpril, Mixidine, mizolastine, mizorib- 
Lydimycin, Lynestrenol, Lypressin, Lysine, lysofylline, lyso- 	 ine, Moclobemide, modafinil, Modaline Sulfate, 
staphin, Maduramicin, Mafenide, magainin 2 amide, Magne-  io Modecainide, moexipril, mofarotene, Mofegiline Hydro- 
sium Salicylate, Magnesium Sulfate, magnolol, maitansine, 	 chloride, mofezolac, molgramostim, Molinazone, Molin- 
Malethamer, mallotoaponin, mallotochromene, Malotilate, 	 done Hydrochloride, Molsidomine, mometasone, Monatepil 
malotilate, mangafodipir, manidipine, maniwamycin A, 	 Maleate, Monensin, Monoctanoin, montelukast, Mon- 
Mannitol, mannostatin A, manumycin E, manumycin F, 	 telukast Sodium, montirelin, mopidamol, moracizine, Mor- 
mapinastine, Maprotiline, maraviroc, marimastat, Marinol, 15 antel Tartrate, Moricizine, Morniflumate, Morphine, Mor- 
Masoprocol, maspin, massetolide, Maytansine, Mazapertine 	 rhuate Sodium, mosapramine, mosapride, motilide, 
Succiniate, Mazindol, Mebendazole, Mebeverine Hydro- 	 Motretinide, Moxalactam Disodium, Moxazocine, Moxi- 
chloride, Mebrofenin, Mebutamate, Mecamylamine Hydro- 	 floxacin, moxiraprine, Moxnidazole, moxonidine, Mumps 
chloride, Mechlorethamine Hydrochloride, meclizine hydro- 	 Skin Test Antigen, Muzolimine, mycaperoxide B, Mycophe- 
chloride, 	 Meclocycline, 	 Meclofenamate 	 Sodium, 2o nolate mofetil, Mycophenolic Acid, myriaporone, Nabazenil, 
Mecloqualone, Meclorisone Dibutyrate, Medazepam Hydro- 	 Nabilone, Nabitan Hydrochloride, Naboctate Hydrochloride, 
chloride, Medorinone, Medrogestone, Medroxalol, Medrox- 	 Nabumetone, N-acetyldinaline, Nadide, nadifloxacin, Nad- 
yprogesterone, Medrysone, Meelizine Hydrochloride, Mefe- 	 olol, nadroparin calcium, nafadotride, nafamostat, nafarelin, 
namic Acid, Mefenidil, Mefenorex Hydrochloride, 	 Nafcillin Sodium, Nafenopin, Nafimidone Hydrochloride, 
Mefexamide, Mefloquine Hydrochloride, Mefruside, Mega-  25 Naflocort, Nafomine Malate, Nafoxidine Hydrochloride, 
lomicin Potassium Phosphate, Megestrol Acetate, Meglu- 	 Nafronyl Oxalate, Naftifine Hydrochloride, naftopidil, nagli- 
mine, Meglutol, Melengestrol Acetate, Meloxicam, Mel- 	 van, nagrestip, Nalbuphine Hydrochloride, Nalidixate 
phalan, Memantine, Memotine Hydrochloride, Menabitan 	 Sodium, Nalidixic Acid, nalmefene, Nalmexone Hydrochlo- 
Hydrochloride, Menoctone, menogaril, Menotropins, 	 ride, naloxone, Naltrexone, Namoxyrate, Nandrolone Phen- 
Meobentine Sulfate, Mepartricin, Mepenzolate Bromide, 30 propionate, Nantradol Hydrochloride, Napactadine Hydro- 
Meperidine Hydrochloride, Mephentermine Sulfate, 	 chloride, napadisilate, Napamezole Hydrochloride, napaviin, 
Mephenytoin, Mephobarbital, Mepivacaine Hydrochloride, 	 Naphazoline Hydrochloride, naphterpin, Naproxen, 
Meprobamate, Meptazinol Hydrochloride, Mequidox, Mera- 	 Naproxen sodium, Naproxol, napsagatran, Naranol Hydro- 
lein Sodium, merbarone, Mercaptopurine, Mercufenol Chlo- 	 chloride, Narasin, naratriptan, nartograstim, nasaruplase, 
ride, Merisoprol, Meropenem, Mesalamine, Meseclazone, 35 natalizumab, Natamycin, nateplase, Naxagolide Hydrochlo- 
Mesoridazine, Mesterolone, Mestranol, Mesuprine Hydro- 	 ride, Nebivolol, Nebramycin, nedaplatin, Nedocromil, Nefa- 
chloride, Metalol Hydrochloride, Metaproterenol Polistirex, 	 zodone Hydrochloride, Neflumozide Hydrochloride, Nefo- 
Metaraminol Bitartrate, Metaxalone, Meteneprost, meter- 	 pam Hydrochloride, Nelezaprine Maleate, Nemazoline 
elin, Metformin, Methacholine Chloride, Methacycline, 	 Hydrochloride, nemorubicin, Neomycin Palmitate, Neostig- 
methadone, Methadyl Acetate, Methalthiazide, Methamphet-  40 mine Bromide, neridronic acid, Netilmicin Sulfate, Neutra- 
amine Hydrochloride, Methaqualone, Methazolamide, 	 mycin, Nevirapin Nexeridine Hydrochloride, Niacin, 
Methdilazine, Methenamine, Methenolone Acetate, Meth- 	 Nibroxane, Nicardipine Hydrochloride, Nicergoline, 
etoin, Methicillin Sodium, Methimazole, methioninase, 	 Niclosamide, Nicorandil, Nicotinamide, Nicotinyl Alcohol, 
Methionine, Methisazone, Methixene Hydrochloride, 	 Nifedipine, Nifirmerone, Nifluridide, Nifuradene, Nifurald- 
Methocarbamol, Methohexital Sodium, Methopholine, 45 ezone, Nifuratel, Nifuratrone, Nifurdazil, Nifurimide, 
Methotrexate, Methotrimeprazine, methoxatone, methoxy 	 Nifurpirinol, Nifurquinazol, Nifurthiazole, Nifurtimox, nilo- 
polyethylene glycol-epoetinbeta, Methoxyflurane, Methsux- 	 tinib, nilotinib hydrochloride monohydrate, nilutamide, Nil- 
imide, Methyclothiazide, Methyl Palmoxirate, Methylatro- 	 vadipine, Nimazone, Nimodipine, niperotidine, niravoline, 
pine Nitrate, Methylbenzethonium Chloride, Methyldopa, 	 Niridazole, nisamycin, Nisbuterol Mesylate, raisin, Nisobam- 
Methyldopate Hydrochloride, Methylene Blue, Methyler-  5o ate, Nisoldipine, Nisoxetin Nisterime Acetate, Nitarsone, 
gonovine Maleate, methylhistamine, methylinosine mono- 	 nitazoxanide, nitecapone, Nitrafudam Hydrochloride, 
phosphate, Methylphenidate, Methylprednisolone, Methylt- 	 Nitralamine Hydrochloride, Nitramisole Hydrochloride, 
estosterone, Methynodiol Diacelate, Methysergide, 	 Nitrazepam, Nitrendipine, Nitrocydine, Nitrodan, Nitro- 
Methysergide Maleate, Metiamide, Metiapine, Metioprim, 	 furantoin, Nitrofurazone, Nitroglycerin, Nitromersol, Nitro- 
metipamide, Metipranolol, Metizoline Hydrochloride, Met-  55 wide, Nitromifene Citrate, Nitrous Oxide, nitroxide antioxi- 
kephamid Acetate, metoclopramide, Metocurine Iodide, 	 dant, nitrullyn, Nivazol, Nivimedone Sodium, Nizatidine, 
Metogest, Metolazone, Metopimazine, Metoprine, Meto- 	 Noberastine, Nocodazole, Nogalamycin, Nolinium Bromide, 
prolol, Metoprolol tartrate, Metouizine, metrifonate, Metri- 	 Nomifensine Maleate, Noracymethadol Hydrochloride, Nor- 
zamide, Metrizoate Sodium, Metronidazole, Meturedepa, 	 bolethone, Norepinephrine Bitartrate, Norethindrone, Nor- 
Metyrapone, Metyrosine, Mexiletine Hydrochloride, 60 ethynodrel, Norfiurane, Norfloxacin, Norgestimate, Norg- 
Mexrenoate Potassium, Mezlocillin, Mianserin Hydrochlo- 	 estomet, 	 Norgestrel, 	 Nortriptyline 	 Hydrochloride, 
ride, mibefradil, Mibefradil Dihydrochloridc, Mibolerone, 	 Noscapine, Novobiocin Nylestriol, Nystatin, Obidoxime 
michellamine B, Miconazole, microcolin A, Midaflur, Mida- 	 Chloride, Ocaperidone, Ocfentanil Hydrochloride, Ocina- 
zolam Hydrochloride, midodrine, mifepristone, Mifobate, 	 plon, Octanoic Acid, Octazamide, Octenidine Hydrochlo- 
miglitol, milacemide, milameline, mildronate, Milenperone, 65 ride, Octodrine, Octreotide, Octriptyline Phosphate, Ofloxa- 
Milipertine, milnacipran, Milrinone, miltefosine, Mimbane 	 cin, Ofornine, okicenone, Olanzepine, Olmesartan, 
Hydrochloride, minaprine, Minaxolone, Minocromil, 	 olmesartan medoxomil, olopatadine, olopatadine hydrochlo- 
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ride, olprinone, olsalazine, Olsalazine Sodium, Olvanil, 	 cidil, Pinadoline, Pindolol, pinnenol, pinocebrin, Pinoxepin 
Omalizumab, Omega-3 acid ethyl esters, omeprazole, 	 Hydrochloride, pioglitazone, Pipamperone, Pipazethate, 
onapristone, ondansetron, Ontazolast, Oocyte Opipramol 	 pipecuronium bromide, Piperacetazine, Piperacillin, Piper- 
Hydrochloride, oracin, Orconazole Nitrate, Orgotein, Orlis- 	 acillin Sodium, Piperamide Maleate, Piperazinc, Pipobro- 
lat, Ormaplatin, Ormetoprim, Ornidazole, Orpanoxin, 5 man, Piposulfan, Pipotiazine Palmitate, Pipoxolan Hydro- 
Orphenadrine Citrate, osaterone, Oseltamivir, otenzepad, 	 chloride, Piprozolin, Piquindone Hydrochloride, Piquizil 
Oxacillin Sodium, Oxagrelate, oxaliplatin, Oxamarin Hydro- 	 Hydrochloride, Piracetam, Pirandamine Hydrochloride, pira- 
chloride, oxamisole, Oxamniquine, oxandrolone, Oxantel 	 rubicin, Pirazmonam Sodium, Pirazolac, Pirbenicillin 
Pamoate, Oxaprotiline Hydrochloride, Oxaprozin, Oxarba- 	 Sodium, Pirbuterol Acetate, Pirenperone, Pirenzepine 
zole, Oxatomide, oxaunomycin, Oxazepam, oxcarbazepine, io Hydrochloride, piretanide, Pirfenidone, Piridicillin Sodium, 
Oxendolone, Oxethazaine, Oxetorone Fumarate, Oxfenda- 	 Piridronate Sodium, Piriprost, piritrexim, Pirlimycin Hydro- 
zole, Oxfenicine, Oxibendazole, oxiconazole, Oxidopamine, 	 chloride, pirlindole, pirmagrel, Pirmenol Hydrochloride, 
Oxidronic Acid, Oxifungin Hydrochloride, Oxilorphan, Oxi- 	 Pirnabine, Piroctone, Pirodavir, pirodomast, Pirogliride Tar- 
monam, Oximonam Sodium, Oxiperomide, oxiracetam, 	 trate, Pirolate, Pirolazamide, Piroxantrone Hydrochloride, 
Oxiramide, Oxisuran, Oxmetidine Hydrochloride, oxo-  15 Piroxicam, Piroximone, Pirprofen, Pirquinozol, Pirsidomine, 
dipine, Oxogestone Phenopropionate, Oxolinic Acid, Oxpre- 	 Pivampicillin Hydrochloride, Pivopril, Pizotyline, placetinA, 
nolol Hydrochloride, Oxtriphylline, Oxybutynin Chloride, 	 Plicamycin, Plomestane, Pobilukast Edamine, Podofilox, 
Oxychlorosene, Oxycodone, oxycodone hydrochloride, 	 Poisonoak Extract, Poldine Methylsulfate, Poliglusam, 
Oxymetazoline Hydrochloride, oxymetholone, Oxymor- 	 Polignate Sodium, Polymyxin B Sulfate, Polythiazide, 
phone Hydrochloride, Oxypertine, Oxyphenbutazone, Oxy-  20 Ponalrestat, Porfimer Sodium, Porfiromycin, Potassium 
purinol, Oxytetracycline, Oxytocin, ozagrel, Ozlinone, Pacli- 	 Chloride, Potassium Iodide, Potassium Permanganate, Povi- 
taxel, palauamine, Paldimycin, palinavir, Palivizumab, 	 done-Iodine, Practolol, Pralidoxime Chloride, Pramipexole, 
palmitoylrhizoxin, Palmoxirate Sodium, pamaqueside, 	 Pramiracetam Hydrochloride, Pramoxine Hydrochloride, 
Pamatolol Sulfate, pamicogrel, Pamidronate Disodium, pam- 	 Pranolium Chloride, Pravadoline Maleate, Pravastatin, Prav- 
idronic acid, Panadiplon, panamesine, panaxytriol, Panco-  25 astatin sodium, Prazepam, Prazosin, Prazosin Hydrochloride, 
pride, Pancuronium Bromide, panipenem, pannorin, 	 Prednazate, Prednicarbate, Prednimustine, Prednisolone, 
panomifene, pantethine, pantoprazole, Papaverine Hydro- 	 prednisolone quetiapine fumerate, Prednisone, Prednival, 
chloride, parabactin, paracetamol, Parachlorophenol, Paral- 	 Pregabalin, Pregnenolone Succiniate, Prenalterol Hydrochlo- 
dehyde, Paramethasone Acetate, Paranyline Hydrochloride, 	 ride, Prenylamine, Pridefine Hydrochloride, Prifelone, 
Parapenzolate Bromide, Pararosaniline Pamoate, Parbenda-  30 Prilocaine Hydrochloride, Prilosec, Primaquine Phosphate, 
zole, Parconazole Hydrochloride, Paregoric, Pareptide Sul- 	 Primidolol, Primidone, Prinivil, Prinomide Tromethamine, 
fate, Pargyline Hydrochloride, parnaparin sodium, Paromo- 	 Prinoxodan, pritosufloxacin, Prizidilol Hydrochloride, 
mycin Sulfate, Paroxetine, paroxetine hydrochloride, 	 Proadifen Hydrochloride, Probenecid, Probicromil Calcium, 
parthenolide, Partricin, Paulomycin, pazelliptine, Pazina- 	 Probucol, Procainamide Hydrochloride, Procaine Hydro- 
clone, Pazoxide, pazufloxacin, pefloxacin, pegaspargase, 35 chloride, Procarbazine Hydrochloride, Procaterol Hydro- 
Pegorgotein, Pegylated interferon alfa-2a, Pelanserin Hydro- 	 chloride, Prochlorperazine, Procinonide, Proclonol, Procy- 
chloride, peldesine, Peliomycipelretin, Pelrinone Hydrochlo- 	 clidine Hydrochloride, Prodilidine Hydrochloride, Prodolic 
ride, Pemedolac, Pemerid Nitrate, Pemetrexed, pemirolast, 	 Acid, Profadol Hydrochloride, Progabide, Progesterone, Pro- 
Pemoline, Penamecillin, Penbutolol Sulfate, Penciclovir, 	 glumide, Proinsulin (human), Proline, Prolintane Hydrochlo- 
Penfluridol, Penicillamine, Penicillin G Benzathine, Penicil-  4o ride, Promazine Hydrochloride, Promethazine, Promethaz- 
lin G Potassium, Penicillin G Procaine, Penicillin G Sodium, 	 ine 	 hydrochloride, 	 Propafenone 	 Hydrochloride, 
Penicillin V Hydrabamine, Penicillin V Benzathine, Penicil- 	 propagermanium, Propanidid, Propantheline Bromide, Pro- 
lin V Potassium, Pentabamate, Pentaerythritol Tetranitrate, 	 paracaine Hydrochloride, Propatyl Nitrate, propentofylline, 
pentafuside, pentamidine, pentamorphone, Pentamustine, 	 Propenzolate Hydrochloride, Propikacin, Propiomazine, 
Pentapiperium Methylsulfate, Pentazocine, Pentetic Acid, 45 Propionic Acid, propionylcamitine, propiram, propiram, 
Pentiapine Maleate, pentigetide, Pentisomicin, Pentizidone 	 propiverine, Propofol, Proponolol hydrochloride, Pro- 
Sodium, Pentobarbital, Pentomone, Pentopril, pentosan, pen- 	 poxycaine Hydrochloride, Propoxyphene Hydrochloride, 
tostatin, Pentoxifylline, Pentrinitrol, pentrozole, Peplomycin 	 Propranolol Hydrochloride, Propulsid, propylbis-acridone, 
Sulfate, Pepstatin, perflubron, perfofamide, Perfosfamide, 	 Propylhexedrine, Propyliodone, Propylthiouracil, Proqua- 
pergolide, Perhexiline Maleate, perillyl alcohol, Perindopril, 50 zone, Prorenoate Potassium, Proroxan Hydrochloride, 
perindoprilat, Perlapin Permethrin, perospirone, Perphena- 	 Proscillaridin, Prostalene, prostratin, Protamine Sulfate, pro- 
zine, 	 Phenacemide, 	 phenaridine, 	 phenazinomycin, 	 tegrin, Protirelin, Protriptyline Hydrochloride, Proxazole, 
Phenazopyridine Hydrochloride, Phenbutazone Sodium 	 Proxazole Citrate, Proxicromil, Proxorphan Tartrate, pruli- 
Glycerate, Phencarbamide, Phencyclidine Hydrochloride, 	 floxacin, pseudoephedrine, Pseudophedrine hydrochloride, 
Phendimetrazine Tartrate, Phenelzine Sulfate, Phenformin, 55 Puromycin, Pyrabrom, Pyrantel Pamoate, Pyrazinamide, 
Phenmetrazine Hydrochloride, Phenobarbital, Phenoxyben- 	 Pyrazofurin, pyrazoloacridine, Pyridostigmine Bromide, 
zamine Hydrochloride, Phenprocoumon, phenserine, phen- 	 Pyridoxine 	 hydrochloride, 	 Pyrilamine 	 Maleate, 
succinal, Phensuximide, Phentermine, Phentermine Hydro- 	 Pyrimethamine, Pyrinoline, Pyrithione Sodium, Pyrithione 
chloride, phentolamine mesilate, Phentoxifylline, Phenyl 
	
Zinc, Pyrovalerone Hydrochloride, Pyroxamine Maleate, 
Amino salicylate, phenylacetate, Phenylalanine, phenylala-  60 Pyrrocaine, Pyrroliphene Hydrochloride, Pyrrolnitrin, Pyrv- 
nylketoconazole, Phenylbutazone, Phenylephrine Hydro- 	 inium Pamoate, Quadazocine Mesylate, Quazepam, Quazi- 
chloride, Phenylpropanolamine Hydrochloride, Phenylpro- 	 none, Quazodine, Quazolast, quetiapine, quetiapine fuma- 
panolamine Polistirex, Phenyramidol Hydrochloride, 	 rate, quiflapon, quinagolide, Quinaldine Blue, quinapril, 
Phenytoin, Phenytoin sodium, Physostigmine, picenadol, 	 Quinapril hydrochloride, Quinazosin Hydrochloride, Quin- 
picibanil, Picotrin Diolamine, picroliv, picumeterol, pidoti-  65 bolone, Quinctolate, Quindecamine Acetate, Quindonium 
mod, Pifarnine, Pilocarpine, pilsicainide, pimagedine, Pimet- 	 Bromide, Quinelorane Hydrochloride, Quinestrol, Quinfa- 
ine Hydrochloride, pimilprost, Pimobendan, Pimozide, Pina- 	 mide, Quingestanol Acetate, Quingestrone, Quinidine Glu- 
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conate, Quinielorane Hydrochloride, Quinine Sulfate, Quin- 	 line Mesylate, Spiramycin, Spirapril Hydrochloride, Spirap- 
pirole Hydrochloride, Quinterenol Sulfate, Quinuclium 	 rilat, Spirogermanium Hydrochloride, Spiromustine, 
Bromide, Quinupristin, Quipazine Maleate, Rabeprazole, 	 Spironolactone, Spiroplatin, Spiroxasone, splenopentin, 
Rabeprazole Sodium, Racephenicol, Racepinephrine, Rafox- 	 spongistatin, Sprodiamide, squalamine, Stallimycin Hydro- 
anide, Ralitoline, raloxifene, raltegravir, raltitrexed, rama-  5 chloride, Stannous Pyrophosphate, Stannous Sulfur Colloid, 
troban, Ramipril, Ramoplanin, ramosetron, ranelic acid, 	 Stanozolol, Statolon, staurosporine, stavudine, Steffimycin, 
Ranimycin, Ranitidine, Ranitidine hydrochloride, ranola- 	 Stenbolone Acetate, stepronin, Stilbazium Iodide, Stilonium 
zine, Rauwolfia Serpentina, recainam, Recainam Hydrochlo- 	 Iodide, stipiamide, Stiripentol, stobadine, Streptomycin Sul- 
ride, Reclazepam, Recombinant factor VIII, regavirumab, 	 fate, Streptonicozid, Streptonigrin, Streptozocin, Strontium 
Regramostim, Relaxin, Relomycin, Remacemide Hydro-  io Chloride Sr-89, succibun, Succimer, Succinylcholine Chlo- 
chloride, Remifentanil Hydrochloride, Remiprostol, Remox- 	 ride, Sucralfate, Sucrosofate Potassium, Sudoxicam, Sufen- 
ipride, Repirinast, Repromicin, Reproterol Hydrochloride, 	 tanil, Sufotidine, Sulazepam, Sulbactam Pivoxil, Sulcona- 
Reserpine, resinferatoxin, Resorcinol, retapamulin, retellip- 	 zole Nitrate, Sulfabenz, Sulfabenzamide, Sulfacetamide, 
tine demethylated, reticulon, reviparin sodium, revizinone, 	 Sulfacytine, Sulfadiazine, Sulfadoxine, Sulfalene, Sulfam- 
rhenium etidronate, rhizoxin, RI retinamide, Ribaminol, Rib-  15 erazine, Sulfameter, Sulfamethazine, Sulfamethizole, Sul- 
avirin, Riboprine, ricasetron, Ridogrel, Rifabutin, Rifamet- 	 famethoxazole, Sulfamonomethoxine, Sulfamoxole, Sulfa- 
ane, Rifamexil,. Rifamide, Rifampin, Rifapentine, Rifaxi- 	 nilate Zinc, Sulfanitran, sulfasalazine, Sulfasomizole, 
min, rilopirox, Riluzole, rimantadine, Rimcazole 	 Sulfazamet, Sulfinalol Hydrochloride, sulfinosine, Sulfin- 
Hydrochloride, Rimexolone, Rimiterol Hydrobromide, 	 pyrazone, Sulfisoxazole, Sulfomethoxazole, Sulfomyxin, 
Rimonabant, rimoprogin, riodipine, Rioprostil, Ripazepam, 20 Sulfonterol Hydrochloride, sulfoxamine, Sulinldac, Sul- 
ripisartan, Risedronate, Risedronate Sodium, risedronic acid, 	 marin, Sulnidazole, Suloctidil, Sulofenur, sulopenem, Sulox- 
Risocaine, Risotilide Hydrochloride, rispenzepine, Risper- 	 ifen Oxalate, Sulpiride, Sulprostone, sultamicillin, Sulthi- 
dal, Risperidone, Ritanserin, ritipenem, Ritodrine, 	 ame, sultopride, sulukast, Sumarotene, sumatriptan, 
Ritolukast, ritonavir, rituximab, rivastigmine, rivastigmine 	 Sumatriptan succinate, Suncillin Sodium, Suproclone, 
tartrate, Rizatriptan, rizatriptan benzoate, Rocastine Hydro-  25 Suprofen, suradista, suramin, Surfomer, Suricainide Maleate, 
chloride, Rocuronium Bromide, Rodocaine, Roflurane, 	 Suritozole, Suronacrine Maleate, Suxemerid Sulfate, swain- 
Rogletimide, rohitukine, rokitamycin, Roletamicide, Rolga- 	 sonine, symakalim, Symclosene, Symetine Hydrochloride, 
midine, Rolicyprine, Rolipram, Rolitetracycline, Rolodine, 	 Taciamine Hydrochloride, Tacrine Hydrochloride, Tacroli- 
Romazarit, romurtide, Ronidazole, Ropinirole, Ropitoin 	 mus, Tadalafil, Talampicillin Hydrochloride, Taleranol, Tali- 
Hydrochloride, ropivacaine, Ropizine, roquinimex, Rosa-  30 nomycin, tallimustine, Talmetacin, Talniflumate, Talopram 
ramicin, rosiglitazone, Rosiglitazone maleate, Rosoxacin, 	 Hydrochloride, Talosalate, Tametraline Hydrochloride, 
Rosuvastatin, Rotavirus vaccine, rotigotine, Rotoxamine, 	 Tamoxifen, tamoxifen citrate, Tampramine Fumarate, Tam- 
roxaitidine, Roxarsone, roxindole, roxithromycin, rubigi- 	 sulosin, Tamsulosin Hydrochloride, Tandamine Hydrochlo- 
none BI, ruboxyl, rufloxacin, rupatidine, Rutamycin, ruzado- 	 ride, tandospirone, tapgen, taprostene, Tasosartan, tauromus- 
lane, Sabeluzole, safingol, safironil, saintopin, salbutamol, 35 tine, Taxane, Taxoid, Tazadolene Succinate, tazanolast, 
Salbutamol sulfate, Salcolex, Salethamide Maleate, Salicyl 	 tazarotene, Tazifylline Hydrochloride, Tazobactam, 
Alcohol, Salicylamide, Salicylate Meglumine, Salicylic 	 Tazofelone, Tazolol Hydrochloride, Tebufelone, Tebuquine, 
Acid, Salmeterol, Salnacediin, Salsalate, sameridine, sam- 	 Teclozan, Tecogalan Sodium, Teecleukin, Teflurane, Tegafur, 
patrilat, Sancycline, sanfetrinem, Sanguinarium Chloride, 	 Tegaserod, Tegretol, Teicoplanin, telenzepine, tellurapyry- 
Saperconazole, saprisartan, sapropterin, sapropterin dihydro-  40 lium, telmesteine, telmisartan, Teloxantrone Hydrochloride, 
chloride, saquinavir, Sarafloxacin Hydrochloride, Saralasin 	 Teludipine Hydrochloride, Temafloxacin Hydrochloride, 
Acetate, sarcophytol A, sargramostim, Sarmoxicillin, Sarpi- 	 Tematropium Methyl sulfate, Temazepam, Temelastine, 
cillin, sarpogrelate, saruplase, saterinone, satigrel, satumo- 	 temocapril, Temocillin, temoporfin, temozolomide, tem- 
mab pendetide, Scopafungin, Scopolamine Hydrobromide, 	 sirolimus, Tenidap, Teniposide, Tenofovir, tenosal, tenoxi- 
Scrazaipine Hydrochloride, Secalciferol, Secobarbital, Seel- 45 cam, tepirindole, Tepoxalin, Teprotide, terazosin, Terazosin 
zone, segiline, Seglitide Acetate, Selegiline Hydrochloride, 	 Hydrochloride, Terbinafine, Terbutaline Sulfate, Tercona- 
Selenium Sulfide, Selenomethionine Se-75, Selfotel, sema- 	 zole, terfenadine, terfiavoxate, terguride, Teriparatide, Teri- 
tilide, semduramicin, semotiadil, semustine, Sepazonium 	 paratide Acetate, terlakiren, terlipressin, terodiline, Terox- 
Chloride, Seperidol Hydrochloride, Seprilose, Seproxetine 	 alene Hydrochloride, Teroxirone, tertatolol, Tesicam, 
Hydrochloride, Seractide Acetate, Sergolexole Maleate, 5o Tesimide, Testolactone, Testosterone, Tetracaine, tetrachlo- 
Serine, Sermetacin, Sermorelin Acetate, sertaconazole, 	 rodecaoxide, Tetracycline, Tetracycline hydrochloride, Tet- 
sertindole, sertraline, sertraline hydrochloride, S-ethynylu- 	 rahydrozoline Hydrochloride, Tetramisole Hydrochloride, 
racil, setiptiline, Setoperone, Sevelamer, sevirumab, sevoflu- 	 Tetrazolast Meglumine, tetrazomine, Tetrofosmin, Tetro- 
rane, sezolamide, Sibopirdine, Sibutramine Hydrochloride, 	 quinone, Tetroxoprim, Tetrydamine, thaliblastine, Thalido- 
Silandrone, Sildenafil, sildenafil citrate, silipide, silteplase, 55 wide, Theofibrate, Theophylline, Thiabendazole, Thiami- 
Silver Nitrate, simendan, Simtrazene, Simvastatin, Sincalide, 	 prine, Thiamphenicol, Thiamylal, Thiazesim Hydrochloride, 
Sinefungin, sinitrodil, sinnabidol, sipatrigine, sirolimus, 	 Thiazinamium Chloride, Thiethylperazine, Thiithixene, 
Sisomicin, Sitagliptin, Sitogluside, sizofiran, sobuzoxane, 	 Thimerfonate Sodium, Thimerosal, thiocoraline, thiofedrine, 
Sodium Amylosulfate, Sodium Iodide I-123, Sodium Nitro- 	 Thioguanine, thiomarinol, Thiopental Sodium, thioperam- 
prusside, Sodium Oxybate, sodium phenylacetate, Sodium 60 ide, Thioridazine, Thiotepa, Thiphenamil Hydrochloride, 
Salicylate, Sodium valproate, Solifenacin, solverol, Solyper- 	 Thiphencillin Potassium, Thiram, Thozalinone, Threoxine, 
tine Tartrate, Somalapor, Somantadine Hydrochloride, 	 Thrombin, thrombopoietin, thymalfasin, thymopentin, thy- 
somatomedin B, somatomedin C, Somatostatin, somatrem, 	 motrinan, Thyromedan Hydrochloride, Thyroxine, Tiacrilast, 
somatropin, Somenopor, Somidobove, Sorbinil, Sorivudine, 	 Tiacrilast Sodium, tiagabine, Tiamenidine, tianeptine, 
sotalol, Soterenol Hydrochloride, Sparfioxacin, Sparfosate 65 tiapafant, Tiapamil Hydrochloride, Tiaramide Hydrochlo- 
Sodium, sparfosic acid, Sparsomy, Sparteine Sulfate, Specti- 	 ride, Tiazofurin, Tibenelast Sodium, Tibolone, Tibric Acid, 
nomycin Hydrochloride, spicamycin D, Spiperone, Spirado- 	 Ticabesone Propionate, Ticarbodine, Ticarcillin Cresyl 
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Sodium, Ticlatone, ticlopidine, Ticrynafen, tienoxolol, Tifu- 	 Viridofulvin, Viroxime, vitaxin, Voglibose, Volazocine, vori- 
rac Sodium, Tigemonam Dicholine, Tigestol, Tiletamine 	 conazole, vorozole, voxergolide, Wafarin , Xamoterol, 
Hydrochloride, Tilidine Hydrochloride, tilisolol, tilnoprofen 	 Xanomeline, Xanoxate Sodium, Xanthinol Niacinate, 
arbamel, Tilorone Hydrochloride, Tiludronate Disodium, 	 xemilofiban, Xenalipin, Xenbucin, Xilobam, ximoprofen, 
tiludronic acid, Timefurone, Timobesone Acetate, Timolol, 5 Xipamide, Xorphanol Mesylate, Xylamidine Tosylate, Xyla- 
Timolol meleate, Tinabinol, Tinidazole, Tinzaparin Sodium, 	 zine Hydrochloride, Xylometazoline Hydrochloride, xylose, 
Tioconazole, Tiodazosin, Tiodonium Chloride, Tioperidone 	 yangambin, zabicipril, zacopride, zafirlukast, Zalcitabine, 
Hydrochloride, Tiopinac, Tiospirone Hydrochloride, Tioti- 	 Zaleplon, zalospirone, Zaltidine Hydrochloride, zaltoprofen, 
dine, Tiotropium, tiotropium bromide, Tioxidazole, Tipen- 	 zanamivir, zankiren, zanoterone, Zantac, Zarirlukast, zate- 
tosin Hydrochloride, tipranavir, Tipredane, Tiprenolol 10 bradine, zatosetron, Zatosetron Maleate, zenarestat, Zenazo- 
Hydrochloride, Tiprinast Meglumine, Tipropidil Hydrochlo- 	 cine Mesylate, Zeniplatin, Zeranol, Zidometacin, Zidovu- 
ride, Tiqueside, Tiquinamide Hydrochloride, tirandalydigin, 	 dine, zifrosilone, Zilantel, zilascorb, zileuton, Zimeldine 
Tirapazamine, tirilazad, tirofiban, tiropramide, titanocene 	 Hydrochloride, Zinc Undecylenate, Zindotrine, Zinocona- 
dichloride, Tixanox, Tixocortol Pivalate, Tizanidine Hydro- 	 zole Hydrochloride, Zinostatin, Zinterol Hydrochloride, Zin- 
chloride, Tnmethobenzamide Hydrochloride, Tobramycin, 15 viroxime, ziprasidone, Zobolt, Zofenopril Calcium, Zofeno- 
Tocainide, Tocamphyl, Tofenacin Hydrochloride, Tolamolol, 	 prilat, Zolamine Hydrochloride, Zolazepam Hydrochloride, 
Tolazamide, Tolazoline Hydrochloride, Tolbutamide, Tolca- 	 Zoledronate, Zolertine Hydrochloride, zolmitriptan, zolpi- 
pone, Tolciclate, Tolfamide, Tolgabide, Tolimidone, Tolin- 	 dem, Zomepirac Sodium, Zometapine, Zoniclezole Hydro- 
date, Tolmetin, Tolnaftate, Tolpovidone, Tolpyrramide, Tolr- 	 chloride, Zonisamide, zopiclone, Zopolrestat, Zorbamyciin, 
estat, Tolterodine, tolterodine tartrate, Tomelukast, 20 Zorubicin Hydrochloride, zotepine, Zucapsaicin, and phar-
Tomoxetine Hydrochloride, Tonazocine Mesylate, Topira- 	 maceutically acceptable salts thereof. 
mate, topotecan, Topotecan Hydrochloride, topsentin, 
Topterone, Toquizine, trasemide, toremifene, Torsemide, 	 EXAMPLE 1 
Tosifen, Tosufloxacin, totipotent stem cell factor (TSCF), 
Tracazolate, trafermin, Tralonide, Tramadol, Tramadol 25 	 The capsule as described herein is used to administer leu- 
Hydrochloride, Tramazoline Hydrochloride, trandolapril, 	 prolide acetate for the treatment of prostate cancer. Leupro- 
Tranexamic Acid, Tranilast, Transcainide, trastuzumab, trax- 	 lide acetate (USP 31) is a synthetic nonapeptide agonist ana- 
anox, Trazodone Hydrochloride, Trebenzomine Hydrochlo- 	 log of luteinizing hormone-releasing factor (LNHR). The 
ride, Trefentanil Hydrochloride, Treloxinate, Trepipam 	 leuprolide acetate molecule is approximately 1209 Daltons in 
Maleate, Trestolone Acetate, tretinoin, Triacetin, triacetylu-  30 weight and two to three nanometers in size. It is soluble in 
ridine, Triafungin, Triamcinolone, Triampyzine Sulfate, Tri- 	 aqueous media at a level of approximately 10 mg/mL. An 
amterene, Triazolam, Tribenoside, tricaprilin, Tricetamide, 	 existing method of administering leuprolide via extended 
Trichlonnethiazide, trichohyalin, triciribine, Tricitrates, Tri- 	 release is disclosed in U.S. Pat. No. 5,728,396 filed Jan. 30, 
clofenol Piperazine, Triclofos Sodium, trientine, Trifenagrel, 	 1997 and incorporated herein by reference. 
triflavin, Triflocin, Triflubazam, Triflumidate, Trifluopera-  35 	 The nanochannel delivery device chip is installed in a 
zine Hydrochloride, Trifluperidol, Triflupromazine, Triflu- 	 capsule as described herein and filled with a 5 mg/mL leu- 
promazine Hydrochloride, Trifluridine, Trihexyphenidyl 	 prolide acetate solution (NDC number 0703-4014-18) foruse 
Hydrochloride, Trilostane, Trimazosin Hydrochloride, tri- 	 in the treatment of prostate cancer. The capsule is sized to 
megestone, Trimeprazine Tartrate, Trimethadione, Tri- 	 approximately 2.8 mL, so that the filled capsule contains 
methaphan Camsylate, Trimethoprim, Trimetozine, Trimetr-  4o approximately 14 mg of leuprolide acetate. If stronger con- 
exate, 	 Trimipramine, 	 Trimoprostil, 	 Trimoxamine 	 centrations of leuprolide acetate solution are used, the capsule 
Hydrochloride, Triolein, Trioxifene Mesylate, Tripamide, 	 volume may be correspondingly reduced. The capsule is 
Tripelennamine Hydrochloride, Triprolidine Hydrochloride, 	 implanted subcutaneously in the inner portion of the upper 
Triptorelin, Trisulfapyrimidines, Troclosene Potassium, tro- 	 arm or upper leg or in the abdomen. The capsule is implanted, 
glitazone, Trolamine, Troleandomycin, trombodipine, 45 with optional use of a tissue separator, through a small inci- 
trometamol, Tropanserin Hydrochloride, Tropicamide, 	 sion in a clinical outpatient procedure and removed two to 
tropine, tropisetron, trospectomycin, trovafloxacin, trovird- 	 three months later through a small incision. For implant and 
ine, Tryptophan, Tuberculin, Tubocurarine Chloride, Tubulo- 	 explant, a small amount of anesthetic is used, for example, a 
zole Hydrochloride, tucaresol, tulobuterol, turosteride, 	 1% lidocaine injection at the site. 
Tybamate, tylogenin, Tyropanoate Sodium, Tyrosine, Tyro-  50 	 The micro- and nano-channel sizes of the nanochannel 
thricin, tyrphostins, ubenimex, Uldazepam, Undecylenic 	 delivery device are chosen (for example, according to the 
Acid, Uracil Mustard, urapidil, Urea, Uredepa, uridine triph- 	 model described in [Grattoni, A. Ferrari, M., Liu, X. Quality 
osphate, Urofollitropin, Urokinase, Ursodiol, valaciclovir, 	 control method for micro- nano-channels silicon devices. US 
Valacyclovir hydrochloride, Valine, Valnoctamide, Valproate 	 Patent Application No. 61/049,287 (April 2008)]), to provide 
semisodium, Valproic Acid, valsartan, vamicamide, vana-  55 a release rate of about 120 µg/day can be obtained for about 90 
deine, Vancomycin, vaninolol, Vapiprost Hydrochloride, 	 days in certain embodiments. 
Vapreotide, Vardenafil, Varenicline, variolin B, Vasopressin, 	 In this example, the nanochannel delivery device configu- 
Vecuronium Bromide, velaresol, Velnacrine Maleate, ven- 	 ration with this behavior uses a 6x6 mm chip size, with 161 
lafaxine, Venlafaxine hydrochloride, Veradoline Hydrochlo- 	 macrochannels with openings of 190x190 µm each, and 
ride, veramine, Verapamil Hydrochloride, verdins, Verilopam 60 within each macrochannel approximately 23 rows of 
Hydrochloride, Verlukast, Verofylline, veroxan, verteporfin, 	 nanochannel structures, consisting of 10 each of inlet and 
Vesnarinone, vexibinol, Vidarabine, vigabatrin, vildagliptin, 	 outlet microchannels, connected through about 20 nanochan- 
Viloxazine Hydrochloride, Vinblastine Sulfate, vinburnine 	 nels according to the description herein. The inlets and outlets 
citrate, Vincofos, vinconate, Vincristine Sulfate, Vindesine, 	 are approximately 5x5 µm in cross-section, with the inlets 
Vindesine Sulfate, Vinepidine Sulfate, Vinglycinate Sulfate, 65 being about 30 µm long and the outlets being about 1.6 µm 
Vinleurosine Sulfate, vinorelbine, vinpocetine, vintoperol, 	 long, and the nanochannels are about 5 µm long and 5 µm 
vinxaltine, Vinzolidine Sulfate, Viprostol, Virginiamycin, 	 wide and 13 nm high. Other configurations with different 
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dimensions may be derived from the mathematical model that 
yield approximately the same release rate and duration in 
other examples. 
EXAMPLE 2 
The capsule and nanochannel delivery device are config-
ured and implanted as described in Example 1. However, 
instead of administering leuprolide acetate, the capsule and 
nanochannel delivery device administer letrozole for the io 
treatment of breast cancer. The limited success of chemo-
therapy for the treatment of breast cancer emphasizes the 
need of novel preventive strategies to minimize the cancer 
occurrence. Recent studies have highlighted that aromatase 
inhibitors are promising chemopreventive agents for breast 15 
cancer through inhibition of estrogen biosynthesis. In par-
ticular, research has suggested that letrozole is an ideal can-
didate for chemoprevention for women in high risk group 
such as BRCA1 positive. However, the low efficacy and the 
side effects associated with the conventional systemic admin- 20 
istration of letrozole are limiting factors for its long term 
usage. 
Breast cancer growth is highly dependent on estrogen, and 
thus inhibition of estrogen is highly effective for the preven-
tion of breast tumor development. Recent studies have high- 25 
lighted aromatase inhibitors such as anastrozole, letrozole, 
and exemestane, as promising molecules that can be used for 
chemoprevention of breast cancer. Aromatase mediates bio-
synthesis of estradiol, the most potent form of estrogen, from 
androgens by the cytochrome P450 enzyme complex (Aro- 30 
matase). Aromatase is present in breast tissue and the nonste-
roidal and steroidal aromatase inhibitors reduce circulating 
estrogen level to 1% to 10% of pretreatment levels, respec-
tively. Therefore, inhibition of aromatase is an important 
approach for reducing growth-stimulatory effects of estro- 35 
gens in estrogen-dependent breast cancer, which constitutes 
approximately 60-70% of breast cancer. Among the aro-
matase inhibitors, letrozole is a highly potent non-steroid 
inhibitor which inhibits approximately 99% of estrogen bio-
synthesis. Additionally, several studies and clinical trials on 40 
chemotherapy of metastatic breast cancer indicated higher 
efficacy with fewer side effects of letrozole when compared to 
Tamoxifen. Hence, research suggests letrozole as a candidate 
for the development of chemopreventive therapy for women 
at increased risk of breast cancer. However, the conventional 45 
oral administration of letrozole showed increased risk of heart 
problems and osteoporosis. The key for the success of chemo-
prevention for breast cancer relies on long term delivery of 
specific drugs while circumventing side effects. As opposed 
to the inefficient oral administration, a constant local release 50 
of chemopreventive agent (i.e. letrozole) in breast tissue 
could significantly reduce occurrence of breast tumor as well 
as systemic side effects. This shows promise for improvement 
in patient quality of life. 
It is believed that the implantable nanochanneled devices 55 
according to the present disclosure will allow the constant and 
sustained local release of letrozole in breast tissues and sig-
nificant reduction of estrogen dependent epithelial cell pro-
liferation with minimum toxicities. 
Prior clinical trials employed letrozole daily doses of 2.5 60 
mg. It is believed that the constant local release of letrozole in 
breast tissues (utilizing nanochanneled devices according to 
the present disclosure) would require lower dosage if com-
pared to oral delivery. In first analysis it is believed that a local 
daily release in the range 25 to 50 ug could be effective. 65 
The achievement of an efficient chemopreventive therapy 
by the use of long-term, constant release implants for local  
50 
administration of chemopreventive agents will have signifi-
cant impact on the quality of life of women in the high risk 
group. It is believed that use of nanochannel delivery devices 
according to the present disclosure will lead to improved 
efficacy of therapy, as well as potential reduction of drug 
doses and reduction of side effects through true constant 
release. A reduction in the number of breast cancer occur-
rences due to effective preventive therapy would also have a 
positive economic impact on patients, their employers and 
insurers through lowered cost of treatment, fewer medical 
visits, and less work time lost. 
The development of a reliable extended release implant-
able technology adds a new dimension to drug delivery for 
breast cancer. Tumor treatment and the suppression of 
metastasis and/or tumor recurrence are natural follow-on 
developments. Technology enhancements to the initial plat-
form could support variable and programmed release, includ-
ing remote, interactive control of the implanted device, fur-
ther enabling capabilities to deploy multiple drugs 
simultaneously. In vivo refilling could also extend the func-
tionality of the nanochannel device and also decrease adverse 
events associated with explanation. As a general drug deliv-
ery method, other indications may be identified, broadening 
the applicability of the innovation. 
EXAMPLE 3 
The capsule and nanochannel delivery device are config-
ured and implanted in a patient as described in Example 1. 
However, instead of administering leuprolide acetate, the 
capsule and nanochannel delivery device administer lapatinib 
for the treatment of breast cancer. 
EXAMPLE 4 
The capsule and nanochannel delivery device are config-
ured and implanted in a patient as described in Example 1. 
However, instead of administering leuprolide acetate, the 
capsule and nanochannel delivery device administer bupe-
norphine for the treatment of opiate dependency. 
EXAMPLE 5 
The capsule and nanochannel delivery device are config-
ured and implanted in a patient as described in Example 1. 
However, instead of administering leuprolide acetate, the 
capsule and nanochannel delivery device administer inter-
feron alpha implant for giant cell angioblastoma. 
EXAMPLE 6 
The capsule and nanochannel delivery device are config-
ured and implanted in a patient as described in Example 1. 
However, instead of administering leuprolide acetate, the 
capsule and nanochannel delivery device administer zidovu-
dine in an intravaginal treatment for preventing HIV being 
transmitted from a pregnant mother to a child. 
EXAMPLE 7 
The capsule and nanochannel delivery device are config-
ured and implanted in a patient as described in Example 1. 
However, instead of administering leuprolide acetate, the 
capsule and nanochannel delivery device administer methotr-
exate for the treatment of certain neoplastic diseases, includ-
ing for example, adult rheumatoid arthritis and severe psoria-
sis. 
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The recommended treatment of adult rheumatoid arthritis 
is 7.5 mg once weekly. This dose translates to approximately 
1.07 mg per day given continuously. The methotrexate mol-
ecule has a molecular weight of 454 Da and the potential 
nanochannel size for constant delivery is approximately 2 
run. 
At the dose of 1.07 mg per day, the nanochannel delivery 
device chip has approximately 806,442 nanochannels with 
microchannel dimensions of 1 µm by 3 µm with a nanochan-
nel length of 1µm. If the implant contains the equivalent of 
122 mg/ml concentration of methotrexate, the resulting 
implant volume is approximately 3 cc for one year of treat-
ment. The recommended treatment for severe psoriasis is 10 
to 25 mg once per week. For the case of 25 mg per week, this 
results in a continuous delivery of approximately 3.57 mg per 
day. At the daily dose 3.57 mg per day the nanochannel 
delivery device chip for this application would have approxi-
mately 2,866,500 nanochannels with microchannel dimen-
sions of 1 µm by 3 µm with a nanochannel length of 1 µm. 
If the implant contains the equivalent of 434 mg/ml con-
centration of methotrexate, the resulting implant volume is 
approximately 3 cc for one year of treatment. A common 
neoplastic disease treatment is 15 to 30 mg per day for 5 days 
then a one week rest period, after the week of rest the treat-
ment is repeated and the cycle repeated 3 to 5 times. If the 
mexthotrexate is delivered continuously and the rest periods 
are no longer needed, the nanochannel delivery device can be 
designed to deliver 30 mg per day for the 25 days of treatment 
time. The nanochannel delivery device chip for this applica-
tion would contain approximately 28,665,000 nanochannels 
with microchannel dimensions of 1 µm by 3µm with a 
nanochannel length of 1 µm. If the equivalent of 250 mg/ml of 
methotrexate is used the implant volume would be approxi-
mately 3 cc for the 25 day treatment. 
As used herein, the term "direct fluid communication" is 
interpreted as fluid communication between two bodies that 
are directly connected, e.g. such that fluid may exit one body 
and immediately enter the second body without flowing 
through an intermediate body. For example, in the embodi-
ment shown in FIGS. 3A-3G, outlet 70 is in direct fluid 
communication with nanochannel 25. However, outlet 70 is 
not in direct fluid communication with inlet 30, because fluid 
must flow through an intermediate body (nanochannel 25) 
after exiting inlet 30 and before entering outlet 70. 
Furthermore, as used herein, the term "inlet" is interpreted 
as a chamber or reservoir within a nanochannel delivery 
device that initially retains a substance being delivered via the 
nanochannel delivery device. Similarly, an "outlet" is inter-
preted as a chamber or reservoir within a nanochannel deliv-
ery device that retains a substance immediately prior to the 
substance exiting the nanochannel delivery device. 
All of the devices, systems and/or methods disclosed and 
claimed herein can be made and executed without undue 
experimentation in light of the present disclosure. While the 
devices, systems and methods of this invention have been 
described in terms of particular embodiments, it will be 
apparent to those of skill in the art that variations may be 
applied to the devices, systems and/or methods in the steps or 
in the sequence of steps of the method described herein with-
out departing from the concept, spirit and scope of the inven-
tion. All such similar substitutes and modifications apparent 
to those skilled in the art are deemed to be within the spirit, 
scope and concept of the invention as defined by the appended 
claims. 
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45 	 The invention claimed is: 
1. An apparatus comprising: 
• capsule, wherein the capsule comprises a nanochannel 
delivery device; 
• bladder located within the capsule, wherein: 
50 	 the bladder contains molecules of a therapeutic agent; 
and 
the nanochannel delivery device is configured to control 
a diffusion rate of the molecules of the therapeutic 
agent from the bladder; 
55 	 a first port where the first port extends through the capsule 
and bladder; and 
• second port where the second port extends through the 
capsule but does not extend through the bladder. 
2. The apparatus of claim 1 wherein the nanochannel deliv-
60 cry device comprises: 
an inlet microchannel; 
a nanochannel; and 
an outlet microchannel, wherein the inlet microchannel 
and the outlet microchannel are in direct fluid commu-
65 	 nication with the nanochannel. 
3. The apparatus of claim 2 wherein the nanochannel deliv-
ery device comprises a substantially planar body comprising 
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a first surface and a second surface opposing the first surface, 
and wherein: 
the nanochannel is disposed within the substantially planar 
body; 
the inlet microchannel extends from the nanochannel to the s 
first surface; and 
the outlet microchannel extends from the nanochannel to 
second surface. 
4. The apparatus of claim 1 wherein the first port and the 
second port are configured so that the first port and the second io 
port can be accessed externally when the capsule is implanted 
in vivo. 
5. The apparatus of claim 1 wherein the capsule is generally 
disc-shaped and comprises a first side and a second side, and 
wherein the first port and the second port are both located on 15 
either the first side or the second side. 
6. The apparatus of claim 1 wherein the capsule comprises 
a first end and a second end, and wherein the first port and the 
second port are aligned when the capsule is viewed from the 
first end or the second end. 	 20 
7. The apparatus of claim 6 wherein the capsule comprises 
a primary axis extending from the first end to the second end 
and wherein a reference line connecting the first port and the 
second port is generally parallel to the primary axis. 
8. The apparatus of claim 1 wherein the first port comprises 25 
a first septum and the second port comprises a second septum. 
9. The apparatus of claim 8 wherein the first septum and the 
second septum are self-sealing after being punctured by a 
needle. 
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